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Jason Leigh Sanders, Ph.D. 
University of Pittsburgh, 2012 
 
Biomarkers of aging are indicators of characteristics of an organism which change over 
time. Validating aging biomarkers will enable researchers to better understand aging mechanisms 
and design interventions which promote healthy aging. This dissertation uses population-based 
cohorts to explore two emerging biomarkers of human aging, leukocyte telomere length (LTL) 
and lens transparency. 
Short LTL records systemic oxidation and inflammation and contributes to cellular 
senescence. Previous studies focused on its association with diagnosed age-related chronic 
disease in one physiologic system and have generated equivocal results. Because disease can be 
undiagnosed and exist in several tissues simultaneously, previous research may have 
underestimated associations with LTL. We studied the association of LTL with an index of 
disease burden, which tabulates age-related chronic disease in five physiologic systems 
regardless of diagnosis. To the extent that an index across systems might capture an underlying 
propensity to age-related changes in all systems, a marker of fundamental aging processes such 
as LTL should be associated with it. We show LTL is associated with this index of disease 
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burden. Thus, LTL might indicate widespread incremental changes in structure or function in 
older adults independent of diagnosed disease.  
Lens transparency may reflect systemic load of molecular glycation and denaturation, 
which have been associated with aging. Correlates of reduced lens transparency in humans are 
undefined. We studied the association of lens transparency to markers of aging and disease. We 
found that older adults with highly transparent lenses have longer LTL, lower prevalence of 
diabetes, better cognition, and lower odds of an ApoE4 allele, the strongest genetic risk factor for 
Alzheimer’s disease. Transparency is unrelated to risk factors for atherosclerosis or non-
invasively measured vascular disease.      
What are the public health implications of this work? First, LTL may aid in the 
development of screening tools and interventions to prevent age-related disease simultaneously 
in multiple physiologic systems. Second, lens transparency may help detect amyloid-related 
brain pathology, which is vital to developing interventions to slow brain aging. Future 
epidemiologic research should focus on correlating changes in LTL and transparency to changes 
in age-related phenotypes and the ability of LTL and transparency to predict age-related 
outcomes.   
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I wish to convey my sincere gratitude to the many individuals who helped me complete this 
dissertation. First, I am indebted to Dr. Anne Newman, my advisor and mentor for over four 
years. Since my arrival at the University of Pittsburgh, I never doubted her commitment to my 
development as a researcher and clinician. She trusted my early desire to work independently. 
She always knew what questions to ask to expose my deficiencies and help me learn, and when 
to push me to accomplish more than I predicted. Dr. Newman served as the mentor for my F30, 
which continues to fund my training, and provided recommendations for my successful 
application for other fellowships and grants. She has generously supported me to travel 
throughout the US and abroad, and introduced me to countless researchers to expand my 
network. Throughout my training she has allowed and even encouraged me to explore areas of 
interest unrelated to my dissertation. She is a model mentor, more than I could have asked for, 
and I cannot thank her enough for her investment in me.   
 I must also acknowledge my excellent committee – Drs. Robert Boudreau, Yvette 
Conley, Lewis Kuller, and Laura Niedernhofer. Dr. Boudreau has been my statistical guiding 
light since I arrived at Pitt. He should be rewarded for his ability to explain complex statistical 
methodology better than anyone else I encountered, and his always-open door. He stands second 
only to Dr. Newman in dedicating time to my research. Dr. Conley, ever affable, helped produce 
the initial question of whether lens transparency was a worthwhile candidate biomarker of aging. 
Her insight on ocular genetics provides much-needed developmental context to our work. Dr. 
Kuller has overseen the Healthy Women Study since its inception, which allowed us to easily 
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investigate the association of lens transparency to many markers of disease and aging. I greatly 
appreciate his willingness to teach given his advanced understanding, his ability to distill decades 
of data into easily-comprehensible facts, and his emphasis on conducting research that matters 
outside the walls of academia. Dr. Niedernhofer has been my teacher as both a committee 
member and an active participant in the Medical Scientist Training Program. Her intellect has 
made her an invaluable resource to help me connect findings culled from populations and 
laboratories, and her energy and curiosity remind me to never lose sight of the beauty in 
generating new knowledge.  
 Furthermore, I am indebted to Dr. Amy Nau, without whom it would not have been 
possible to gather lens transparency data in the Healthy Women Study, and Eileen Cole, who 
recruited participants for our Aging Lens Substudy. The faculty, staff, and students of the Center 
for Aging and Population Health and Health Studies Research Center have been supportive and 
nurturing since my arrival in 2007. I thank all of the participants of the Health, Aging, and Body 
Composition Study, the Cardiovascular Health Study, and the Healthy Women Study for their 
decades of service. I am also fortunate for the aid of the administrators of the Medical Scientist 
Training Program, Drs. Clayton Wiley, Richard Steinman, and Manjit Singh, and the faculty and 
staff of the School of Medicine and Graduate School of Public Health who have shepherded my 
growth and continue to advocate for students’ best interests. 
 Finally, I thank my family and friends. They have been bottomless sources of love, 
learning, and worthwhile distraction. I cannot overstate how much I value them in my life. 
Without them I could not have achieved this much, and it certainly would have been less 
enjoyable along the way.  
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1.0  INTRODUCTION 
 
Traditionally, the aging process was equated with unalterable decline and the development of 
disease. Although it is uncertain if a primary process of aging can be fully distinguished from the 
secondary process of disease, recent research has identified that aging and disease are not 
synonymous, and subsequently that aging can be optimized. This has been most clearly 
demonstrated in animal models with genetic manipulation and caloric restriction that delay 
aging, morbidity, and mortality. In these systems mortality rate has been the primary marker of 
aging, but for human studies in vivo markers of aging are needed. Specifically, markers of 
primary aging are needed as intermediate outcomes to understand the aging process and potential 
early benefits of preventive interventions.  
This review begins by illustrating global trends in aging and priority areas for aging 
research, focusing on identifying and validating new biomarkers of aging. It provides a definition 
of a “biomarker of aging” and methodology to evaluate potential biomarkers. Next, previous 
research on two putative biomarkers, leukocyte telomere length and lens transparency, is 
described. Finally, research directions are posited to advance understanding of leukocyte 
telomere length and lens transparency, which in the future may be used as biomarkers to clarify 
the biology and physiology of aging. 
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2.0  BACKGROUND 
 
2.1: What is aging, and how does aging relate to disease? 
For the purposes of this dissertation I will begin with defining the terms “aging” and “disease,” 
which will provide guidance for considering if a marker indicates aging, disease, both, or neither. 
Aging is a process that has three specific characteristics. First, aging is universal – it happens to 
everyone, it is inescapable. It would be very difficult to confuse a 20 year old for a 40 year old or 
a 40 year old for a 70 year old. While disease is selective, burdening certain individuals within a 
population and sparing others, everyone exhibits changes with age regardless of their disease 
status. Second, aging is irreversible – it cannot be entirely undone. Although genetic 
manipulation,1 caloric restriction,2 and stem cell transplantation in progeroid mice3 have 
demonstrated that the rate of aging can be slowed, aging cannot be completely reversed and will 
progress towards the ultimate endpoint of death. This is in contrast to disease, some of which can 
be cured or kept at bay for years or decades. Third, aging is deleterious, that is, it converts a 
robust organism able to respond adequately to stress into a frail organism that is susceptible to 
failure in the face of stress. Each individual may have their own optimal point or average 
setpoint for what is “robust” or “frail,” but aging will progressively impair one’s ability to 
respond to stress. These three characteristics – universal, irreversible, deleterious – can be used 
when considering if a marker measures aging – i.e., that marker occurs or exists in everyone and 
changes in amount, form, or purpose with age; its age-related change cannot be completely 
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reversed; and its age-related change ultimately hinders the individual more than it benefits the 
individual.   
The relationship of aging to disease is somewhat unclear and can be described in several 
ways. These descriptions impact if one views a marker as illustrating aging, disease, both, or 
neither. One description posits aging is a distinct process (universal, irreversible, deleterious) 
that is entirely independent of the development of disease. This theory is based on the relatively 
consistent observation that a decline in function is seen between and within species with widely 
different physiology and pathology, supporting the idea that organisms share a common aging 
process that is independent of species-specific disease.4 The human body undergoes many 
changes over time that occur without disease and are deleterious, such as thinning and wrinkling 
of skin and graying of hair; loss of visual accommodation, hearing sensitivity, and smell; 
increased blood pressure; decreased maximal heart rate, kidney function, bone mineral density, 
muscle mass, peripheral nerve discrimination, and thirst drive; impaired thermoregulation and 
immune function; intracellular accumulation of lipofuscin; increased neurofibrillary tangles and 
senile plaques; cross-linking of collagen; and many others.5 These changes might be considered 
consequences or correlates of aging rather than disease, with the caveat that they may be highly 
tissue, organ, or process-specific. They may reflect aging of a single parameter of the body rather 
than providing insight on the aging of entire organism.  
The separation of aging and disease may also be partly artificial, though, and belie our 
poor understanding of the aging-disease dichotomy.6 It is not difficult to identify age-associated 
changes (some noted above) and consider these changes independent of disease because they do 
indeed occur in the absence of disease. But, it is possible that aging and disease pathogenesis are 
inextricable and, in the extreme, are in fact the same process expressed in different terms, at 
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different amounts, or at different stages along a continuum that are arbitrarily separated by 
humans.6 For example, the Baltimore Longitudinal Study of Aging recruited faculty in Baltimore 
from across the age span and excluded people with a history of any diagnosed health condition 
for the express purpose of exploring physiological changes with aging rather than disease. 
Investigators documented that glomerular filtration rate (GFR) measured with creatinine 
clearance decreases on average ~1 mL/min/year. Nonetheless, over 20+ years, 30% of 
individuals maintained kidney function, others decreased at >2 mL/min/year, and a small number 
had a statistically significant increase in GFR.7 If kidney disease is categorized using GFR 
cutoffs, with a GFR <60 mL/min delineating stage 1 chronic kidney disease and GFR <15 
mL/min delineating end stage renal disease, when does declining GFR biologically change from 
being a marker of renal aging to a marker of kidney disease? In the brain, senile plaques and 
neurofibrillary tangles accumulate with age in the absence of clinically-diagnosed Alzheimer’s 
disease.8-12 Although younger patients with Alzheimer’s disease have far greater densities of 
plaques and tangles compared to age-matched controls, the difference between cases and 
controls is somewhat mitigated at older ages (>80 years old). Furthermore, there is a wide range 
of cognitive performance among patients with similar levels of plaques and tangles, even when 
those levels are high.8-12 These associations become more difficult to interpret as cognition itself 
is more finely divided into normal, mild cognitive impairment, and dementia. Are plaques and 
tangles markers of brain aging, disease, or both? As another example, bone mineral density 
declines with age, but with the advent of noninvasive imaging to quantify density (e.g., dual-
energy X-ray absorptiometry), “normal” values have been established using age and sex specific 
lifetime peak values. There are now clinical conditions, osteopenia and osteoporosis, defined by 
comparing one’s bone mineral density to these “normal” values. Is low bone density a marker of 
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skeletal aging or a disease? The clear distinction between aging and disease has been eroded by 
tools which can measure disease earlier in its course. This complicates whether measurements 
provide insight on the biology of aging, disease, or both.  
Furthermore, although it is increasingly rare with noninvasive measurements to identify 
individuals who age well in many domains, there are indeed exceptional individuals who attain 
this status.13 Theoretically, in contrast to these extremely healthy agers all others may be seen as 
“diseased.” The argument to separate aging and disease is thus partly rooted in biology and 
measurement (juxtaposing changes that occur “with normally aging” from changes that occur 
“with disease”), which are more objective, and partly in semantics and interpretation (i.e., how 
does one partition aging and disease?), which are more subjective. Separating aging from disease 
may illustrate humans’ long-held desire to conquer disease and then aging itself, which may 
necessitate conceptualizing and describing aging and disease differently, and stems from a 
combination of emotion and philosophy.  
A final description of the aging-disease relationship concerns how aging is a risk factor 
for disease. Across populations, aging is one of the strongest risk factors for many diseases, 
particularly chronic diseases, whereas other disease risk factors are typically associated with 
specific diseases in specific groups of people. These observations can be explained partly by the 
distribution of aging (aging is experienced by everyone) versus the distribution of other disease 
risk factors (which are not experienced by everyone), but it is also due to the effect of aging. 
Time-dependent damage to molecules and tissues broadly accumulates and eventually 
overwhelms homeostatic processes. This occurs even in the absence of other disease risk factors 
due to organisms’ exposure to ubiquitous damaging agents like radiation (exogenous exposure) 
and reactive oxygen species generated from mitochondrial energy synthesis (endogenous 
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exposure). Therefore, a background of time-dependent damage that we call “aging” defines the 
base level of risk for the development of disease, but it can also interact with other disease risk 
factors to augment the risk trajectory for disease. Subsequently, aging is a strong risk factor for 
many diseases across tissues. This relationship of aging to disease makes validating biomarkers 
tricky. If a biomarker is associated with age, then perhaps it is a biomarker of aging, but because 
age is a risk factor for disease, then is the biomarker also a biomarker of disease? If the 
biomarker is associated with changes which occur with age, but it is also associated with other 
disease risk factors, how many associations and what strength of associations imply the 
biomarker is more one of aging than of disease? As more accurate, specific, and diverse 
measurement tools are developed, answering these questions could become increasingly difficult.  
Herein, for simplicity, aging will be considered a process that is universal, irreversible, 
and deleterious, and a marker of aging will have few to no associations with risk factors for 
chronic disease other than chronologic age. Disease will be considered something not universal 
(i.e., has identified risk factors other than chronologic age, such as lifestyle and environmental 
exposures), possibly irreversible (i.e., there are available preventive measures to remove risk 
factors or clinical treatments for overt disease), but still deleterious. If a marker is an indicator of 
aging, disease, both, or neither will depend upon the biology of the marker itself and the current 
state of knowledge of associations with that marker in human populations. 
 
2.2: Global trends in aging 
In 2007, the National Institute on Aging and US Department of State identified nine global 
trends in aging that characterize the changing face of world:14 
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1. Life expectancy is increasing. This raises questions about the potential for the human 
lifespan. 
2. People aged 65 and over will soon outnumber children <5 years old for the first time in 
history, demonstrating an increase in the raw number of older adults. 
3. The world’s population ≥80 years old is projected to increase 233% between 2008 and 
2040, compared with 160% for the population ≥65 and 33% for the total population of all 
ages. Thus, there is near exponential growth in the proportion of the population that is old 
compared to more linear growth for younger age groups. 
4. Some populations are aging while their size declines. The joint effect of longer survival 
and lower birth rates has created a demographic phenomenon termed squaring of the 
pyramid, which describes the redistribution of a population from one with a large 
foundation of younger individuals and fewer older adults to one with an increasingly 
similar proportion of younger and older individuals. 
5. Non-communicable diseases are now the major cause of death among older people in 
both developed and developing countries. Preventive and therapeutic interventions which 
target chronic disease will be increasingly important to refine and apply in both wealthy 
and poor nations to mitigate the medical, social, and economic effects of chronic disease. 
6. Family structures are changing. As people live longer and have fewer children, older 
adults become a larger component of the family unit, and the benefits and burdens of 
caring for older family members are magnified. 
7. Patterns of work and retirement are shifting. Shrinking ratios of workers to pensioners 
and people spending a larger portion of their lives in retirement increasingly tax existing 
health and pension systems. 
8 
8. Social insurance systems are evolving. Countries are evaluating the sustainability of these 
systems and revamping old-age security provisions. 
9. New economic challenges are emerging. Population aging already has and will continue 
to have large effects on social entitlement programs, labor supply, and total savings. 
Trends 1-4 illustrate the demographic shift occurring through time – the rising tide of older 
adults sweeping across the world. Trend 5 describes the accompanying boom of chronic disease 
which tax the health system most. Trends 6-9 demonstrate that global aging will have social and 
economic ramifications governments must address lest the negative consequences beginning to 
ripple through society continue to grow. Together, these trends clearly depict the quickening 
pace of aging throughout the world and the pervasive effects these changes will have on 
populations and individuals. 
 
2.3: Priority areas for aging research 
The Academy of Medical Sciences of the United Kingdom drafted a roadmap for aging research 
in the hopes that new knowledge could mitigate the detrimental effects of global aging and steer 
populations along a better course, often referred to as healthy aging. In their report 
“Rejuvenating Ageing Research,” the Academy states that four broad priority areas for aging 
research should be:15 
1. Developing our understanding of the basic biology of healthy aging. 
2. Integrating knowledge of the processes that underpin aging and age-related diseases. 
3. Measuring and understanding the determinants of healthy aging in older people at a 
population level. 
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4. Translating advances in the basic biological science of aging into effective 
interventions to promote healthy aging.  
These priority areas match the National Institute on Aging’s Strategic Plan, particularly the goal 
to “Improve our understanding of healthy aging and disease and disability among older adults.”16 
With this guidance, researchers must ask themselves: How best can we approach these priority 
areas? What will enable us to develop our understanding of the biology of healthy aging and 
translate understanding into effective interventions? As the report suggests, identification and 
validation of new biomarkers of aging will in part provide answers to these questions.15 
Biomarkers are particularly important in human research because tabulating mortality, an 
endpoint often used in the laboratory, requires long follow-up in humans and is a crude indicator 
of quality of life.   
 
2.4: Working definition of a biomarker of aging 
In 1988 Baker and Sprott defined a biomarker of aging as, “a biological parameter of an 
organism that either alone or in some multivariate composite will, in the absence of disease, 
better predict functional capability at some late age than will chronological age.”17 This 
definition has stood the test of time yet deserves comment.18,19 First, the authors thoughtfully 
mention that biomarkers should not only be considered on a one-by-one basis, but that 
combinations of biomarkers might be advantageous. Subsequently, researchers must consider 
theoretical and practical limitations on which biomarkers can be combined and how biomarkers 
may be combined to form a composite measurement. For example, it may be inappropriate to 
combine biomarkers on widely different levels of biological organization, such as expression 
level of a protein and difficulties in activities of daily living, because it is difficult to interpret 
10 
how these biomarkers interact. Similarly, it may be inappropriate to combine biomarkers with 
widely different ranges, such as a dichotomous measurement (e.g., yes/no determination), ordinal 
measurement (e.g., number of diagnosed chronic conditions), and a continuous measurement 
(e.g., gait speed).   
Second, the authors include the phrase “in the absence of disease,” alluding to the hotly 
debated issue of whether aging and disease are separable, and siding with biomarkers predicting 
future events independent of disease.6 As noted in 2.1, there are hallmarks of aging which are 
independent of disease and aspects of aging and age-related disease which overlap. Depending 
on which description of aging is applied, a biomarker of aging may be argued as an indicator of 
primary aging (i.e., aging completely independent from disease – a process that is universal, 
irreversible, and deleterious), an indicator of age-related chronic disease, or an indicator of both. 
Preferably, a biomarker of aging would allow monitoring of a basic aging process independent of 
disease. But, due to the strong tie between aging and many chronic diseases, our current 
imperfect ability to disentangle normal age-related changes from abnormal age-related changes 
from disease-related changes, and the increasing use of subclinical measurements which identify 
“disease” at earlier points in its course, it is possible that strong biomarkers of aging may also be 
biomarkers of age-related disease.   
 Third, Baker and Sprott write that biomarkers should be used for prediction. This is 
logical, though it can be explicitly added that if biomarkers were useful for prediction they might 
serve as points of intervention for prevention of unhealthy aging and/or disease. Fourth, the 
authors declare that biomarkers should predict “functional capability.” Although there is no 
accepted definition of aging, aging can be visualized as a progressive decline in function over 
time, particularly the inability to restore homeostasis when stressed, so this conceptualization 
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seems an appropriate anchor for defining a biomarker of aging. Nonetheless, “functional 
capability” is an unclear term. Functional ability occurs at many levels: DNA repair enzymes 
maintain genomic integrity; mitosis-associated factors enable successful cell division; ion 
channels allow cells to communicate successfully and organs to operate properly; organ-specific 
function is critical to maintain homeostasis; physical and cognitive function permit an organism 
to navigate surroundings and respond to stress; and social function is an important capability that 
impacts health and wellbeing. All of these, and many more, are “functional capabilities” that 
change with age and that a biomarker could potentially predict. Ultimately, function is only one 
of many outcomes which are useful to study when evaluating putative biomarkers of aging.  
Fifth, the authors assert that a biomarker should predict functional capacity better than 
chronologic age. This idea stems from the observation that organisms of the same species with 
the same chronologic age exhibit great heterogeneity in health, fitness and life expectancy,4 and 
that chronologic age is therefore a suboptimal predictor of health status. It must be noted that, 
broadly, chronologic age remains the most robust predictor of future events, so prediction better 
than chronologic age is very difficult to achieve. In bench research, biomarkers may provide 
strong insight on the biology of aging without achieving dominance over chronologic age in 
statistical models derived from clinical or population studies. Furthermore, in statistical models, 
biomarkers may increase predictive accuracy meaningfully without being a stronger predictor 
than chronologic age. Subsequently, it is generally not accepted as a rule that biomarkers of 
aging must be stronger predictors than chronologic age in statistical models, but it is desirable. 
Over time the definition posed by Baker and Sprott has been questioned by both the 
authors and others.18-20 In general, two aspects of the definition are widely supported: biomarkers 
of aging should be correlated with age and provide insight on a biological process important to 
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aging. Clinical utility and superiority to chronological age for prediction have been challenged as 
necessary aspects of a definition due to their rigidity. Outcomes used for prediction are diverse 
and should not be limited to a narrow view of what constitutes “function.” This definition and 
others should serve more as a guide than gospel and should not confine research or clinical 
translation.         
 
2.5: Evaluating putative biomarkers of aging 
There are several proposed criteria to evaluate putative biomarkers of aging.17-19,21 Although 
there are no hard and fast requirements, these criteria, rooted in theoretical and practical 
considerations, are useful for assessing a putative biomarker’s worth and comparing the value of 
one biomarker to another. These criteria can be summarized as: 
1. Statistical criterion: A biomarker should be correlated with age and predict the rate of 
aging better than chronological age.17,18,20,21 In other words, it should tell exactly 
where a person is, in regards to some measurable parameter of aging, in their total 
lifespan. Fulfillment of this criterion can be investigated in several ways. First, using 
regression coefficients in a statistical model, the magnitude of the association of the 
biomarker with the outcome of interest can be directly compared to the magnitude of 
the association of chronologic age to the outcome. Ideally, when both are 
standardized, the coefficient of the biomarker is larger than the coefficient of age. 
Second, the magnitude of the standardized coefficient of the biomarker can be 
compared to the magnitude of the unstandardized coefficient of chronologic age to 
illustrate how many years of chronologic aging is depicted by a standard difference in 
biomarker levels. For example, if the coefficient of a biomarker on muscle mass was 
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ten units per standard deviation of the biomarker and the coefficient of age on muscle 
mass was two units per year of age, then 1 standard deviation in the biomarker would 
be equivalent to 5 years of chronologic aging on muscle mass. Biomarkers with more 
years of chronologic aging depicted by a standard difference in biomarker level are 
likely stronger biomarkers of aging. Third, one can test the ability of the biomarker to 
attenuate the effect of age. In a statistical model this can be achieved simply: one 
model is built including age as a covariate, and the next model is built including age 
and the biomarker. The degree to which the coefficient of age is attenuated by the 
addition of the biomarker provides evidence for how much the effect of chronologic 
age is explained by the biomarker. Greater attenuation suggests a stronger biomarker 
of aging. Significant attenuation, or more broadly, mediation, can be formally tested 
using mediation regression equations.22 If longitudinal data is available, mediation 
can be identified with autoregressive models or latent growth modeling depending on 
assumptions of the relationship between changes in the mediator, independent 
variable, and dependent variable. Of note, continuous measurements may provide 
more statistical range and variance than categorical measurements. Subsequently, 
biomarkers which can be measured continuously may be able to account for more 
variance in a given outcome, so they may be more powerful predictors on this basis 
alone. It is important to consider what represents the “rate of aging” when testing a 
biomarker’s predictive ability. A rate implies change over time, so ideally the 
biomarker would be used to predict a change in an outcome over years. This 
introduces additional statistical nuance if measurements are derived from populations 
because person-specific (e.g., linear regression with random intercept) or population-
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average (e.g., generalized estimating equation) models can be fit to estimate the 
biomarker’s ability to predict an outcome’s change in an individual or average change 
for the population, and each slope is interpreted differently. More often than using a 
rate of change in an individual, a biomarker is used to predict a population’s 
mortality, or rate of death, or some representation of longevity, such as high gait 
speed and cognitive function. Finally, when predicting an outcome, various statistical 
values can be used to illustrate the quality of prediction. Examples include the amount 
of variance in the outcome accounted for by a biomarker (e.g., using partial r2 values) 
and the overall accuracy of prediction (e.g., using the area under the curve method to 
determine a concordance statistic).     
2. Biological criterion: A biomarker should monitor a basic process that underlies aging. 
This basic process is likely conserved across species. Fulfillment of this criterion 
requires careful examination of the literature and one’s own data. It is possible that 
species-specific biomarkers of aging exist though the commonality of aging across 
species implies that a core set of processes are shared, and that identifying biomarkers 
of these processes will provide the most insight on the biology of aging. Basic 
processes include those operating at the molecular, cellular, tissue, organ, organ 
system, and whole organism levels. These include alterations in the somatic genetic 
code (viral inclusions, errors of DNA replication and repair), transcriptional 
accessibility (epigenetic changes), transcriptional volume (mRNA content), 
translational volume (protein production), post-translational modification (glycation, 
oxidation, nitration, phosphorylation, racemerization, isomerization, ubiquitination), 
tissue histology and morphology (changes in tissue elasticity, lipofuscin 
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accumulation, plaque formation), oxidative stress, inflammation, cellular senescence, 
organ function, and physical and cognitive function. Because biomarker research 
advances with the goal of translating biomarkers to the clinic for diagnosis, 
monitoring therapy, or treatment, knowing which basic process a biomarker monitors 
as a passive indicator or active mechanistic contributor also helps ensure informed 
translation to minimize unforeseen negative consequences.    
3. Clinical criterion: A biomarker should be able to be tested repeatedly and accurately 
without harming the person. Ideally, it is also measured inexpensively, efficiently, 
and reproducibly. Fulfillment of this criterion maximizes the usefulness of the 
biomarker as a potential clinical tool. Nonetheless, if a biomarker provides 
meaningful data but its measurement is impractical, investigators should not dismiss 
it outright because future innovations may allow easy, cheap, safe, and accurate 
measurement. 
4. Experimental criterion: A biomarker should act and be measurable in both humans 
and laboratory animals so that it can be tested in animals before being validated in 
humans. Observational and experimental studies in model systems are often simpler, 
cheaper, and quicker than similar studies in humans, and can be used to vet 
biomarkers in a semi-high-throughput fashion before expending resources on human 
studies. Even complex biomarkers, such as indicators of mobility and activity, have 
been measured in lower order animals like C. elegans and rodents. Although some 
biomarkers will be specific to humans or act differently in humans, validation across 
species can uncover fundamental mechanisms underlying aging and disease. 
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In addition to these criteria, it is important to note what outcomes are used to evaluate 
biomarkers, as described in 2.1. For example, decline in pulmonary function is universal, 
irreversible, and deleterious, and thus it would appear valid to test a biomarker’s ability to 
predict pulmonary function if the biomarker were being validated as a biomarker of aging. In 
contrast, it would likely not be appropriate to use chronic obstructive pulmonary disease (COPD) 
as an outcome, because this represents a disease phenotype rather than an aging phenotype, and 
mechanisms leading to an age-related decline in pulmonary function, such as stiffening of the 
airways and alveoli and decreased thoracic muscle strength, may be quite different from 
mechanisms leading to COPD, such as smoking. Furthermore, assessment of biomarkers is 
complicated by the fact that biomarker can serve as both a predictor and an outcome: in the 
previous example pulmonary function was used as an outcome, but it could also be used as a 
potential biomarker of aging because it fulfills the above criteria, and thus it could serve as a 
predictor of an aging-related outcome such as incident disability. (Indeed, in the following 
papers, leukocyte telomere length, a putative biomarker of aging, will be used as both an 
outcome (4.0: Paper 1) and a predictor (5.0: Paper 2)). 
  
2.6: Examples of putative biomarker of aging 
Many biomarkers of aging have been posited; examples are listed in Table 2.9.1. They range 
from alterations in the genome (e.g., DNA methylation) to whole-body function (e.g., gait 
speed). In general, biomarkers at lower levels of organization (genetic, molecular) have been 
examined in human populations less often than biomarkers at higher levels of organization 
(tissue, organ) because of the novelty of high-throughput genetic and molecular assays. Study of 
many tissue and organ-based biomarkers, such as aortic calcification and pulmonary capacity, 
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have been driven by their strong associations with widespread environmental exposures (e.g., 
smoking) and burdensome chronic diseases (e.g., coronary artery disease, COPD). This again 
illustrates the dichotomy between aging and disease. 
In vivo measurement of pathology in some tissues, such as white matter hyperintensities 
in the brain, remains relatively difficult or expensive on a population level, but function can be 
measured simply and cost-effectively (e.g., Digit Symbol Substitution Test) and serve as a 
valuable adjunct. Although some biomarkers can be categorized easily in one organizational 
level (e.g., activities of daily living), other biomarkers may span several organizational levels. 
For example, serum glucose and lipids (not listed in the table) are molecules, though they could 
be classified as markers of tissue function including the small intestine, pancreas, liver, skeletal 
muscle, fat stores, and even brain. Furthermore, biomarkers frequently reflect several processes 
which may contribute to aging rather than a single process. Investigators must pay close attention 
to the sensitivity and specificity of biomarkers to illustrate particular processes and/or levels of 
organization and acknowledge lack of specificity and sensitivity when appropriate.          
In the following pages, two putative biomarkers of aging, telomere length and lens 
transparency, will be examined using the criteria described previously. This provides a basis for 
future studies to investigate their value as biomarkers of aging. Telomere length and lens 
transparency were selected for investigation for several reasons. First, both are relatively novel: 
lens transparency has been uninvestigated in population-based studies as a biomarker of aging, 
and although telomere length has been studied for a decade in epidemiologic research, many 
questions regarding its validity remain unanswered. Thus, future studies will be valuable to the 
scientific community. Second, these biomarkers are measured in different tissues and may reflect 
different processes which contribute to aging. Telomeres are part of DNA and telomere length is 
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chiefly measured in peripheral mononuclear lymphocytes using molecular assays. Telomere 
length is believed to integrate measurement of systemic oxidation, inflammation, and cellular 
senescence, and may reflect the aging immune system and/or the immune system’s interaction 
with the rest of the body, particularly the vasculature. Transparency is a physical property of the 
lens that is a function of protein integrity and is measured using optical devices. It can be 
measured repeatedly as an in vivo tissue-specific marker, but the proteins that comprise the lens 
are used throughout the body for the same purpose: to maintain protein conformation, especially 
under stress. Few direct markers of the maintenance of protein integrity are available to use in 
epidemiologic research, so lens transparency might be particularly valuable for measuring this 
key aspect of aging.      
 
2.7: Telomere length as a biomarker of aging 
Telomeres are repeating TTAGGG nucleoprotein caps flanking nuclear DNA. With replication 
of nuclear DNA during mitosis, telomere length progressively shortens because the replication 
machinery cannot copy the absolute ends of DNA, termed the end replication problem. With 
critically short telomeres, the cell exits the cell cycle and becomes senescent.23,24 Importantly, 
this process protects against unbridled cellular division, which can lead to cancer. 
Telomere length has been postulated as a marker and/or fundamental regulator of cellular 
and thus organismal aging.25,26 The following sections summarize the literature on telomere 
length as a biomarker of aging, particularly with respect to aforementioned criteria for evaluating 
a putative biomarker of aging: 1) monitoring a basic process that underlies aging; 2) predicting 
the rate of aging; 3) able to be tested repeatedly and accurately without harming the person; 4) 
acting in both humans and laboratory animals. 
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2.7.1: Telomere length monitoring a basic aging process 
Currently, determinants of telomere length are poorly understood, and thus it is unclear what 
biologic processes telomere length may reflect. At birth telomere length is highly heterogeneous, 
ranging from roughly 5,000-15,000 basepairs. Linkage analyses and genome wide association 
studies have identified few possible loci influencing LTL, most notably those close to TERC, 
which appears mechanistically plausible because it encodes the template RNA component of 
telomerase, the enzyme which elongates telomeres.27-31 Previous reports show LTL is 
heritable27,28,32-34 and modified by paternal age at conception.35-38   
Of note are hereditary diseases caused by mutations in the telomerase complex. 
(Telomere length can also be lengthened by homologous recombination during mitosis and 
chromosomal end joining, though the latter introduces genomic instability.) Patients with these 
diseases, including dyskeratosis congenita (DKC), bone marrow failure syndromes (BMFS), and 
idiopathic pulmonary fibrosis (IPF), may be considered to suffer from premature aging because 
they all display chromosomal instability and accelerated cellular senescence, particularly in 
tissues which proliferate frequently.39 The clinical characteristics most common to these three 
conditions are compartment-specific or complete bone marrow failure, which could be seen as a 
more extreme form of age-associated senescence of hematologic progenitor cells, and cancer, 
which is also age-associated. Although some mutations, such as those in TERC and hTR, are 
associated with all of these diseases, presentation is nonetheless distinct. For example, the age of 
onset for DKC is before age 60 (typically between ages 10-30), for BMFS is all ages, and for IPF 
is usually after age 40. Short telomeres appear in all DKC patients, some BMFS patients, and in 
an unknown proportion of IPF patients. Other aspects of these diseases, such as pulmonary 
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fibrosis, nail dystrophy, and leukoplakia, are not seen with normal aging. Subsequently, these 
diseases do not exactly mirror normal aging, so it is difficult to use them as models for a 
potential impact of short telomeres on aging in the general population.   
 Werner’s syndrome provides stronger evidence for a mechanistic role for telomere length 
in aging. Werner’s syndrome is characterized by a mutation in the WRN gene that encodes a 
DNA helicase and exonuclease important for DNA replication, repair, and telomere 
maintenance. Patients have short telomeres and display normal development until lack of a 
pubertal growth spurt, which is accompanied by hypogonadism, short stature, flat feet, cataracts 
(bilateral in nearly 100% of patients), dermatologic pathology, graying/thinning hair, type II 
diabetes, osteoporosis, soft tissue calcification, premature atherosclerosis, and cancer.40 By their 
30s and 40s patients look like they are several decades older. In general, Werner’s syndrome 
patients display a phenotype that appears more like accelerated aging compared to patients with 
DKC, BMFS, and IPF. Nonetheless, Werner’s syndrome is not entirely comparable to normal 
aging. In particular, the dermatologic pathology (tight skin, hyperkeratosis, ulceration) and types 
of cancer (mesenchymal cancers such as sarcoma, multiple synchronous cancers, and rare 
cancers) experienced by Werner’s patients are not similar to the dermatologic changes (skin 
wrinkling, sagging, and thinning) and cancers (predominantly epithelial of the colon, prostate, 
and female reproductive organs) seen with normal aging. Subsequently, Werner’s syndrome 
suggests but does not prove that telomere length plays a role in normal aging.   
What biological processes, then, might telomere length reflect? There is a great deal of in 
vitro and in vivo evidence that telomere length is affected by two processes in particular: cellular 
replication and oxidation. Regarding replication, as stated previously, the DNA replication 
machinery is unable to copy the extreme ends of chromosomes during mitosis. Thus, telomeric 
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DNA is progressively lost with each cell division. It is estimated that roughly 50 base pairs are 
lost due to the end replication problem.41 Most age-associated shortening occurs during rapid 
somatic expansion, i.e., growth from birth through puberty.25,42 With critically short telomeres 
the cell exits the cell cycle and becomes senescent.23,24 Subsequently, telomere length may 
reflect the growth rate or remaining replicative potential of a population of cells.  
Telomere length also shortens with increasing oxidative stress.25,43 In fact, in human 
diploid fibroblasts cultured under normal conditions, the major determinant of telomere 
shortening appears to be single stranded breaks in DNA caused by oxidative stress.44 The large 
effect of oxidation on telomeric DNA occurs because of a specific deficiency in base excision 
repair.44,45 Single stranded breaks result in telomere shortening during replication,46 most likely 
due to temporary stalling of the replication machinery.47 In vitro, oxidative stress increases the 
rate of telomere shortening by an order of magnitude.44,48,49 Reduction of oxidative stress 
decreases the rate of telomere shortening and postpones replicative senescence.46 Depending on 
where the single stranded break occurs, the lesion can cause either no effect on telomere length 
or up to a 1000 base pair loss of telomeric DNA.41 Modeling studies that predict oxidative stress 
is the major contributor to telomere shortening match experimental results.41,43  
In sum, evidence suggests that, of basic biological processes, telomere length most likely 
reflects somatic growth before the end of puberty and cellular senescence and oxidative stress 
after puberty. Most other evidence is derived from correlation in general population samples 
(detailed in 2.7.2). Subsequently, it is unknown what biological pathways telomere length may 
indicate about aging beyond cellular senescence and oxidative stress. It is possible that short 
telomeres induce senescence, which upregulates secretion of inflammatory factors that promote 
aging. In this case short telomere length may be a cause of inflammation and aging more than a 
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consequence of these processes. Furthermore, it is unknown if accelerated telomere shortening is 
a cause of accelerated aging in the general population because data on phenotypic associations 
with short telomeres are derived from clinical studies of patients with distinct genetic syndromes.  
 
2.7.2: Association of telomere length with age, sex, race, markers of health status, 
inflammation, age-related chronic disease, function, and mortality 
Leukocyte telomere length (LTL) has been studied in association with many phenotypes in 
cross-sectional epidemiologic studies. Major findings from studies with at least several hundred 
participants are listed in Table 2.9.2. If LTL was truly associated with a phenotype one would 
ideally observe consistency across populations, measurement methods, and statistical models. 
This consistency has only been observed for associations with age, gender, and race. Shorter 
LTL is associated with older age, male gender,33,50-61 and Caucasians race.33,59,62 The strength of 
the association with age is highly dependent on the age range of the population. Male gender and 
Caucasian race appear to be associated with a mean LTL that is several hundred basepairs 
shorter relative to LTL in women and African-Americans or Hispanics, respectively. The causes 
of these large gender and race effects are unknown.  
Associations between LTL and other markers of health status are in general equivocal 
and do not appear dependent on differences between study populations, measurement method, or 
statistical adjustment. These include sociobehavioral factors (smoking,50,51,57-59,63,64 alcohol 
consumption,50,51,65 physical activity,51,55,59,60 socioeconomic status66,67), body mass 
index,33,50,51,57-59,63,64,68 lipids,51,58,62,68 markers of glucose metabolism,51,56-58,60,68 and blood 
pressure.51,52,57,58,68 LTL has been inconsistently associated with markers of subclinical 
cardiovascular disease including carotid or femoral intima-media thickness,53,57,63,69 ankle-
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brachial index,57 coronary artery calcium,70 and pulse wave velocity.52 Despite these 
discrepancies, some have argued that there is a robust association with 
atherosclerosis33,51,53,54,56,57,63,71-75 because there are plausible mechanistic reasons for an 
association between shorter LTL and atherosclerosis.76 In particular, with inflammation there is 
increased demand for hematopoetic cells that propagates up the lineage chain until it includes 
hematopoetic stem cells. Increased stem cell division leads to progressively shorter telomeres in 
both stem cells and differentiated cells that continue to divide in the periphery (e.g. 
lymphocytes). In total, the hematopoetic pool becomes “aged” as the population of cells edges 
closer to senescence. Subsequently, with age and inflammation there would be less division of 
circulating hematopoetically-derived cells and epithelial progenitor cells, which would then be 
less able to maintain the vascular wall in response to oxidative stress and plaque growth.76 
Alternatively, because oxidative stress and inflammation are associated with atherosclerosis, and 
there are consistent associations between markers of oxidation and inflammation (e.g., 
interleukin-6, C-reactive protein, homocysteine, isoprostane urinary 8-epi-PGF2α) and shorter 
LTL,51,56,57,60,77 atherosclerosis and shorter LTL may be non-causally linked via these shared 
mechanisms.  
 Pulmonary function65,78 and bone mineral density,60,61,79 markers of specific tissues which 
decline with age independent of disease, are likely not or only weakly associated with LTL. Grip 
strength, a marker of physical function, has not been associated with LTL.65,78,80 An association 
between LTL and cognitive function is equivocal. In 382 women not diagnosed with dementia or 
cognitive impairment, shorter LTL was independently associated with worse memory and 
learning,81 which was corroborated by data from the Nurses’ Health Study82 and a hospital-based 
case-control study,83 but not by a cohort of 449 inpatients in which there was no difference in 
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LTL between patients who were cognitively normal, had mild cognitive impairment, or were 
demented.84 A report from the Health Aging and Body Composition Study, where LTL was 
examined in association with cognitive function in 2,734 non-demented community dwelling 
older adults, provides inconclusive results.85 Furthermore, LTL is likely not associated with 
ApoE genotype, the strongest genetic risk factor for Alzheimer’s disease.85,86  
Telomere length has been used in several epidemiologic studies as a predictor of lifespan 
or death. Cawthon first reported an association between shorter LTL and increased mortality in 
individuals aged 60 or older.87 In this study, increased mortality was specifically due to higher 
rates of cardiovascular disease and infectious disease-specific death. Since that report was 
published, some other studies have found that shorter LTL is associated with increased 
mortality88-92 and others have not.57,65,93-95 Of note, Epel et al. found that shorter LTL was only 
associated with CVD-specific mortality in women and not men, and not with overall mortality.90 
In most of these studies, models have been minimally adjusted, typically only for age, and 
occasionally for sex or race. Differences in measurement methods for LTL (Southern blot vs. 
qPCR) may contribute to inconsistency between studies (see 2.7.3). Furthermore, with increasing 
age, the variability in LTL in a population may decrease.93,94 Because these studies were 
conducted in individuals who were on average older than 60 years, it is possible that they had 
reduced power to detect associations between LTL and mortality. In sum, LTL appears weakly 
associated with overall mortality, and possibly more strongly with CVD or infectious-disease 
specific mortality. 
 Finally, several longitudinal studies have been conducted to determine predictors of 
change in LTL over time.71,90,91,96-99 In these studies, time between samples of LTL ranged from 
2.5 to 10 years. All except one71 relied on qPCR to measure LTL. All found that baseline LTL 
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was the strongest, and often the only, predictor of the subsequent LTL measurement, and several 
noted that 11-34% of the population increased in LTL during the time period.71,91,96,98,99 In 
patients with stable coronary artery disease, Farzaneh-Far et al. found that higher omega-3 fatty 
acid levels were associated with less decline in LTL,98 though this has not been corroborated. 
Although studies of changes in LTL have the potential to provide the strongest evidence for what 
LTL may reflect in humans, those published to date have substantial methodologic flaws.100,101 
In particular, the time between telomere measurements was short, which resulted in small 
changes in mean LTL during the follow-up period. If telomere attrition in late life is 
approximately 30-100 basepairs per year,100 five years of change would result in only 150-500 
basepairs of shortening, which was generally observed in these longitudinal studies. Given that 
inter-individual variation in LTL is approximately 5,000-10,000 basepairs (depending on mean 
age of the population) and most longitudinal studies of LTL change have used quantitative 
polymerase chain reaction for measurement, which has a higher coefficient of variation (see 
2.6.3.2), and have had a small sample size, it is highly likely that these studies were 
underpowered to detect possible associations between change in LTL and outcomes given the 
degree of measurement variability. In fact, it is possible that the changes in LTL observed during 
the follow-up periods were partly or mostly artifacts from measurement error. Longitudinal 
studies with much longer follow-up time and larger sample size are necessary to convincingly 
determine predictors of change in LTL and what change in LTL might predict.       
 
2.7.3: Measurement of telomere length 
Measurement of telomere length requires nucleated cells. In laboratory investigations of non-
humans, any tissue with nucleated cells can theoretically be sampled with tissue sampling or 
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sacrifice of the research animal. For human studies, though, cells must be sampled with minimal 
harm to study participants. Typically, this entails a blood draw and isolation of white blood cells. 
Thus, telomere length in population-based human studies is almost exclusively measured as 
leukocyte telomere length. Subsequently, obtaining samples for telomere length is relatively 
harmless. It should also be acknowledged that although there is synchrony in telomere length 
among hematopoetic cells,102 LTL may not be a perfect surrogate for telomere length in other 
tissues.  
 There are several platforms for measuring LTL. Measurement reproducibility and 
accuracy is platform-dependent. The original technique, Southern blot,103 remains the gold 
standard. Cawthon introduced an assay using quantitative polymerase chain reaction (qPCR)104 
and recently an updated multiplexed version with higher throughput.105 The third notable method 
involves coupling individual cell sorting using flow cytometry and metaphase DNA staining 
using fluorescent in situ hybridization (Flow-FISH),106 which was modified into a high 
throughput quantitative FISH (HT Q-FISH) technique.107 Single telomere length analysis 
(STELA) was developed to measure the length of telomeres on single chromosomal arms.108 
Each platform has different strengths and weaknesses and measures a different part of the 
telomere complex. Furthermore, measurement error is introduced in multiple places (e.g., within 
and between gel error for Southern blot; within and between wells and plates error for qPCR), 
but this error is rarely incorporate into statistical analysis. Because of heterogeneity in results 
from population-based studies of LTL, there is considerable debate over how measurement 
platform may impact findings and weaken comparability of results across platforms.26 Also of 
note is that Southern blot and qPCR, the methods chiefly used in epidemiology, return mean 
LTL. It is unknown if cellular senescence is preferentially induced in the presence of one 
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critically short telomere or shorter average telomere length. Thus, measurements from these 
platforms may not capture the biology of telomere length important to aging. 
 
2.7.3.1: Southern blot 
The Southern blot technique for measuring LTL was developed by Aviv and colleagues chiefly 
to examine LTL in epidemiologic studies.103 Nonetheless, it can be modified to measure 
telomere length in any nucleated cell type with intact DNA if telomeres are within the detectable 
limits of the technique. “After extraction, DNA is inspected for integrity, digested, resolved by 
gel electrophoresis, transferred to a membrane, hybridized with labeled probes and exposed to X-
ray film using chemiluminescence.”103 The protocol notes that a skilled technician could process 
approximately 130 samples per week. 
Strengths of Southern blot include its reproducibility (coefficient of variance typically 
<2%) and expression of values in absolute base pair units (though measurements are terminal 
restriction fragments due to the use of restriction enzymes to digest the DNA). It also allows 
determination of telomere length distribution, which can be used as a parameter of interest 
besides mean LTL, though seldom is because it requires accurate measurement of the width of 
the gel bands relative to reference DNA, which is difficult. Weaknesses of Southern blot include 
requiring a considerable amount of DNA (3 μg per sample) and measuring both the telomeric 
and subtelomeric regions. Inclusion of the subtelomeric region may result in artificial inflation of 
the mean LTL. Cawthon has commented that differences in the subtelomeric region can also 
cause variation in terminal restriction fragment lengths when different restriction enzymes are 
used,104 which has been observed with direct comparison of results following digestion with 
HinfI/RsaI, the most common restriction enzyme used for Southern blot, vs. HphI/MnII.33  
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2.7.3.2: Quantitative polymerase chain reaction 
Cawthon’s original qPCR assay was created to provide a high throughput technique to measure 
LTL.104 This method measures the relative average LTL in genomic DNA by determining the 
ratio of telomere repeat copy number to single copy gene copy number (T/S ratio) in 
experimental samples relative to a reference sample. The mean LTL in base pairs is calculated by 
multiplying the T/S ratio by the length of the reference gene. In the original description of the 
assay, the overall coefficient of variance was 5.8% and the linear correlation between T/S ratio 
and terminal restriction fragment length was 0.677 (P=1.5x10-24). Cawthon stated that average 
LTL differing in as little as 11.4% could be resolved using this technique at 95% confidence.104 
Recently, Cawthon introduced a multiplex version of the qPCR assay to eliminate variance in 
T/S ratio introduced by pipetting different quantities of DNA into separate wells, and reduce cost 
and increase efficiency by requiring half the number of reactions.105 T/S ratios obtained via the 
multiplexed assay are more highly correlated with terminal restriction fragment lengths 
(R2=0.844). The intra-assay coefficient of variance is 5.22%, and the inter-assay coefficient of 
variance is 3.13%.105  
PCR has the advantages of requiring far less DNA (50 ng per sample) and achieving true 
high throughput performance. In general, the variance of qPCR is believed to be >2%, and in the 
literature is often quoted as 5%-10%. Because LTL is highly heterogeneous between individuals 
of the same age, and rates of LTL shortening vary by an unknown amount, this higher variance 
can weaken the ability to resolve significant differences between mean LTLs.103 For example, in 
cross-sectional studies of LTL, the observed difference in mean LTL between case and control 
groups is commonly several dozen to several hundred basepairs.100,103 With an assay coefficient 
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of variance of 2%, individuals with a baseline LTL of 5,000-15,000 basepairs could register a 
difference in LTL of 100-300 basepairs simply due to measurement error, which could easily 
obscure observed differences in mean LTL between cases and controls. Furthermore, stability of 
the reference gene is not guaranteed, and there is no agreed-upon reference gene despite frequent 
use of albumin or beta-globin.103-105 For these reasons, qPCR has been questioned as an accurate 
technique for telomere epidemiology despite having higher throughput and lower cost. 
 
2.7.3.3: Flow-FISH and STELA 
Lansdorp developed the original Flow-FISH technique to allow measurement of mean telomere 
length with metaphase staining from any subpopulation of circulating peripheral cells isolated 
using flow cytometry as a first step.106 Subsequently, Flow-FISH has the distinct advantages of 
returning telomere length for individual cells of distinct cell type and the distribution of telomere 
lengths of that cell type. Because internal controls and highly specific nucleic acid probes are 
used to hybridize to the TTAGGG telomeric repeats, Flow-FISH is more accurate than other 
methods which are prone to including sub-telomeric sequences (Southern blot), influencing 
telomere length depending on the restriction enzyme used (Southern blot), missing some 
sequence due to less-specific probes (qPCR), or relying on stability of a reference gene to 
measure relative LTL (qPCR). Human error is reduced by automation of most pipetting and cell 
sorting, and systemic error can be minimized by inclusion of internal controls with known 
telomere lengths. The original protocol suggests that telomere lengths from 22 different 
individuals can be measured in 12 hours over 2-3 days. Despite returning more information than 
other platforms, Flow-FISH is much more expensive, far less efficient, and requires greater 
technical expertise, limiting its use in population-based research.  
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HT Q-FISH was developed by Canela et al. to maintain the accuracy and flexibility of 
Flow-FISH while capitalizing on the efficiency achieved by plate-based technologies (e.g., 
qPCR), and to allow measurement of telomere length from any cell type that can be grown under 
conventional tissue culture conditions.107 HT Q-FISH can analyze 96 samples with at least 1,000 
nuclei in 2 hours. Because time is greatly reduced and more samples can be analyzed 
simultaneously, there is a reduction in error from variation in metaphase staining conditions over 
time and across samples.107 The technique reportedly costs less than traditional Flow-FISH. Thus 
far, HT Q-FISH has not been widely employed in epidemiologic studies.   
Baird et al. described STELA as a viable platform for measuring telomere length in 
2003.108 STELA was developed to provide the highest level of granularity possible when 
measuring telomere length, i.e. measuring telomere length for individual chromosomes rather 
than averaging telomere lengths across all peripheral leukocytes, subpopulations of peripheral 
cells, or across chromosomes in a single cell. Subsequently, STELA is a powerful tool to 
examine telomere dynamics. For example, it can be used to investigate how inter-individual or 
even inter-chromosomal differences in the genetic code (e.g., single nucleotide polymorphisms), 
genetic structure (e.g., proximity of binding proteins), or genetic machinery (e.g., fidelity of 
replication and repair complexes) may impact telomere length. Because of its high granularity 
and very low throughput, STELA is more amenable to basic studies of telomere biology and has 
not been used in epidemiologic studies.   
 
2.7.4: Telomere length in laboratory animals  
Although telomeres appear in all eukaryotes, telomere length varies widely among eukaryotic 
organisms. This impacts how useful particular model systems are for studying telomere length as 
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it relates to human aging. Yeast have telomeres that are as short as 300 basepairs.109 
Subsequently, yeast are more amenable to studies of telomere structure and dynamics. Telomeres 
in inbred mice are much longer (20,000-150,000 basepairs) than telomeres in humans and mice 
have a higher baseline expression of telomerase.23,110 In terms of aging in mice compared to 
aging in humans, mice also have a higher rate of somatic expansion and shorter lifespan. But, 
mice are the most flexible model system to study aging in vertebrates. Subsequently, to use mice 
to study telomere length as it might relate to humans, the telomerase-deficient mouse was created 
through knockout of the murine TERC gene.111 These mice have markedly shorter telomere 
length than typical inbred mice and their telomeres degrade at a much faster rate. Numerous 
studies in Terc-/- mice have demonstrated that they have a much greater rate of chromosomal 
end-to-end fusions, limited viability after several generations, male and female infertility, 
embryonic mortality due to defective closure of the neural tube, small size and severe intestinal 
atrophy, spleen atrophy and reduced proliferation of B and T lymphocytes, impaired germinal 
center function, reduced angiogenic potential, reduced proliferation of bone marrow derived 
stem cells, heart dysfunction, and reduced proliferation of neural stem cells.110 These mice also 
display a lower incidence of cancer. Rescue with addition of telomerase (comparison to Terc+/- 
mice) restores homozygous knockout mice to a relatively normal phenotype with far less 
chromosomal instability.112 The large effect telomere length may have on longevity was recently 
demonstrated when researchers knocked in telomerase activity to aged telomerase-deficient mice 
with short telomeres.113 Before knock-in these mice exhibited very short telomeres and marked 
age-related degeneration across tissues. Knock-in of telomerase lengthened telomeres, reduced 
DNA damage signaling and associated cellular checkpoint responses, allowed resumption of 
proliferation in quiescent cultures, and eliminated degenerative phenotypes across multiple 
32 
organs including testes, spleens, and intestines. Somatic telomerase reactivation reversed 
neurodegeneration with restoration of proliferating Sox2(+) neural progenitors, Dcx(+) newborn 
neurons, and Olig2(+) oligodendrocyte populations. These studies provide strong evidence that a 
minimum telomere length is necessary for maintenance of viability and proper development in 
vertebrates. Nonetheless, they belie the difficulty in using model organisms to study telomere 
length because the telomerase-deficient mouse displays phenotypic characteristics that are far 
from normal mouse or human aging. 
 
2.7.5: Summary of previous findings on telomere length as a biomarker of aging 
Data derived from in vitro and in vivo studies strongly suggests telomere length reflects cellular 
senescence and oxidative stress. Data from epidemiologic and clinical studies is less conclusive. 
Although shorter LTL appears associated with older age, male gender, and white race, LTL has 
been inconsistently or not associated with other characteristics of aging or age-related chronic 
disease. Inconsistency may be partly due to differences between study populations, measurement 
methods, and statistical modeling, though it may also imply an association does not exist. 
Animal studies have provided important data on telomere dynamics and the impact of a 
minimum telomere length on organismal health, but because telomere length is highly species-
specific and alterations in model systems do not appear like normal aging, it is difficult to 
extrapolate conclusions from lower order animals to humans. Currently, it remains inconclusive 
if telomere length is a biomarker of aging for a whole organism or a biomarker of aging in 
specific tissues in human populations.     
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2.8: The lens 
The lens sits in the anterior chamber of the eye behind the cornea, aqueous humor, and iris, and 
in front of the vitreous humor. It is suspended by the ciliary zonules, which in turn pull on the 
lens to alter its conformation, allowing the lens to properly focus light on the retina. The lens is 
encased in a thin capsule. The lens itself has a central core, or nucleus, which is surrounded by 
the lens cortex. Thus, the structure has been likened to a candy peanut M&M, with the lens 
capsule represented by the thin candy coating encompassing the lens, the lens cortex represented 
by the chocolate covering, and the central lens nucleus represented by the peanut. The lens is 
roughly circular, convex when viewed from outside the body, and has distinct anterior and 
posterior faces.  
The lens is unique compared to other human tissues in that nuclear lens cells (primary 
fiber cells) are present at birth and remain essentially unchanged throughout life, so its contents 
are not altered by turnover or removal processes. The lens grows in thickness throughout life by 
cells progressively layering on the nucleus and building the cortex (secondary fiber cells), similar 
to the growth and appearance of an onion. More specifically, cells differentiate and migrate from 
the anterior lens epithelium to the rostral and caudal tips of the cortex, the lens poles. As the cells 
migrate to and turn at the poles, reaching a line termed the equator, they become secondary fiber 
cells, eventually flattening, lengthening, and stacking on each other. Throughout differentiation, 
migration, and flattening, the secondary fiber cells produce large amounts of lens crystallin, the 
natively clear protein that eventually comprises more than 90% of the protein mass of the lens, 
50% being alpha-crystallin.114 Simultaneously, secondary fiber cells degrade all their organelles, 
which if remaining would scatter light and render the lens useless. The end result is a core of 
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primary fiber cells surrounded by layers of secondary fiber cells that are cell membranes full of 
crystallin protein and very little else, including no organelles. 
 
2.8.1: Lens biology and associations with aging in model organisms and humans 
The biology of the human lens makes lens transparency a particularly attractive candidate 
biomarker of aging. Lens transparency decreases when crystallins, which are normally clear and 
water-soluble, undergo oxidation, glycation, and other biochemical changes that alter their 
conformation, causing them to aggregate, precipitate, and scatter light.114,115 Alpha-crystallin is 
composed of alpha-A (non-stress inducible) and alpha-B (stress inducible) crystallins, which 
both function as chaperones, proteins critical to maintaining cellular integrity by preserving 
protein conformation, especially under stress.114,116,117 Lens epithelial cells induced to 
overexpress alpha-A or alpha-B crystallin have enhanced resistance to thermal, photochemical, 
and other stress conditions.118,119 In contrast, knockout of the alpha-A crystallin gene causes 
higher levels of lens epithelium cell death, even without stress.120 Because lens crystallins exist 
in a relatively homogenous environment surrounded by other lens crystallins, they function to 
maintain the conformation of each other. Lens proteins that aggregate and precipitate reduce 
transparency directly but also indirectly by not being able to maintain the conformation of 
adjacent crystallins, which may in turn aggregate and precipitate. Lens transparency thus reflects 
the integrity of the crystallins and the ability of the lens to maintain protein conformation.   
In addition to the lens, alpha-A crystallin is found in embryonic tissue, pituitary gland, 
placenta, and spleen, while alpha-B crystallin is found in brain, kidney, heart, extraembryonic 
tissue, mammary gland, liver, muscle, testis, thymus, lung, pancreas, thyroid, skin, uterus, ovary, 
colon, diaphragm, limb, and placenta.121 In these tissues crystallin also acts as a chaperone. 
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Eerily, alpha-crystallin dysfunction or absence mimics an aging phenotype, particularly in 
skeletal muscle and brain. In alpha-B crystallin-knockout mice, there is marked and accelerated 
skeletal muscle degeneration (sarcopenia) and kyphosis.122 This is supported by other studies 
showing that alpha-B crystallin links the differentiation and apoptosis-resistance programs in 
myocytes, prevents apoptosis, and maintains the tubulin cytoskeleton in skeletal muscle cells.123-
125 In brain, alpha-B crystallin is present in limbic and paralimbic regions, which are commonly 
affected in Alzheimer’s patients, and the number of alpha-B crystallin positive neurons increases 
in parallel with neuronal loss.126 Alpha-B crystallin is upregulated in astrocytes associated with 
senile plaques and cerebral amyloid angiopathy in Alzheimer’s patients,127 and it inhibits 
aggregation of A-beta peptide in vitro.128 In summary, alpha-crystallins are intimately and 
ubiquitously involved in cellular maintenance that is necessary for survival with aging. Depletion 
of or defects in alpha-crystallin is associated with a range of age-related pathologies, while 
elevation of alpha-crystallin appears protective. Because alpha-crystallin is most prevalent and 
homogenous in the human lens, lens transparency might sensitively reflect the biologic integrity 
of a human during the lifespan.  
Strong evidence that the lens may reflect aging could come from studies of caloric 
restriction, which extends lifespan in several species.4 Unfortunately, although caloric restriction 
studies have begun in humans, restriction is usually short term, and the lens has not been 
examined in these studies. Nonetheless, phenotypic changes have been observed in the mouse 
and rat lens with caloric restriction. In several strains of mice and rats that display lifespan 
extension with caloric restriction, in vitro and in vivo analysis demonstrate restriction reduces 
onset of age-related cataract, slows decline in age-related proliferative capacity of lens 
epithelium, and reduces age-related lens epithelial telomere shortening.129-134 This provides 
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further evidence that the lens may register aging throughout the body, specifically processes 
which are affected by caloric restriction.  
Epidemiologic evidence that the lens may reflect aspect of organismal aging comes from 
studies of age-related cataract. In large ophthalmologic cohorts in the United States, Bahamas, 
and Australia, cataract has been associated with cardiovascular disease, diabetes, obesity, 
inflammation, smoking, sunlight exposure (a DNA-damaging agent), and mortality.135 
Furthermore, there is a significant reduction in the age-specific rate and lifetime cumulative 
incidence of age-related cataract in individuals >90 years old with preserved cognition, a group 
exhibiting successful aging.136 This evidence adds more weight to the potential usefulness of the 
lens as a biomarker of aging, though it is crucial to note that age-related cataract is a phenotype 
different from reduced lens transparency. Age-related cataract, or cataract surgery (a surrogate 
hard outcome), is a clinical phenotype derived from either physician diagnosis or medical billing 
codes whereas lens transparency is directly measured using optical devices. While age-related 
cataract is almost exclusively diagnosed in the latter half of life, lens transparency decreases 
beginning at age 14-15 years old.137 Cataractous lenses are different from aged human lenses in 
gene expression patterns.138 The clinical classification of the presence of “cataract” or “no 
cataract” also does not reflect the subtle morphological, histological, and biochemical changes 
that occur with lens aging, such as changes in lens curvature, thickness, or distensibility.137,139-141 
Subsequently, although previous studies of age-related cataract are supportive, new studies 
focused on lens transparency must be conducted to determine the validity of this different 
phenotype as a biomarker of aging. 
From a feasibility standpoint, lens transparency is easily acquired because it is measured 
non-invasively and non-hazardously using optical devices such as Scheimpflug slit-lamp 
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photography.137,142 It also provides a wide range, from 100% to 0% transparency, conceivably 
allowing fine risk stratification. Indeed, in the Aging Lens Substudy of the Cardiovascular 
Health Study, using Scheimpflug photography we detected a mean transparency of 76.61% (SD 
17.75%) and a range of lens transparency from 8.29%-99.82% in approximately 60 Caucasian 
and African-American participants aged 79-88. This exemplifies the wide variability of 
transparency that exists even amongst a group of older individuals with a narrow age range, 
reinforcing the idea that transparency might depict the biologic variability seen in aging.  
 
2.8.2: Measurement of lens transparency 
Lens transparency can be assessed in several ways. Originally, grading systems were developed 
to indicate the severity of opacity in studies of cataract. These include the Age-Related Eye 
Disease Study (AREDS) criteria,143  LOCS-III or the OCCCGS systems.144,145 During a dilated 
eye exam, a trained grader compares the participant’s lens to standardized photographs obtained 
with a photographic slit lamp. This adds to the complexity and duration of the eye exam and 
significantly increases cost, but it offers an accurate assessment of lens transparency. Depending 
on the system used and type of opacity examined (e.g., nuclear vs. cortical), measurements are 
ordinal, quasi-continuous, or fully continuous (e.g., 0-100% opacity). 
Other imaging techniques, such as Scheimpflug photography, can provide a more 
accurate assessment of the nucleus with computer-aided determination of lens transparency using 
linear densitometry, can be acquired quickly, and can allow finer quantification of transparency, 
but they can be expensive and require additional training.137,142,146 For Scheimpflug imaging, 
multiple measurements of each intact lens can be taken during a dilated eye exam. The optical 
density measurements are averaged to give a quantitative measurement of lens transparency for 
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each eye. Computerized assessment allows analysis of any part of the lens, which can provide 
more specific information, and should further minimize bias, though variability can result from 
some manual aspects of measurement such as marking which piece of the lens should be 
analyzed by the computer. Using Scheimpflug photography, Datiles et al. originally reported the 
intraclass correlation for the mean densities in the nucleus was 0.95, for the anterior cortex was 
0.88, and for the posterior cortex was 0.84.142 Excellent reproducibility has been reported by 
others.137,146-150 Nuclear cataract lens density determined with Scheimpflug imaging has also 
been highly correlated with measurements taken using the LOCS-III grading criteria.150  
 
2.8.3: Summary of previous research on the lens as a biomarker of aging 
The biology of the lens makes it an attractive candidate marker of aging though it has been 
virtually unexplored in human aging studies. Studies in rodents, particularly those using 
crystallin gene knockout and caloric restriction, suggest the lens may register aspects of aging 
and that crystallins may play a key role in maintaining tissue integrity across tissues and 
throughout the lifespan, particularly in response to common chemical and molecular stressors. 
Human studies are dominated by those of diagnosed age-related cataract, a phenotype distinct 
from reduced lens transparency. In these studies, cataract has been associated with mortality, 
age-related chronic disease (particularly diabetes, cardiovascular disease, and potentially 
dementia), and behavioral risk factors for accelerated aging and disease (e.g., smoking). Studies 
of lens transparency measured with direct imaging have been concerned with developing the 
imaging techniques themselves and calculating their reproducibility and concordance with 
cataract grading systems rather than investigating the association of lens transparency to markers 
of aging and disease. These studies illustrate the high reliability of Scheimpflug photography and 
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that lens transparency decreases with age beginning in adolescence. To date, there is little 
epidemiologic data on the association of lens transparency and measurements of aging and 
disease. Because cataract, cataract surgery, and lens transparency are distinct phenotypes, it is 
unknown whether they will have similar associations with markers of aging and disease, i.e., 
whether these different phenotypes are exchangeable in studies of aging. Determining their 
relative validity requires calculating associations between cataract or lens transparency and 
markers of aging and disease in the same cohort using similar techniques. Generating this data 
may be the most worthwhile to vet lens transparency as a biomarker of aging. 
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Table 2.9.1: Examples of potential biomarkers of aging under investigation 
Level of 
organization 
Marker Potentially measured aspect of 
aging 
Potentially associated 
disease if low* 
Potentially associated 
disease if high* 
Genetic DNA Acetylation Transcriptional accessibility, 
epigenetic imprinting 
  
 DNA Methylation Transcriptional accessibility, 
epigenetic imprinting 
 microRNA expression Post-transcriptional regulation 
 Thymine dimer DNA repair capacity, radiation 
exposure 
Cancer, Xeroderma 
pigmentosum 
 8-oxoguanine DNA repair capacity, oxidation Cancer 
Molecular & 
Cellular 
Interleukin-6 Inflammation, infection, oxidation Cardiovascular disease, 
cancer, diabetes, frailty, 
sarcopenia, infection, 
cognitive decline 
 C-reactive protein Inflammation, infection, oxidation, 
liver function 
Liver disease Cardiovascular disease, 
cancer, diabetes, frailty, 
sarcopenia, infection, 
cognitive decline 
 Telomere length Inflammation, oxidation, cellular 
senescence, oncogenic potential 
Idiopathic pulmonary 
fibrosis, bone marrow 
failure syndrome, 
dyskeratosis 
congenita, Werner's 
syndrome 
Cancer 
 p16 Cellular senescence, oncogenic 
potential 
Cancer  
 Dehydroepiandrosterone 
sulfate 
Sex steroid hormone reserve  
 Insulin-like growth factor Energy metabolism, growth Growth insufficiency 
 Advanced glycation end 
products 
Non-enzymatic glycation and 
oxidation of proteins and lipids 
Diabetes, cardiovascular 
disease, dementia 
 Isoprostanes Lipid peroxidation, oxidation Neurodegeneration, coronary 
heart disease 
 KLOTHO Insulin sensitivity, Vitamin D 
regulation  
Hyperphosphatemia, 
reduced bone 
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mineralization, kidney 
disease 
 Lipofuscin Fatty acid oxidation, lysosomal 
digestion 
Lipofuscinoses 
(neurodegeneration), liver 
disease, kidney disease 
Tissue & 
Organ 
Aortic calcification Arteriosclerosis  Arteriosclerosis 
 Pulse wave velocity Arterial stiffness  Hypertension 
 Forced expiratory volume Pulmonary reserve, muscle strength COPD  
 Brain volume Cognitive reserve Dementia  
 White matter 
hyperintensities 
Integrity of white matter and 
subcortical tract connectivity 
Hypertension, dementia 
 Cystatin-C Kidney function, inflammation Kidney disease, 
cardiovascular disease 
 Nerve conduction 
amplitude, monofilament 
sensitivity 
Peripheral nerve function Peripheral neuropathy, 
diabetes 
 Lens transparency Maintenance of protein conformation, 
glycation, oxidation 
Cataract  
 Lean mass Sarcopenia Frailty  
Organismal 
function 
Gait speed Muscle function, peripheral and 
central nervous system function, 
cardiopulmonary fitness 
 Digit Symbol Substitution 
Test 
Processing speed, visual-motor 
function 
Dementia  
 Fatigue Energy metabolism, 
cardiopulmonary fitness, mental 
wellbeing  
 Activities of daily living Mental and physical health  
  Frailty Energy, strength, mental wellbeing 
*Associations may be correlative and/or causal. Most data is derived from human studies, though data for some markers (e.g., KLOTHO) is 
predominantly from animal models. 
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Table 2.9.2: Association of telomere length with age, sex, race, markers of health status, age-related chronic disease, and markers of 
inflammation and oxidation 
Study Sample Study Study 
design 
Variable Measurement 
method 
Association P-value 
Batty 
2009 
1542 Caucasian men, age 45-
64, without MI 
WOSCOPS Cross 
sectional 
Age (year) PCR -8.5 bp 0.001 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Age (year) Southern blot -26 bp <0.0001 
Benetos 
2001 
193 Caucasian men and 
women, age 54-58, not on 
hypertensive medication 
 Cross 
sectional 
Age (year) Southern blot r = -0.45 (Men), 
r = -0.48 
(Women) 
<0.0001, 
<0.0001 
Benetos 
2004 
163 men, age 58-65, with 
chronic treated essential 
hypertension 
 Cross 
sectional 
Age (year) Southern blot r = -0.25 <0.01 
Brouilette 
2003 
203 cases with MI before age 
50, 180 controls 
 Cross 
sectional 
Age (year) Southern blot NA <0.0001 
Cherkas 
2008 
2401 Caucasian twins, age 
18-81 
TwinsUK Cross 
sectional 
Age (year) Southern blot r = -0.38 <0.001 
Demissie 
2006 
327 Caucasian men, age 40-
89 
FHS Cross 
sectional 
Age (year) Southern blot r = -0.41 <0.0001 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
Age (year) Southern blot -31 bp <0.001 
Hunt 2008 1742 Caucasian and 711 
African-American, age 19-93 
NHLBI-FHS, 
BHS 
Cross 
sectional 
Age (year) Southern blot  -20 bp 
(Caucasian), -29 
bp (African-
American) 
<0.0001, 
<0.0001 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
Age (year) PCR r = -0.002 
(Men), -0.230 
(Women) 
0.96, 
<0.001 
Roux 
2009 
981 Caucasian, African 
American and Hispanic men 
and women, age 45-84 
MESA Cross 
sectional 
Age (year) PCR -0.003 T/S 
(Men), -0.007 
T/S (Women) 
0.0002, 
<0.0001 
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Sanders 
2009 
2750 Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional 
Age (year) PCR r = -0.065 
(Men), -0.055 
(Women) 
0.017, 
0.038 
Tang 2010 963 Chinese men and 904 
women, age 65+ 
 Cross 
sectional 
Age (year) PCR Negatively 
correlated in 
men but not 
women 
0.037, 
0.78 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Male Southern blot -172 bp <0.0001 
Benetos 
2001 
193 Caucasian men and 
women, age 54-58, not on 
hypertensive medication 
 Cross 
sectional 
Male Southern blot -280 bp (age-
adjusted) 
0.016 
Hunt 2008 1742 Caucasian and 711 
African-American, age 19-93 
NHLBI-FHS, 
BHS 
Cross 
sectional 
Male Southern blot FHS: -120 bp 
(Caucasian), -
260 bp (African-
American). 
BHS: 10 bp 
(Caucasian), -
130 bp (African-
American) 
FHS: 
<0.0001 
BHS: 
0.26 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
Male PCR Shorter in men <0.0001 
Roux 
2009 
981 Caucasian, African 
American and Hispanic men 
and women, age 45-84 
MESA Cross 
sectional 
Male PCR -0.041 T/S 0.0005 
Tang 2010 963 Chinese men and 904 
women, age 65+ 
 Cross 
sectional 
Male PCR -550 bp <0.001 
Chen 
2009 
472 Caucasian and 190 
African American men and 
women, age 26-48 
BHS Cross 
sectional 
Caucasian race Southern blot -541 bp (Men), -
517 (Women) 
<0.001, 
<0.001 
Hunt 2008 1742 Caucasian and 711 
African-American, age 19-93 
NHLBI-FHS, 
BHS 
Cross 
sectional 
Caucasian race Southern blot FHS: -180 bp 
(Men), -320 bp 
All 
<0.0001 
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(Women). BHS: 
-500 bp (Men), -
680 bp (Women) 
Roux 
2009 
981 Caucasian, African 
American and Hispanic men 
and women, age 45-84 
MESA Cross 
sectional 
Caucasian race PCR -0.041 T/S (vs. 
African-
American), -
0.044 (vs. 
Hispanic) 
0.025, 
0.015 
Batty 
2009 
1542 Caucasian men, age 45-
64, without MI 
WOSCOPS Cross 
sectional 
BMI (kg/m2) PCR -1 bp 0.79 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
BMI (kg/m2) Southern blot -4 bp (Men), -4 
bp (Women) 
0.41, 
0.35 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
BMI (kg/m2) Southern blot -10 bp 0.13 
Hunt 2008 1742 Caucasian and 711 
African-American, age 19-93 
NHLBI-FHS, 
BHS 
Cross 
sectional 
BMI (kg/m2) Southern blot r = -0.071 0.002 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
BMI (kg/m2) PCR r = -0.041 
(Men), -0.106 
(Women) 
0.35, 
0.021 
O'Donnell 
2008 
1062 Caucasian men and 
women, age 33-86 
FHS Cross 
sectional 
BMI (kg/m2) Southern blot r = -0.08 0.01 
Roux 
2009 
981 Caucasian, African 
American and Hispanic men 
and women, age 45-84 
MESA Cross 
sectional 
BMI (kg/m2) PCR 0.001 T/S 0.58 
Valdes 
2005 
1122 Caucasian women 
twins, age 18-76 
TwinsUK Cross 
sectional 
BMI (kg/m2) Southern blot -0.077 TRF 0.031 
Yang 
2009 
Chinese, 379 controls and 
388 hypertensive patients, 
age 30-80 
 Cross 
sectional 
BMI (kg/m2) PCR Controls NS, 
Cases NS 
0.61, 
0.24 
Batty 
2009 
1542 Caucasian men, age 45-
64, without MI 
WOSCOPS Cross 
sectional 
Ever smoking PCR 35 bp 0.17 
O'Donnell 1062 Caucasian men and FHS Cross Current smoking Southern blot -130 bp 0.02 
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2008 women, age 33-86 sectional 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Smoking (pack-
year) 
Southern blot -20 bp (Men), 6 
bp (Women) 
0.16, 
0.75 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
Smoking (pack-
year) 
Southern blot -2 bp 0.27 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
Smoking (pack-
year) 
PCR r = 0.084 (Men), 
-0.115 (Women) 
0.46, 
0.23 
Roux 
2009 
981 Caucasian, African 
American and Hispanic men 
and women, age 45-84 
MESA Cross 
sectional 
Smoking (pack-
year) 
PCR -0.0007 T/S 0.054 
Valdes 
2005 
1122 Caucasian women 
twins, age 18-76 
TwinsUK Cross 
sectional 
Smoking (pack-
year) 
Southern blot -0.11 TRF 0.045 
Batty 
2009 
1542 Caucasian men, age 45-
64, without MI 
WOSCOPS Cross 
sectional 
Alcohol 
(units/week) 
PCR 3 bp 0.93 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Alcohol 
(units/week) 
Southern blot -8 bp (Men), -7 
bp (Women) 
0.63, 
0.68 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Physical activity 
(MET x 
times/wk) 
Southern blot 25 bp (Men), -3 
bp (Women) 
0.15, 
0.81 
Cherkas 
2008 
2401 Caucasian twins, age 
18-81 
TwinsUK Cross 
sectional 
Physical activity 
(questionnaire) 
Southern blot -88 to -213 bp 
(depending on 
comparison) 
<0.05 
Roux 
2009 
981 Caucasian, African 
American and Hispanic men 
and women, age 45-84 
MESA Cross 
sectional 
Leisure MET-
mins (1000 s) 
PCR -0.009 T/S 0.13 
Sanders 
2009 
2750 Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional 
Weekly physical 
activity (kcal) 
PCR r = -0.036 
(Men), -0.029 
(Women) 
0.19, 
0.28 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Total cholesterol 
(10 mg/dL) 
Southern blot -2 bp (Men), 1 
bp (Women) 
0.75, 
0.84 
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Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
Total cholesterol 
(10 mg/dL) 
PCR r = 0.026 (Men), 
0.070 (Women) 
0.58, 
0.13 
Yang 
2009 
Chinese, 379 controls and 
388 hypertensive patients, 
age 30-80 
 Cross 
sectional 
Total cholesterol 
(10 mg/dL) 
PCR Controls NS, 
Cases NS 
0.97, 
0.18 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
HDL (10 mg/dL) Southern blot -20 bp (Men), 55 
bp (Women) 
0.15, 
0.64 
Chen 
2009 
472 Caucasian and 190 
African American men and 
women, age 26-48 
BHS Cross 
sectional 
HDL (10 mg/dL) Southern blot -31 bp 
(childhood), -44 
bp (adulthood) 
0.024, 
0.058 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
HDL (10 mg/dL) PCR r = 0.111 (Men), 
0.072 (Women) 
0.053, 
0.41 
Yang 
2009 
Chinese, 379 controls and 
388 hypertensive patients, 
age 30-80 
 Cross 
sectional 
HDL (10 mg/dL) PCR Controls inverse 
association, 
Cases NS 
0.046, 
0.24 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
LDL (10 mg/dL) Southern blot -0.7 bp (Men), 3 
bp (Women) 
0.93, 
0.70 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
LDL (10 mg/dL) PCR r = 0.040 (Men), 
0.160 (Women) 
0.49, 
0.07 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Triglycerides (10 
mg/dL) 
Southern blot 2 bp (Men), 1 bp 
(Women) 
0.21, 
0.83 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
Triglycerides (10 
mg/dL) 
PCR r = -0.047 
(Men), 0.004 
(Women) 
0.34, 
0.95 
Yang 
2009 
Chinese, 379 controls and 
388 hypertensive patients, 
age 30-80 
 Cross 
sectional 
Triglycerides (10 
mg/dL) 
PCR Controls NS, 
Cases NS 
0.48, 
0.051 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Glucose (10 
mg/dL) 
Southern blot 4 bp (Men), -25 
bp (Women) 
0.85, 
0.29 
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Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
Glucose (10 
mg/dL) 
Southern blot -15 bp 0.06 
Sanders 
2009 
2750 Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional 
Glucose (10 
mg/dL) 
PCR r = -0.061 
(Men), -0.045 
(Women) 
0.025, 
0.089 
Yang 
2009 
Chinese, 379 controls and 
388 hypertensive patients, 
age 30-80 
 Cross 
sectional 
Glucose (10 
mg/dL) 
PCR Controls NS, 
Cases NS 
0.72, 
0.87 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
OGTT 0 min PCR r = -0.040 
(Men), -0.001 
(Women) 
0.41, 
0.98 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
OGTT 120 min PCR r = -0.202 
(Men), -0.063 
(Women) 
0.045, 
0.45 
Demissie 
2006 
327 Caucasian men, age 40-
89 
FHS Cross 
sectional 
HOMA-IR score Southern blot r = -0.16 0.007 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
Insulin (10 
mg/dL) 
Southern blot -100 bp 0.009 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
Insulin (10 
mg/dL) 
PCR r = -0.026 
(Men), 0.096 
(Women) 
0.65, 
0.28 
Sanders 
2009 
2750 Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional 
Insulin (10 
mg/dL) 
PCR r = -0.064 
(Men), -0.069 
(Women) 
0.028, 
0.014 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
SBP (10 mmHg) Southern blot 15 bp (Men), -4 
bp (Women) 
0.34, 
0.80 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
SBP (10 mmHg) Southern blot -34 bp 0.15 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
SBP (10 mmHg) PCR r = 0.064 (Men), 
-0.038 (Women) 
0.15, 
0.41 
Yang 
2009 
Chinese, 379 controls and 
388 hypertensive patients, 
 Cross 
sectional 
SBP (10 mmHg) PCR Controls NS, 
Cases NS 
0.09, 
0.81 
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age 30-80 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
DBP (10 mmHg) Southern blot 17 bp (Men), -5 
bp (Women) 
0.40, 
0.82 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
DBP (10 mmHg) Southern blot -83 bp 0.06 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
DBP (10 mmHg) PCR r = 0.013 (Men), 
0.010 (Women) 
0.77, 
0.82 
Yang 
2009 
Chinese, 379 controls and 
388 hypertensive patients, 
age 30-80 
 Cross 
sectional 
DBP (10 mmHg) PCR Controls NS, 
Cases NS 
0.08, 
0.69 
Benetos 
2001 
193 Caucasian men and 
women, age 54-58, not on 
hypertensive medication 
 Cross 
sectional 
Pulse pressure 
(mmHg) 
Southern blot -3.7 / TRF 
fragment (Men), 
0.4 / TRF 
fragment 
(Women) 
0.005, 
NS 
Nordfjall 
2008 
989 Caucasian, age 48-68 MDCC, NS-
MONICA 
Cross 
sectional 
Pulse pressure 
(mmHg) 
PCR r = 0.075 (Men), 
-0.056 (Women) 
0.09, 
0.23 
Benetos 
2001 
193 Caucasian men and 
women, age 54-58, not on 
hypertensive medication 
 Cross 
sectional 
Pulse wave 
velocity (m/sec) 
Southern blot -0.5 / TRF 
fragment (Men), 
-0.2 / TRF 
fragment 
(Women) 
0.047, 
NS 
Benetos 
2004 
163 men, age 58-65, with 
chronic treated essential 
hypertension 
 Cross 
sectional 
Presence of 
carotid artery 
plaque 
Southern blot -0.22 TRF length 
with presence of 
carotid plaque 
<0.05 
De Meyer 
2009 
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Presence of 
carotid artery 
plaque 
Southern blot -0.006 / TRF 
(Men), -0.202 / 
TRF (Women) 
0.96, 
0.09 
De Meyer 
2009 
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Presence of 
femoral artery 
plaque 
Southern blot -0.101 / TRF 
(Men), -0.251 / 
TRF (Women) 
0.28, 
0.02 
De Meyer 2509 Caucasian men and Asklepios Cross Presence of Southern blot -0.083 / TRF 0.36, 
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2009 women, age 35-55, without 
overt CVD 
study sectional carotid or 
femoral plaque 
(Men), -0.243 / 
TRF (Women) 
0.01 
De Meyer 
2009 
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Carotid intima-
media thickness 
(mm) 
Southern blot -0.003 / TRF 
(Men), -0.003 / 
TRF (Women) 
0.54, 
0.40 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
Common carotid 
intima-media 
thickness (mm) 
Southern blot -260 bp 0.10 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
Internal carotid 
intima-media 
thickness (mm) 
Southern blot -110 bp 0.07 
O'Donnell 
2008 
1062 Caucasian men and 
women, age 33-86 
CHS Cross 
sectional 
Internal carotid 
intima-media 
thickness (mm) 
Southern blot r = -0.055 0.15 
De Meyer 
2009 
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
Femoral intima-
media thickness 
(mm) 
Southern blot -0.004 / TRF 
(Men), 0.000 / 
TRF (Women) 
0.73, 
0.99 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
Ankle-brachial 
index 
Southern blot 270 bp 0.09 
Mainous 
2010 
325, aged 40–64, free of 
diagnosed diabetes, CHD, 
stroke and cancer 
 Cross 
sectional 
Coronary artery 
calcium 
PCR r = -0.15 0.009 
Brouilette 
2003 
203 cases with MI before age 
50, 180 controls 
 Cross 
sectional 
MI before age 50 Southern blot -300 bp <0.0001 
Honig 
2006 
125 Demented cases, 132 
Non-demented controls, age 
66-103 
WHICAP Cross 
sectional 
Dementia PCR -0.058 T/S 0.034 
Honig 
2006 
125 Demented cases, 132 
Non-demented controls, age 
66-103 
WHICAP Cross 
sectional 
ApoE4 allele (≥1) PCR -0.042 T/S NS 
Yaffe 
2009 
2734 Non-demented 
Caucasian and African-
American men and women, 
HABC Cross 
sectional, 
longitudinal 
ApoE4 allele (≥1) PCR Not available 0.16 
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age 70-79 
Yaffe 
2009 
2734 Non-demented 
Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional, 
longitudinal 
3MS PCR Not available 0.28 
Yaffe 
2009 
2734 Non-demented 
Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional, 
longitudinal 
DSST PCR Not available 0.02 
Sanders 
2009 
2750 Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional 
Hip BMD PCR r = -0.017 
(Men), -0.007 
(Women) 
0.53, 
0.79 
Tang 2010 963 Chinese men and 904 
women, age 65+ 
 Cross 
sectional 
Hip BMD PCR 2 bp (Men), 0 bp 
(Women) 
0.42, 
0.99 
Sanders 
2009 
2750 Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional 
Femoral neck 
BMD 
PCR r = -0.003 
(Men), -0.016 
(Women) 
0.92, 
0.55 
Tang 2010 963 Chinese men and 904 
women, age 65+ 
TwinsUK Cross 
sectional 
Femoral neck 
BMD 
PCR 3 bp (Men), -1 
bp (Women) 
0.11, 
0.46 
Valdes 
2007 
2150 Caucasian women 
twins, age 18-80 
TwinsUK Cross 
sectional 
Femoral neck 
BMD 
Southern blot r = 0.040 0.052 
Valdes 
2007 
2150 Caucasian women 
twins, age 18-80 
TwinsUK Cross 
sectional 
Forearm BMD Southern blot r = 0.054 0.013 
Valdes 
2007 
2150 Caucasian women 
twins, age 18-80 
TwinsUK Cross 
sectional 
Spine BMD Southern blot r = 0.058 0.005 
Bekaert 
2007  
2509 Caucasian men and 
women, age 35-55, without 
overt CVD 
Asklepios 
study 
Cross 
sectional 
IL-6 (highest 
half) 
Southern blot -133 bp (Men), -
83 bp (Women) 
<0.01, 
>0.05 
Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
IL-6 (pg/mL) Southern blot -50 bp 0.03 
Sanders 
2009 
2750 Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional 
IL-6 PCR r = -0.074 
(Men), -0.008 
(Women) 
0.008, 
0.77 
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Fitzpatrick 
2007 
419 men and women, age 65-
93 
CHS Cross 
sectional 
CRP (mg/L) Southern blot -59 bp 0.02 
Sanders 
2009 
2750 Caucasian and African-
American men and women, 
age 70-79 
HABC Cross 
sectional 
CRP PCR r = -0.051 
(Men), 0.004 
(Women) 
0.063, 
0.88 
Demissie 
2006 
327 Caucasian men, age 40-
89 
FHS Cross 
sectional 
Isoprostane 
urinary 8-epi-
PGF2α 
Southern blot r = -0.16 0.005 
Richards 
2008 
1319 Caucasian twins, age 
18-81 
TwinsUK Cross 
sectional 
Homocysteine 
(highest tertile) 
Southern blot -111 bp 0.004 
Study acronyms: BHS, Bogalusa Heart Study. CHS, Cardiovascular Health Study. FHS, Framingham Heart Study. HABC, Health, Aging, 
and Body Composition Study. MDCC, Malmö Diet and Cancer Cohort. MESA, Multi-Ethnic Study of Atherosclerosis. NS-MONICA, 
Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Diseases. NHLBI-FHS, National Heart, Lung, and Blood 
Institute Family Heart Study. WHICAP, Washington Heights-Inwood Columbia Aging Project. WOSCOPS, West of Scotland Coronary 
Prevention Study.  
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3.0 SPECIFIC AIMS 
 
 
LTL and lens transparency require further validation as biomarkers of aging and/or age-related 
chronic disease. We aim to overcome limitations of previous studies to advance understanding of 
the usefulness of these markers.  
 
Leukocyte telomere length 
Most studies of LTL concern only clinically diagnosed disease, but disease builds over time and 
can exist in subclinical, preclinical, undiagnosed, or misdiagnosed states. Depending on the 
selection criteria to identify a study cohort (e.g., demographics, function, health status), the 
burden of subclinical disease varies widely, but in general, in cohorts of older individuals 
without clinically diagnosed disease, the prevalence and severity range of subclinical disease can 
be substantial when assessed using noninvasive methods.151-154 Importantly, undiagnosed disease 
powerfully predicts incident adverse events independent of diagnosed disease.13,151-157 
Subsequently, previous studies relying on yes/no disease categorization may have missed 
associations between LTL and age-related disease. Moreover, studies of LTL and age-related 
disease have focused on a single organ or biological system rather than “disease burden” across 
systems. This distinction is relevant since LTL apparently records systemic burden of 
inflammation and oxidative stress and may report a synchrony of aging throughout the body. 
Fortunately, in the Cardiovascular Health Study, an index of disease burden has been constructed 
54 
and validated as a predictor of mortality and incident disability independent of age and diagnosed 
disease.13 
Specific aim 1: Using a more encompassing depiction of health, disease burden, which 
can be defined as the sum of noninvasively measured markers of structure or function in different 
organ systems, we determined if: 1) shorter LTL is associated with greater age-related disease 
burden; 2) shorter LTL is less strongly associated with disease in individual systems, or 
diagnosed chronic conditions (cardiovascular disease, stroke, pulmonary disease, diabetes, 
kidney disease, arthritis, or depression). 
 
Lens transparency 
It is unknown whether lens transparency measured on a continuous scale, diagnosis of cataract, 
or cataract surgery are equivalently useful to investigate the lens as a potential biomarker of 
aging. Determining which measure of lens transparency is best will enable researchers to more 
effectively validate lens transparency as a biomarker. To explore these different phenotypes, we 
studied the association of the lens with LTL in two groups of individuals: 1) a large cohort of 
community-dwelling older adults, the Health, Aging and Body Composition Study (Health 
ABC), in which participants self-reported physician diagnosis of cataract and cataract surgery; 2) 
an ophthalmic sub-study of Health ABC, the Age-Related Maculopathy Ancillary Study 
(ARMA), which had more sensitive measurement of cataract severity using AREDS grading 
criteria whereby a trained examiner graded cataract severity using standard photos during a slit 
lamp exam. Using these two groups we were able to distinguish lens transparency, illustrated by 
very clear lenses according to AREDS grading criteria, from cataract, illustrated by self-report of 
physician diagnosis of cataract or cataract surgery.  
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Specific aim 2: To determine if 1) longer LTL is associated with a lower prevalence of 
self-reported cataract or cataract surgery; 2) longer LTL is associated with a lower incidence of 
cataract surgery; and 3) longer LTL is associated with a lower odds of lens opacity measured 
using AREDS grading criteria. 
Although the loss of lens transparency correlates with increasing age, it had not been 
examined with respect to the presence of other markers of aging or subclinical diseases. For 
better enumeration of the association between directly-measured lens transparency and aging or 
disease, we created the Aging Lens Sub-study to the Healthy Women Study. The Healthy 
Women Study was a community-based longitudinal cohort study that began in 1983-84 and was 
refunded for a fourth examination of the determinants of risk factor changes among women 
during peri- and postmenopause. When participants returned for continued evaluation, we added 
a measure of lens transparency using Scheimpflug photography, which uses linear densitometry 
to provide a quantitative measure of transparency. Again, to distinguish lens transparency from 
cataract, we also recorded self-report of cataract surgery. We conducted a cross-sectional study 
of the association of current measures of aging and disease with lens transparency and cataract 
surgery, and to more carefully investigate temporality, we conducted a retrospective longitudinal 
study by testing the association of previous measures of aging and disease with current lens 
transparency or history of cataract surgery. 
Specific aim 3: To determine the association of lens transparency and cataract surgery 
to 1) risk factors for coronary atherosclerosis, the extent of noninvasively measured coronary 
atherosclerosis, fasting plasma glucose or insulin; 2) markers of cognitive function.  
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4.1  ABSTRACT 
 
Background: Most studies of leukocyte telomere length (LTL) focus on diagnosed disease in 
one system. A more encompassing depiction of health is disease burden, defined here as the sum 
of noninvasively measured markers of structure or function in different organ systems. We 
determined if: 1) shorter LTL is associated with greater age-related disease burden; 2) shorter 
LTL is less strongly associated with disease in individual systems, or diagnosed chronic 
conditions (cardiovascular disease, stroke, pulmonary disease, diabetes, kidney disease, arthritis, 
or depression). 
 
Methods: LTL was measured by Southern blots of terminal restriction fragment length. Age-
related disease was measured noninvasively and included carotid intima-media thickness, lung 
vital capacity, white matter grade, cystatin-C, and fasting glucose; each graded 0 (best tertile), 1 
(middle tertile), or 2 (worst tertile); and summed (0 to 10) to estimate disease burden. Of 419 
participants randomly selected for LTL measurement, 236 had disease burden assessed (mean 
(SD) age 74.2 (4.9) years, 42.4% male, 86.8% white, 13.2% black). 
 
Results: Mean (SD) LTL was 6312 (615) bp and disease score was 4.7 (2.1) points. A SD higher 
disease score (β(SE) = -132(47) bp, P<0.01), age (β(SE) = -107(46), P=0.02), or carotid 
thickness (β(SE) = -95(40) bp, P=0.02) was associated with shorter LTL but diagnosed 
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conditions or number of conditions were not associated with LTL. Disease score attenuated the 
effect of age on LTL by 35%.  
 
Conclusions: LTL was associated with a characterization of age-related disease burden across 
multiple physiologic systems which was comparable to, but independent of, its association with 
age. 
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4.2  BACKGROUND 
 
Although biologic age may be impossible to define completely, it will be better understood by 
uncovering biomarkers of aging. In the future these biomarkers might guide preventive or 
therapeutic interventions before clinical onset of age-related disease. Leukocyte telomere length 
(LTL) might be such a biomarker because it ostensibly records the accruing burden of 
inflammation and oxidative stress, processes thought to contribute to aging and disease 
pathogenesis.23,25,158 LTL undergoes progressive shortening with age and in the general 
population it is comparatively short in individuals with atherosclerosis or those at risk for this 
aging-related disease.159 The evidence for LTL as an overall biomarker of aging remains unclear, 
though, due to variation in the strength of detected associations, differences in results based on 
measurement method and selected outcome, lack of data coupling longitudinal measurements of 
LTL and aging phenotypes, and theoretical considerations of whether a single marker can 
accurately and strongly record aging across the lifespan.26,101,160   
Most studies of LTL concern only clinically diagnosed disease, but in cohort studies of 
older individuals without clinically diagnosed disease, the prevalence and severity range of 
subclinical disease can be substantial when assessed using several noninvasive methods.151-154 
Furthermore, undiagnosed disease can powerfully predict incident adverse events independent of 
diagnosed disease.151-157 Defining disease in categorical (yes/no) terms is imprecise, whereas 
using quantitative biomarkers might provide a more realistic picture of age-related disease load. 
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Therefore previous studies relying on disease categorization may have missed associations 
between LTL and age-related disease. 
Most studies exploring the links between LTL and age-related disease have focused on a 
single organ or biological system rather than “disease burden” across systems. Here, we define 
“disease burden” as the sum of noninvasively measured markers of age-related dysfunctions in 
structure or physiology of different organ systems. This distinction is relevant since LTL 
apparently records systemic burden of inflammation and oxidative stress. Thus, a study of LTL 
and disease burden is warranted to clarify the validity of LTL as a biomarker of aging or age-
related disease. 
Recently, Newman et al. developed a physiologic index of comorbidity (index), a 10-
point scale that tabulates the severity of age-related chronic disease using noninvasive tests of the 
vasculature, lungs, kidneys, brain, and glucose metabolism.13 This estimates an individual’s 
disease burden regardless of whether disease is clinically recognized. Given its more continuous 
range it demonstrated the spectrum of chronic disease in a general population of community-
dwelling older adults. The index explained 40% of the age effect on mortality risk and illustrated 
that high disease burden, even when clinically unrecognized, was significantly associated with 
mobility limitation and failure to complete activities of daily living. The index appears to be a 
valid measure of disease burden and stratifies individuals into a wide range of risk. 
Using data on LTL and age-related disease burden from the Cardiovascular Health Study 
(CHS), we conducted this analysis to test two hypotheses: 1) shorter LTL is associated with 
greater age-related disease burden; 2) shorter LTL is less strongly associated with disease in 
individual systems, or diagnosed chronic conditions (cardiovascular disease, stroke, pulmonary 
disease, diabetes, kidney disease, arthritis, or depression). 
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4.3  RESEARCH DESIGN AND METHODS 
 
4.3.1: Population 
The CHS is an ongoing community-based study of cardiovascular risk in 5888 men and women 
over the age of 65 years, from four regions of the United States.161 The cohort was enrolled in 
1989-1990 (N=5201) and was supplemented with added minority recruitment in 1992-1993 
(N=687). Participants and eligible household members were identified from a random sample of 
Medicare enrollees at each field center. Participants were ≥65 years old and to be eligible they 
could not have cancer under active treatment, could not be wheelchair- or bed-bound in the 
home, and did not plan to move out of the area within 3 years. Using blood samples from the 
1992-1993 examination, 419 CHS participants were originally randomly selected for LTL 
measurement. Of these, 236 had index scores available and form the study population for this 
analysis (mean (SD) age 74.2 (4.9) years, range 65-91 years, interquartile range 71-77 years, 
42.4% male, 86.8% white, 13.2% black). Participants without index scores available were less 
educated (61.2% with less than a college education vs. 49.6% with less than a college education, 
P=0.02), less likely to be white (76.0% vs. 86.4% vs, P<0.01), and had high fibrinogen (334 
mg/dL vs. 316 mg/dL, P=0.01). They had similar LTL (6312 bp vs. 6367 bp, P=0.36), age (74.2 
years vs. 74.2 years, P=0.97), gender (39.3% men vs. 42.4% men, P=0.53), smoking history 
(53.6% ever smoked vs. 51.3% ever smoked, P=0.64), body mass index (BMI) (27.8 kg/m2 vs. 
26.9 kg/m2, P=0.06), C-reactive protein (CRP) (3.02 mg/L vs. 2.59 mg/L, P=0.12), and total 
cholesterol, high density lipoprotein cholesterol, and triglycerides (all P>0.3), indicating that 
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selection bias was likely minimal. The CHS is approved by the Institutional Review Boards of all 
participating institutions. 
 
4.3.2: Physiologic index of comorbidity 
The instruments and methods used to construct the index have been described previously.13 
Briefly, the clinical examination conducted in 1992-1993 included cardiovascular and pulmonary 
function tests, blood tests for glucose tolerance and kidney function, and a brain MRI. The 
choice of tests to include in the index was based on previous reports that each is individually an 
important predictor of mortality, and that each represents a major, common age-related chronic 
disease.161,162 Carotid ultrasound was obtained in the left and right internal and common carotid 
arteries to assess near and far wall thicknesses and Doppler flow. The mean of the maximum 
wall thickness of the internal carotid artery was used to represent the extent of vascular 
disease.163 Spirometry was conducted according to the standards of the American Thoracic 
Society.161 Fasting glucose was assessed as described previously.164 Cystatin-C, a serum marker 
of glomerular filtration rate, was assessed using a BNII nephelometer that used a particle-
enhanced immunonephelometric assay.165 Brain MRI was obtained according to a standard 
scanning protocol and data was interpreted at a central MRI Reading Center by a neurologist 
trained in a standardized protocol.166 The white matter grade score was used to indicate small-
vessel vascular disease in the brain.162 
To construct the index, each of the five measures was divided into three groups with the 
best values classified as 0 and the worst as 2.13 Although the choice of cut points was arbitrary, 
the best score of ‘‘0’’ was generally found to represent a healthy normal value, and values of 
‘‘2’’ were in the range of individuals with diagnosed chronic disease. Individual scores were 
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summed for a total score ranging from 0 to 10. For the carotid wall thickness, tertile cut points 
were scored as 0: 0.60–1.06 mm, 1: 1.06–1.53 mm, 2: 1.53– 3.94 mm. Because there was little 
overlap between men and women for forced vital capacity, tertile cut points for forced vital 
capacity were sex-specific (Women: 0: 2.6–3.8 L, 1: 2.2–2.6 L, 2: 0.6–2.2 L; Men: 0: 3.9–6.5 L, 
1: 3.2–3.9 L, 2: 0.3–3.2 L). Tertile cut points for cystatin-C were scored as 0: 0.6–1.0 mg/L, 1: 
1.0–1.1 mg/L, 2: 1.1–3.5 mg/L. For white matter grade, tertile cut points were scored as 0: 0–1 
units, 1: 2 units, 2: 3–9 units on the 0–9 ordinal scale. Fasting glucose was the only measure not 
classified by tertile. Although results were similar, for clinical interpretation, this presentation 
uses cut points classified according to clinical cut points defined by the American Diabetes 
Association (0: <100 mg/dL, 1: 100–126 mg/dL, 2: >126 mg/dL).167 
 
4.3.3: Terminal restriction fragment length 
CHS participants eligible for LTL measurement were randomly selected from those who 
completed the 1992-1993 clinic examination, consented to DNA preparation/use, had at least 12 
ug of DNA available, and had stored leukocytes for additional DNA preparation. The integrity of 
the DNA was assessed through electrophoresis on 1.0% agarose gels and LTL was measured as 
the mean length of the terminal restriction fragments (TRFs) by the Southern blot method 
previously described.57,103 Each sample was analyzed twice for LTL measurement (on different 
gels on different occasions), and the mean was used for statistical analyses. The Pearson 
correlation coefficient for the duplicates of this sample was 0.97, with an average inter-assay 
coefficient of variation (CV) of 1.5%. The laboratory conducting the TRF length measurements 
was blinded to all characteristics of participants. 
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4.3.4: Demographic, behavioral health, and clinical disease variables 
Covariates were selected for their documented or proposed association with age-related diseases 
included in the index or LTL. Age, sex, race (black, white, or other), and education were 
ascertained by self-report. Smoking was assessed by a standardized interview.168 Blood pressure, 
height, and weight were assessed by standardized protocols. BMI was calculated as kilograms 
per meter squared. CRP was assessed with a high-sensitivity enzyme-linked immunosorbent 
assay.169 The inter-assay CV was 5.50%. Plasma fibrinogen was measured using a 
semiautomated modified clot-rate method. The mean monthly CV for the fibrinogen assay was 
3.09%. For consistency, we tabulated clinically diagnosed chronic conditions using the same 
methods as in the original report of the index.13 Pulmonary disease, diabetes, kidney disease, and 
arthritis were assessed by self-report of physician diagnosis to depict what would be diagnosed 
disease. Depression was defined on the basis of a score >10 on a modified 10-item CES-D 
score.170,171 Reports of cardiovascular disease and stroke were confirmed by review of 
medications and medical records.161 Using this information, a count of diagnosed chronic 
conditions was constructed for each person with a maximum of 7 for these conditions: 
cardiovascular disease, stroke, pulmonary disease, diabetes, kidney disease, arthritis, and 
depression.13 
 
4.3.5: Statistical analysis 
To depict population characteristics and identify potential confounders, we evaluated the 
association between covariates and the index or LTL using a test for trend, χ2-test or Fisher’s 
exact test, where appropriate. A lowess smoothed curve was used to inform modeling of the 
association of the index to LTL. It implied a linear form, which was supported by a goodness-of-
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fit test after model building. We hypothesize that LTL is a predictor of disease outcomes, but set 
up this cross-sectional analysis with LTL as the dependent variable in order to express 
association in terms of base pairs of LTL. This is consistent with most other reports in the 
literature. Furthermore, it allowed us to compare age and disease directly in their associations 
with LTL. Subsequently, we built a series of general linear models using the index as the 
predictor and LTL as the outcome adjusting for covariates as follows: unadjusted model; model 1 
(adjusted for age, gender, and race); model 2 (model 1 plus education, BMI, and current smoking 
status); model 3 (model 2 plus fibrinogen and natural logarithm of CRP); model 4 (model 3 plus 
the number of diagnosed chronic conditions). In the full model, we tested for interactions 
between the index and each covariate. Variance inflations factors were calculated for model 
covariates and confirmed that collinearity was minimal (all VIFs <2). The percent variance in 
LTL independently explained by the index or age, after adjustment for covariates, was 
determined using the part correlation.172   
To test if LTL was associated with disease in individual physiologic systems we 
calculated the Pearson correlation coefficient between LTL and each index component. We also 
built general linear models with each component predicting LTL adjusting for age, gender, and 
race. To see if mean LTL was different by presence or absence of diagnosed chronic conditions 
we used the two-sample T-test or Wilcoxon rank sum test. In model 4 (above), we also replaced 
the count of diagnosed chronic conditions with the conditions themselves to test if they were 
associated with LTL independent of potential confounders. For all analyses we used a two-sided 
alpha of 0.05 to determine significance and SAS 9.2 (SAS Institute, Cary, NC). 
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4.4  RESULTS 
 
Mean (SD) LTL was 6312 (615) bp and index score was 4.7 (2.1) points. Higher disease burden 
was associated with being older, higher CRP and fibrinogen, smoking, coronary heart disease, 
and diabetes (Table 4.7.1). LTL was associated with age (Pearson r = -0.269, P<0.001) and 
smoking (current smoker 6260 bp vs. past smoker 6196 bp vs. never smoker 6421 bp, P=0.03). 
Though LTL was not associated with gender (women 6374 bp vs. men 6226 bp, P=0.07) and 
race (whites 6299 bp vs. blacks 6392 bp, P=0.43), trends were as expected. LTL was not 
associated with BMI, education, CRP, fibrinogen, or a count of diagnosed chronic conditions (all 
P>0.1).     
The index was significantly inversely correlated with LTL (Pearson r = -0.296, P<0.001). 
In an unadjusted model, each SD higher index score was associated with a 183 bp shorter LTL 
(P<0.001) (Table 4.7.2). For comparison, when modeled by itself a SD higher age was associated 
with a 165 bp shorter LTL (P<0.001). In a model with only the index and age, the two factors 
attenuated the association of each other to LTL (index β(SE) = -134(42) bp per SD, P<0.01; age 
β(SE) = -102(44) bp per SD, P=0.02), but each remained significantly associated with LTL.  
In the fully adjusted model, a SD higher index score was associated with a 132 bp shorter 
LTL (P<0.01). A SD higher age was associated with a 107 bp shorter LTL (P=0.02), illustrating 
the association of disease burden was independent of, and similar to, the association of age with 
LTL. The association of a SD in the index score (2.1 points) was equivalent to the association of 
5.9 years of age with LTL. When the index was removed from the full model, the effect of age 
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increased from -107 bp per SD to -165 bp per SD (P<0.001), indicating the index attenuated the 
effect of age by 35%. There was no interaction with the index and other covariates were not 
significantly associated with LTL. Disease burden independently accounted for 3.1% of the 
variance in LTL, while age independently accounted for 2.1% of the variance in LTL. 
Regarding continuous components of the index, higher carotid artery thickness, white 
matter grade, and serum cystatin-C, but not forced vital capacity or serum fasting glucose, were 
significantly correlated with shorter LTL (Table 4.7.3). In linear models adjusted for age, gender, 
and race, only carotid thickness was independently associated with LTL, though white matter 
grade was borderline associated with LTL (Table 4.7.3). After further adjustment for BMI, 
education, smoking, CRP, fibrinogen, and a count of diagnosed chronic conditions, the effect of 
a SD higher carotid thickness (β(SE) = -95(40) bp, P=0.02) was about 3/4 that of the effect of the 
index. Including all index components in the same model resulted in similar findings, illustrating 
that the components were operating relatively independently. 
Regarding diagnosed chronic conditions, LTL was shorter with coronary heart disease 
(6152 bp vs. 6351 bp, P=0.04) but not with other conditions (Figure 4.8.1). When age was 
adjusted for, coronary heart disease was no longer associated with LTL (6163 bp vs. 6348 bp, 
P=0.06), and the association was attenuated more with additional adjustment for race, smoking, 
BMI, education, and CRP (6196 bp vs. 6343 bp, P=0.14). For comparison, when the index was 
dichotomized, those in the unhealthier half of the index (5-10 points) had markedly shorter LTL 
than those in the healthier half of the index (0-4 points) (6102 bp vs. 6525 bp, P<0.001) (Figure 
4.8.1).   
Because carotid thickness seemingly accounted for a substantial portion of the 
association of the index to LTL we conducted a post-hoc analysis removing carotid thickness 
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from the index to determine if non-vascular disease burden remained independently associated 
with LTL. In an unadjusted model, a SD in the index without carotid thickness was associated 
with LTL (β(SE) = -147(39) bp, P<0.001). Adjustment for age, gender, and race attenuated the 
association (β(SE) = -95(43) bp, P=0.03). Additional adjustment attenuated the association to 
borderline non-significance (β(SE) = -89(47) bp, P=0.06). 
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4.5  DISCUSSION 
 
We hypothesized that shorter LTL is associated with greater age-related disease burden, and that 
shorter LTL is less strongly associated with disease in individual systems, or diagnosed chronic 
conditions. Our cross-sectional analysis shows that LTL was indeed strongly and independently 
associated with disease burden, a characterization of age-related chronic disease in five major 
physiologic systems independent of clinical diagnosis. In contrast, LTL was less strongly 
associated with disease in individual systems, except possibly carotid thickness, and was not 
associated with diagnosed chronic conditions or a count of diagnosed chronic conditions. Based 
on this data, we advocate that in older adults LTL may be associated most with processes which 
contribute to atherosclerosis and/or hypertension, and perhaps additional processes which 
contribute to structural and physiological changes in other organs, such as accumulation of white 
matter hyperintensities. It is possible that LTL might indicate widespread incremental changes in 
structure or function in older adults, but most powerfully vascular changes. 
These results provide insight on measuring the biologic age of a human. LTL is a 
proposed indicator of aging so it is standard to correlate LTL with age. We found that a SD in the 
physiologic index or chronologic age had a similar, independent association with LTL. Age 
attenuated the effect of the index substantially but the index in turn accounted for 35% of the age 
effect on LTL. Although one could claim that the association of the index to LTL is partially 
explained by age, another perspective is that the association of age to LTL is partially explained 
by the index. These findings lend credence to the use of noninvasive tests of physiologic 
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structure and function to monitor the integrity of an aging adult. It demonstrates that novel 
biomarkers, such as LTL, hold great promise for unraveling the underlying aging process.     
The significant association between LTL and carotid thickness and weaker associations 
with other systems may illustrate how organs age differently. Carotid thickness reflects 
seemingly normal medial thickening with age, vascular remodeling in response to hypertension, 
and atherosclerosis. The literature describes a robust association between LTL and 
atherosclerosis.33,51,53,54,56,57,63,71-75 In our analysis carotid thickness did not account for the 
complete association between LTL and disease burden. White matter grade may illustrate normal 
brain aging in addition to hypertension and dementia. Using techniques other than MRI, some 
reports suggest that LTL may register cognitive aging or dementia. Notably, in 382 women not 
diagnosed with dementia or cognitive impairment, shorter LTL was independently associated 
with worse memory and learning.81 This is supported by data from the Nurses’ Health Study82 
and a hospital-based case-control study,83 but not by a cohort of 449 inpatients in which there 
was no difference in LTL between patients who were cognitively normal, had mild cognitive 
impairment, or were demented.84 A report from the Health Aging and Body Composition study, 
where LTL was examined in association with cognitive function in 2734 non-demented 
community dwelling older adults, provides inconclusive results.85 The data presented here may 
support the idea of organ-specific aging or disease progression rather than simultaneous decline 
in organ function. It should be noted, though, that different magnitudes of associations between 
LTL and select tissues may depend on the specificity of markers for those tissues, and also 
differences in power to detect significant associations using dichotomized or classified outcomes 
vs. continuous outcomes with a wider variance. Future studies must carefully compare results in 
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light of measurement methods which focus on different points along the aging-disease 
continuum.  
Our data must also be interpreted in light of our construct for disease burden. We wanted 
to count major physiologic systems only once and not give extra weight to cardiovascular 
disease.  These conditions were selected because they are the most common chronic conditions 
in older adults. In our previous work we showed quite clearly that these five systems characterize 
mortality risk quite comprehensively.13 Furthermore, we showed that a count of diagnosed 
conditions, including those not ascertained by the five-component physiologic index, can 
identify high risk individuals but not the lowest risk individuals, as is achieved by the five-point 
physiologic index. The lack of association of LTL with individual diagnosed conditions is likely 
due to the lower power of using dichotomous variables, but also due to the fact that there is a 
wide range of measurable disease in those not yet diagnosed. The partial overlap could 
potentially place the physiologic index at a disadvantage in prediction compared to a 
comorbidity count, which is addressed more fully in the prior publication.13 Other approaches for 
measuring disease burden can be argued and more work is needed to determine the optimal 
balance between information gained and maintaining a biologically logical construct.  
This study is strengthened by the use of Southern blot, the gold standard, to measure 
LTL. Although LTL was measured in a random sample of the CHS cohort, which should 
minimize selection bias, we acknowledge the potential for selection bias which may have 
resulted from using a subset of this random sample. Nonetheless, the original report from the 
CHS random LTL sample also found no association with BMI, fasting glucose, and 
hypertension, and similar trends with carotid thickness, gender, CRP, and smoking.57 We found 
LTL was longer in women and blacks, and non-significance was likely due to our relatively 
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small sample size. Though there is a potential for survival bias when studying older individuals, 
this survival bias would most likely have the effect of truncating the distribution of telomere 
length at the short end and disease at the high end. If the association were weaker or stronger at 
the extremes or if there were a threshold, we would have less power to detect it. Therefore the 
reported associations here are likely to be conservative. Studies across a wider age range could 
be more powerful. Carotid thickness is a continuous variable and depicts a wider range of disease 
than dichotomous classification of yes/no presence of disease – subsequently, it is also possible 
that we identified a significant association of LTL to carotid thickness but not diagnosed 
coronary disease or cerebrovascular disease due to differences in power. The rich data available 
in the CHS allowed us to adjust for confounders identified in the literature, but we acknowledge 
residual confounding is possible. Finally, because the CHS is a general cohort study of 
community-dwelling older adults, the results may be relatively generalizable, though they should 
be replicated in other larger samples, particularly to achieve a higher prevalence of some rarer 
diagnosed chronic conditions like cerebrovascular disease and kidney disease, and in younger 
individuals to see if this association persists in midlife, which may increase confidence in LTL’s 
ability to record aging or pathogenesis of age-related disease across the lifespan. 
In conclusion, we found that LTL was strongly associated with disease burden and less 
strongly or not at all with disease in individual systems or diagnosed chronic conditions. 
Research that employs more encompassing measures of age-related disease, such as the 
physiologic index, may be most useful for identifying markers of biologic age. 
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4.7  TABLES 
 
Table 4.7.1: Characteristics of study participants by physiologic index score group: the 
Cardiovascular Health Study, 1992-1993 examination 
 
Physiologic Index Score Group 
Characteristics 0-2 (N=40) 3-4 (N=77) 5-6 (N=67) 7-10 (N=52) P* 
Demographics 
        Age, y, mean (SD) 71.1 (2.8) 72.9 (3.6) 75.6 (5.6) 76.8 (4.8) <0.001 
   Male gender, n (%) 10 (25.0) 35 (45.5) 32 (47.8) 23 (44.2) 0.11 
   Black race, n (%) 8 (20.0) 8 (10.4) 7 (10.5) 9 (17.3) 0.35 
Behavioral risk factors 
        Education less than college, N (%) 18 (45.0) 32 (41.6) 39 (58.2) 28 (53.9) 0.20
   BMI, kg/m2, mean (SD) 26.8 (3.4) 26.6 (4.0) 27.0 (4.5) 27.4 (3.8) 0.19 
   Smoking status 
           Current, n (%) 4 (10.0) 3 (3.9) 10 (14.9) 8 (15.4) 0.03
      Past, n (%) 15 (37.5) 26 (33.8) 33 (49.3) 23 (44.2) 
       Never, n (%) 21 (52.5) 48 (62.3) 24 (35.8) 21 (40.4) 
 Diagnosed chronic health conditions 
        Coronary heart disease, n (%) 3 (7.5) 12 (15.6) 18 (26.9) 14 (26.9) 0.04
   Cerebrovascular disease, n (%) 1 (2.5) 2 (2.6) 4 (6.0) 3 (5.8) 0.69 
   Diabetes, n (%) 1 (2.5) 4 (5.2) 16 (23.9) 14 (26.9) <0.001 
   Obstructive lung disease, n (%) 12 (30.0) 20 (26.0) 24 (35.8) 14 (26.9) 0.59 
   Kidney disease, n (%) 0 (0) 1 (1.3) 2 (3.0) 1 (1.9) 0.83 
   Arthritis, n (%) 18 (45.0) 41 (53.3) 30 (44.8) 19 (36.5) 0.31 
   Depression (CES-D >10), n (%) 2 (5.0) 8 (10.4) 7 (10.5) 7 (13.5) 0.62 
   No. of conditions, 0-7, mean (SD) 0.9 (0.8) 1.1 (0.9) 1.5 (1.0) 1.4 (1.1) <0.01 
Inflammation/coagulation markers 
        CRP, mg/l, mean (SD) 2.73 (2.75) 4.19 (8.64) 4.17 (4.07) 6.25 (9.81) <0.001 
   ln(CRP), mean (SD) 0.671 (0.788) 0.835 (0.945) 1.03 (0.922) 1.23 (1.02) <0.001 
   Fibrinogen, mg/dl, mean (SD) 300 (54.8) 309 (61.8) 319 (55.6) 335 (59.8) <0.001 
BMI, body mass index. CES-D, Center for Epidemiologic Studies Depression scale. CRP, C-reactive 
protein.  
*P-value from test of trend, chi-square test, or Fisher's exact test. 
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Table 4.7.2: Linear regression models of the association of leukocyte telomere length to physiologic index score 
 
Age itself* Index itself* Model 1† Model 2‡ Model 3§ Model 4‖ 
Covariate β (SE) P β (SE) P β (SE) P β (SE) P β (SE) P β (SE) P 
Index score, 1 SD  -183 (38) <0.001 -132 (42) <0.001 -130 (45) <0.01 -124 (46) <0.01 -132 (47) <0.01 
Demographics 
             Age, 1 SD -165 (39) <0.001 
  
-102 (44) 0.02 -106 (45) 0.02 -111 (46) 0.02 -107 (46) 0.02 
   Male gender  
  
-123 (77) 0.11 -118 (78) 0.13 -128 (80) 0.11 -122 (80) 0.13 
   Black race  
  
73 (111) 0.51 92 (115) 0.42 88 (115) 0.45 84 (115) 0.47 
Behavioral risk factors 
           Education less than college 
   
0 (78) 0.99 -4 (79) 0.96 -12 (81) 0.88 
   Body mass index, 1 SD 
   
-9 (40) 0.82 -9 (42) 0.83 -15 (43) 0.73 
   Current smoking status 
   
-36 (129) 0.78 -46 (131) 0.72 -45 (131) 0.73 
Inflammation and coagulation markers 
           ln(CRP), 1 SD  
      
-61 (44) 0.17 -65 (44) 0.14 
   Fibrinogen, 1 SD 
     
41 (46) 0.37 44 (46) 0.34 
No. of diagnosed chronic health conditions, 1 point 
     
33 (42) 0.43 
*Unadjusted. The difference in base pairs in mean leukocyte telomere length given a 1 standard deviation higher continuous covariate or the 
presence of a categorical covariate. 
†Adjusted for age, gender, and race. 
‡Additionally adjusted for education, body mass index, and current smoking status. 
§Additionally adjusted for ln(CRP) and fibrinogen. 
‖Additionally adjusted for number of diagnosed chronic health conditions. 
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Table 4.7.3: Association of leukocyte telomere length to disease in components of the 
physiologic index 
Component of the 
Physiologic Index* Mean (SD) LTL (bp) Pearson r† P† 
 Linear β 
(SE)‡ P‡ 
Carotid Artery Thickness 
     0 (0.60-1.06 mm) 6540 (602) 
    1 (1.06-1.53 mm) 6252 (591) -0.214 0.001 -100 (39) 0.01 
2 (1.53-3.94 mm) 6168 (600) 
    
      White Matter Grade 
     0 (0-1 units) 6422 (607) 
    1 (2 units) 6386 (644) -0.180 <0.01 -71 (41) 0.09 
2 (3-9 units) 6121 (554) 
    
      Serum Fasting Glucose 
     0 (<100 mg/dL) 6365 (618) 
    1 (100-126 mg/dL) 6256 (632) -0.063 0.33 -49 (39) 0.21 
2 (>126 mg/dL) 6239 (560) 
    
      Serum Cystatin-C 
     0 (0.6-1.0 mg/L) 6413 (651) 
    1 (1.0-1.1 mg/L) 6344 (578) -0.084 0.20 1 (41) 0.98 
2 (1.1-3.5 mg/L) 6187 (606) 
    
      Forced Vital Capacity 
     0 (W: 2.6-3.8 L, M: 3.9-6.5 L) 6369 (592) 
    1 (W: 2.2-2.6 L, M: 3.2-3.9L) 6352 (635) -0.019 0.77 11 (52) 0.83 
2 (W: 0.6-2.2 L, M: 0.3-3.2 L) 6218 (612) 
    *Zero represents a normal physiologic value. Two represents higher disease burden. 
†Correlation of leukocyte telomere length with disease in each component of the index, modeled as 
a continuous variable. 
‡The difference in base pairs in mean leukocyte telomere length given a standard deviation higher 
component of the physiologic index, adjusted for age, gender, and race. Units are: carotid artery 
thickness, 0.49 mm; white matter grade, 1.4 units; serum fasting glucose, 28.9 mg/dL; serum 
cystatin-C, 0.30 mg/L; forced vital capacity, 0.89 L. 
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4.8  FIGURES 
 
 
  Figure 4.8.1: Mean (SD) LTL by index score category or presence of diagnosed chronic conditions 
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5.1  ABSTRACT 
 
Lens transparency, or the magnitude of cataract severity, is a potential in vivo marker of aging 
distinguishable from diagnosed cataract. To explore lens transparency as a marker of aging we 
determined its association with leukocyte telomere length (LTL), measured with qPCR. Cataract 
severity was directly measured in 259 participants and prevalent cataract and incident cataract 
surgery were ascertained in 2,750 participants of the Health, Aging, and Body Composition 
Study. LTL was unassociated with clinical cataract outcomes. Six of 259 had successfully aged 
lenses and a mean LTL of 5,700 bp while 253/259 with poorly aged lenses had a mean LTL of 
4,770 bp. Participants with a 1,000 bp greater mean LTL had nearly half the odds of any cataract 
(OR=0.47, 95% CI 0.22-1.02) after adjustment. Lens transparency might be associated with 
longer LTL in community-dwelling older adults and should be investigated further as a possible 
biomarker of aging.   
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5.2  BACKGROUND 
 
Individual health is highly variable. During their lifetimes, some individuals experience disease, 
accidents, and poor health; others seemingly escape these burdens. Underlying this variability is 
a single process that all living things experience: aging. It is critical to determine how we age if 
we hope to optimize the wellbeing of individuals. Specifically, markers of primary aging are 
needed as intermediate outcomes to understand the aging process and potential early benefits of 
preventive interventions. 
The human lens is a marker of interest for several reasons. Lens changes, such as greater 
thickness and reduced transparency, can be detected in vivo in young adulthood, prior to the 
onset of disease and disability, and can be distinguished from known diseases of the lens such as 
cataract.137,173-175 Lens proteins (crystallins) are set down in fetal development and are the only 
proteins in the body that do not turn over during life. Thus changes in lens proteins due to aging 
are not obscured by removal or repair processes and may reflect lifelong exposure. Furthermore, 
the same tissue can be repeatedly measured. Crystallins are natively clear proteins that belong to 
the family of chaperone proteins which critically maintain protein conformation, particularly 
under stress, throughout the body.115-117 Disruption of lens crystallins, which leads to decreased 
transparency, may therefore reflect widespread breakdown of maintenance machinery, a process 
that underlies aging across tissues.116,117 Indeed, the absence of crystallins that are normally 
found in the lens, brain, heart, skin, and skeletal muscle is associated with aging 
phenotypes.121,122,176 Because crystallins are natively clear, lens transparency can also be 
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measured quickly, accurately, non-invasively and non-hazardously.137,142,177 These qualities 
make lens transparency an attractive candidate marker of aging, though it has been nearly 
uninvestigated in population aging research. 
To explore lens transparency as a marker of aging requires determining its association 
with other potential aging markers. Leukocyte telomere length (LTL), which shortens with age, 
inflammation, and oxidation, has become an increasingly prominent marker of aging.25 It has 
been associated with longevity and some age-related outcomes independent of chronic disease in 
some, but not all, community-dwelling cohorts examined.26,95,178,179 Subsequently, LTL could be 
a useful marker against which to correlate lens transparency. The hypothesis that lens 
transparency may be associated with LTL is also supported by the longstanding observation that 
the vast majority of individuals with the premature aging disorder Werner syndrome, which is 
characterized by accelerated telomere shortening, have early onset of bilateral cataracts.180,181  
In this analysis we sought to explore the human lens as a possible marker of aging by 
studying the association of cataract with LTL in a large cohort of community-dwelling older 
adults, the Health, Aging and Body Composition Study (Health ABC), and an ophthalmic sub-
study of Health ABC, the Age-Related Maculopathy Ancillary Study (ARMA). In doing so, we 
distinguish lens transparency, a possible primary aging phenotype, from cataract, a disease 
phenotype. We specifically hypothesized that 1) longer LTL is associated with a lower 
prevalence of cataract; 2) longer LTL is associated with a lower incidence of cataract surgery; 
and 3) longer LTL is associated with a lower odds of lens opacity.  
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5.3  RESEARCH DESIGN AND METHODS 
 
5.3.1: Health ABC study population 
We used the Health ABC study population to examine prevalence of cataract and incident 
cataract surgery. All Medicare-eligible people in Memphis, TN and Pittsburgh, PA were 
identified to volunteer in the Health ABC study. The study also sought an enriched sample of 
African-Americans. Because the Health ABC study was originally designed to examine incident 
mobility disability, eligibility criteria were no reported difficulty in walking for 1/4 mile, 
walking up 10 steps, getting in and out of bed or chairs, bathing or showering, dressing, or 
eating; no need of using a cane, walker, crutches, or other special equipment to get around; not 
enrolled in a lifestyle intervention trial; free of life-threatening illness; and had plans to stay in 
the geographic area for ≥3 years. Due to these criteria the study population is slightly healthier 
than the age-matched general population. The University of Pittsburgh and the University of 
Tennessee Institutional Review Boards approved all procedures related to Health ABC, and all 
research adhered to the Declaration of Helsinki. For the cross-sectional analysis of the 
association of baseline cataract diagnosis with LTL, the cohort included 2,750 Health ABC 
participants (41% black, 48% male, aged 70-79) who had available LTL measurements (89.4% 
of the original Health ABC cohort). The prospective analysis of incident cataract surgery 
included all those who did not report a diagnosis of cataract in either eye at baseline (N=1,505). 
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5.3.2: ARMA study population 
We used the ARMA study, an ophthalmic sub-study within Health ABC, to examine lens 
transparency. The ARMA study included sensitive measures of lens transparency and recruited 
subjects from the Health ABC site in Memphis, TN to take part in a study of the role of 
carotenoids and inflammation in macular aging and the pathogenesis of age-related maculopathy. 
ARMA participants consisted of an enriched sample of subjects originally enrolled in the Health 
ABC study examined between Year 6 and Year 7 of the Health ABC study. Recruitment was 
based on stratification by a cumulative vision score from the Health ABC Year 3 tests (i.e., based 
on the outcome of binocular best corrected visual acuity to Bailey-Lovie charts, binocular 
contrast sensitivity measured with Pelli-Robson charts, and stereoacuity characterized with the 
Frisby test).182 Inclusion criteria were non-random and included: self-reported diagnosis of age-
related macular degeneration (AMD) (N=55); best vision function score (N=100); or worst 
vision function score (N=200). Exclusion criteria were: diagnosis of type 1 or type 2 diabetes of 
≥6 years duration or presence of diabetic retinopathy at the time of the eye exam; known history 
of glaucoma, or documented presence thereof on examination; diagnosis of autoimmune disease 
or monoclonal gammopathy; illiteracy based on the inability to perform visual acuity tests, which 
negated reliable calculation of vision score, unless the patient was referred for diagnosis of 
AMD. Our cross-sectional analysis of lens transparency included all 259 Health ABC 
participants who had their mean LTL determined at baseline and who also had their lens 
transparency measured as part of the ARMA study. Though ARMA participants were non-
randomly selected from the Health ABC study Memphis cohort using vision scores, selection 
was unassociated with baseline mean LTL (p=0.76), age, gender, smoking history, BMI, total 
cholesterol, and history of hypertension, heart disease, or cancer (all p>0.05). However, ARMA 
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participants were less likely to be black, more likely to use statins, and had lower mean HDL, 
oxidized LDL (oxLDL), C-reactive protein (CRP), interleukin-6 (IL-6), and fasting glucose (all 
p<0.05), which was expected given the ARMA selection criteria.    
  
5.3.3: Cataract ascertainment and lens transparency measures 
At the baseline Health ABC clinic visit, trained interviewers asked subjects if a physician ever 
told them they had a cataract in one eye (unilateral cataract) or both eyes (bilateral cataract). We 
analyzed unilateral and bilateral cataract independently as measures of prevalent baseline 
cataract. Because retrospective determination of cataract diagnosis could introduce recall bias, 
we also analyzed incident cataract surgery documented prospectively by trained interviewers at 
annual clinic visits and at 6 month intervals with a home, phone, or proxy questionnaire. 
Screening for ARMA included a dilated anterior segment exam by one observer (A.I.) to 
verify the presence of the crystalline lens and to ascertain the presence of cataract (nuclear, 
cortical, or both). Lens transparency was graded according to the validated Age-Related Eye 
Disease Study (AREDS) criteria.143 AREDS grading was accomplished by comparing an 
individual’s lens transparency measured using a slit lamp at the time of examination to standard, 
graded photographs. The AREDS grading system for nuclear cataract is a semi-continuous, 8-
step based scale, with 1 indicating complete transparency and 8 indicating complete cataract, and 
where opacity of intermediate severity between steps can be classified by 0.5 intervals. The 
AREDS scale for anterior cortical and posterior cortical cataract is measured as the percent of the 
viewing field occupied by the opacity (0-100%).  
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5.3.4: Telomere measurement  
DNA was extracted from isolated peripheral blood mononuclear leukocytes. Average LTL was 
measured using a validated qPCR method, as described previously.104 This method measures the 
relative average LTL in genomic DNA by determining the ratio of telomere repeat copy number 
to single copy gene copy number (T/S ratio) in experimental samples relative to a reference 
sample. The coefficient of variation for the relative T/S ratios was 5.8%. Assuming a normal 
distribution for relative T/S ratios in repeated measurements of the same sample, samples 
differing in average LTL by as little as 11.4% should be distinguishable by this method at the 
95% confidence level. A T/S “ratio unit” of 1.0 measured by the qPCR method is equivalent to a 
mean LTL of 4,270 base pairs, the known LTL of the reference DNA used in this study. Thus, 
the LTL unit presented was converted to base pairs by using this conversion factor.   
 
5.3.5: Covariates 
Trained interviewers administered the baseline Health ABC questionnaire between April 1997 
and May 1998 to assess demographic and socioeconomic characteristics, health behaviors, health 
status, and medical history. Within 2 weeks of the interview subjects visited the University of 
Pittsburgh or University of Tennessee clinics for baseline biologic, anthropometric, and 
functional measures and a blood draw. We selected possible confounders measured at baseline 
based on those documented in the literature. Demographic characteristics included age, gender, 
race (white or black), and study site. Smoking was categorized as never, former, or current. Body 
mass index (BMI, kg/m2) was calculated using baseline height and weight. The prevalence of 
physician-diagnosed diabetes, ischemic heart disease, congestive heart failure, cerebrovascular 
disease, and cancer (excluding non-melanoma skin cancer) was determined using algorithms 
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based on self-reporting and medication use. Diabetes was defined as an elevated fasting glucose 
(>126 mg/dL) or abnormal 2-hour oral glucose tolerance test (>200 mg/dL). Blood pressure was 
measured with the participant seated for 5 minutes and then one minute after standing. 
Participants were asked to bring all prescription and over the counter medications used in the 
previous two weeks. Medications were coded using the Iowa Drug Information System.183 Assay 
reproducibility was checked using a blind duplicate system whereby 5% of aliquots had a 
duplicate aliquot prepared. Blind duplicate aliquots were analyzed simultaneously and results 
were matched to determine the Pearson correlation coefficient and coefficient of variation. 
 
5.3.6: Statistical analysis 
We assessed whether covariates could be potential confounders by quantifying their association 
with LTL, cataract, cataract surgery, or lens transparency using Pearson correlation coefficients, 
the student’s T-test, χ2 statistic and analysis of variance. We chose the significance level p<0.10 
as a cutoff for inclusion of possible confounders in multivariate models. Age, BMI, cholesterol, 
HDL, LDL, oxLDL, CRP, IL-6, fasting insulin, and fasting glucose were treated as continuous 
covariates while gender, race, study site, smoking (ever/never), comorbidities, and medication 
use were treated categorically. oxLDL, CRP, IL-6, and fasting insulin levels were log-
transformed in models to account for skewness, though non-transformed descriptive statistics are 
reported.  
We added LTL to all models in kilobasepairs such that ratio measures reflect the odds of 
outcome associated with a 1,000 bp increase in mean LTL. LTL was measured on 45 qPCR 
plates so we included a random effect variable in all models to account for slight LTL 
measurement variation between plates. For analyses of cataract in Health ABC, we used logistic 
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regression to generate odds ratios and 95% confidence intervals to determine the association 
between LTL (predictor) and baseline cataract (outcome). We employed multivariate logistic 
regression for adjustment. We used a frailty model for Cox proportional hazards regression to 
calculate the hazard ratio for incident cataract surgery (outcome) using LTL as the predictor. 
Multivariate proportional hazards regression was used to adjust for confounding.  
Because we were interested in exploring the lens as a marker of successful aging, in the 
ARMA study, we decided a priori upon a stringent classification of a truly transparent lens to 
clearly distinguish successful lens aging from cataract. Using the AREDS grading criteria, we 
defined successful lens aging as ≤3.0 nuclear grade and 0% cortical grade. An aged lens was 
defined as having nuclear opacity >3.0 grade or cortical opacity >0% grade or previous 
placement of an intraocular lens (N=102). Specific types of cortical opacity were also classified 
using the AREDS criteria. The reference group for all logistic models of lens transparency was 
participants with a transparent lens (≤3.0 nuclear grade and 0% cortical grade, N=6). We used 
logistic regression and multivariate logistic regression for all ARMA analyses. 
We simultaneously tested for interaction between LTL and all included covariates using a 
significance level of 0.10. Non-significant interactions were excluded from the final multivariate 
models. We used a significance level of 0.05 except as noted earlier. SAS 9.1 (SAS Institute, 
Cary, NC) was used for all analyses except proportional hazards regression (Stata 10.0, 
StataCorp, College Station, TX).   
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5.4  RESULTS 
 
Prevalent cataract 
Mean LTL at baseline for all participants was 4,860 bp (SD, 1,360 bp). Though correlations were 
weak (all r<0.103), LTL was shorter with greater age, BMI, oxLDL, IL-6, fasting glucose, and 
fasting insulin, and longer with greater HDL and total cholesterol (all p<0.10). At baseline, mean 
LTL was 377 bp greater in women (p<0.0001), 107 bp greater in Blacks (p=0.043), and 131 bp 
greater in statin users (p=0.016). Smoking history was associated with shorter LTL (p=0.0008).  
At baseline, 36.4% and 25.6% of participants reported a history of unilateral and bilateral 
cataract, respectively. Both unilateral and bilateral cataract was significantly associated with age 
and gender (Table 5.7.1, bilateral cataract data not shown). Participants reporting a history of 
unilateral cataract had greater BMI, were more likely to be from Pittsburgh, and had a greater 
burden of comorbidities. Crude analyses illustrated no association between LTL and unilateral or 
bilateral cataract (Table 5.7.2). After adjustment for relevant confounders, the magnitude of 
effect increased slightly but remained non-significant. 
 
Incident cataract surgery 
Over nine years of follow-up, 353 of 1,505 participants underwent cataract surgery for an 
average nine-year risk of 23.5% and a rate of 17.2/1,000 person-years. The average length of 
follow-up was 8.1 years. Incident cataract surgery was associated with age, gender, cholesterol, 
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study site, and statin use (Table 5.7.1). LTL was not associated with nine-year risk of cataract 
surgery before or after adjustment (aHR=1.02, 95% CI 0.94-1.10) (Table 5.7.2). 
 
Lens transparency 
Mean LTL at baseline for all ARMA participants was 4,790 bp (SD, 1,050 bp). At the 
time of the ARMA study eye exam, 97.7% of participants had evidence of any cataract, 
including 95.0% with nuclear opacity (AREDS grade >3.0), 79.2% with anterior cortical opacity, 
and 52.5% with posterior cortical opacity. The 6 individuals with successfully aged lenses 
(nuclear grade ≤3.0 and 0% cortical grade) had a mean LTL of 5,700 bp and no history of 
smoking, cerebrovascular disease or cardiovascular disease. For each 1,000 bp increase in mean 
LTL, subjects were nearly 50% less likely to have any cataract or an intraocular lens (i.e. an aged 
lens) (Table 5.7.3). There was a similar protective effect for nuclear opacity, any cortical opacity 
and cortical opacity subtypes. Adjustment for confounders included in the previous cataract 
models did not alter estimates appreciably.        
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5.5  DISCUSSION 
 
This is the first report of the association between cataract and LTL in human subjects. Using a 
stringent a priori-determined cutoff to define successful lens aging, it is striking that we 
identified individuals with a mean LTL nearly 1,000 bp longer than other individuals with less 
transparent lenses. Our analysis suggests that higher lens transparency was likely associated with 
longer LTL. Both transparency and LTL may indicate cumulative oxidation.25,184 Alternatively, 
senescence of the lens epithelium has been associated with non-enzymatic alterations in lens 
crystallins and this may correlate with senescence-related immune aging. In contrast, diagnosed 
cataract, a clinical disease phenotype, was not associated with LTL. This could be because self-
reported physician diagnosis of cataract is a biased measure, because cataract surgery is more 
dependent on access to care or impact on quality of life than the severity of the cataract, or 
because diagnosed cataract is a marker of disease and not necessarily aging. Cataractous lenses 
are different from aged human lenses in gene expression patterns,138 and the clinical 
classification of “cataract” or “no cataract” does not reflect the subtle morphological, 
histological, and biochemical changes that occur with lens aging.137,139-141 These data provide 
preliminary evidence that lens transparency might be an in vivo marker of primary aging whereas 
diagnosed cataract is likely not. With further exploration, lens transparency might emerge as a 
valuable intermediate marker for use in intervention studies attempting to modify the aging 
process.      
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Using our stringent definition of transparency, we identified only 6 individuals free of 
opacity in the ARMA sub-study. Subsequently, this definition illustrates a truly rare phenotype 
of successful aging. This rarity is akin to using the oldest old, such as centenarians and super-
centenarians, to search for longevity-associated factors, yet may be more feasible because the 
phenotype can be identified at younger ages. Interestingly, at the Health ABC baseline clinic 
visit, these 6 participants had no history of smoking, cerebrovascular disease or cardiovascular 
disease in addition to markedly longer LTL, yet their mean age was 72.3 years (range 70-75). 
This is further proof that sensitive lens measurements may provide a window on whole organism 
aging.  
The lens has several real and hypothesized advantages as a marker of aging. First, the 
lens is unique in that nuclear lens cells are present at birth and do not turn over throughout life. 
Therefore, the lens has the potential to reflect risk factors for aging that are encountered 
throughout life, and the same tissue can be measured repeatedly. Second, though a somewhat 
immune privileged site, the lens is exposed to the internal and external environments. 
Subsequently, transparency might reflect both in vivo and ex vivo risk factors for aging. Third, 
using modern imaging techniques, transparency can be measured on a continuous scale, allowing 
finer risk stratification. Fourth, lens imaging is non-invasive, non-hazardous, and quick, so it 
may be easily adopted by researchers and clinicians. The utilization of a grading system, such as 
the AREDS one applied here143 or the LOCS-III or the OCCCGS systems,144,145 offers a simple, 
fast, inexpensive, reproducible, and accurate means to ascertain lens transparency. Although 
AREDS grading is designed to be applied by trained graders after the eye exam on standard 
photos obtained with a photographic slit lamp, adding to the complexity and duration of the eye 
exam and significantly increasing cost, it surely offers an accurate and minimally biased 
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assessment of lens transparency. Other imaging techniques, such as Scheimpflug photography, 
can provide a more accurate assessment of the nucleus, can be acquired quickly, and allow finer 
quantification of transparency, though it can be expensive and requires training. 
Our results are strengthened by several factors. This study represents one of the largest 
samples of LTL measurements available in prospective longitudinal studies, a necessity given 
the inherent heterogeneity in human LTL.100 Coupled with measurement of lens transparency 
and LTL using validated methods,104,143 low loss-to-follow-up and long average length of follow-
up, we believe our estimates are minimally affected by random error and bias. Similar to 
previous studies, we also found that LTL was greater in women, blacks, non-smokers,64 and 
those without cardiovascular disease.57,75,87 The adjusted odds ratios for covariates included in 
our multivariate models also agree with those previously published,185-188 suggesting our models 
are accurate because they are consistent with those from other populations. Though the ARMA 
sample was small, which limited power, adjustment for other confounders did not alter the 
magnitude of estimates appreciably. 
Our study does have some limitations. Although we determined that the ARMA 
population was relatively similar to the overall Health ABC cohort at baseline, selection of the 
ARMA study population was non-random with respect to outcome, which could introduce 
selection bias. It is possible that residual confounding affects our final estimates due to 
incomplete adjustment, as well as possible inaccuracies in lens transparency estimation 
introduced by the AREDS grading system. Although we found no significant interactions, 
unidentified modification might remain. Finally, we did not examine associations with posterior 
subcapsular cataract, though this is a rare lesion.185-187 
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In conclusion, we found that greater lens transparency is likely associated with longer 
LTL in a sample of community-dwelling older adults. This suggests that lens transparency might 
serve as an in vivo marker of primary aging. We recommend that future studies of this 
association employ a prospective approach to more accurately portray the biological dynamic 
which occurs, namely studying telomere attrition and declining transparency using repeated 
measures. This would also mirror how these markers might be employed in the future to monitor 
biologic age across the lifespan. Because lens transparency decreases beginning in adolescence 
and LTL is heterogeneous at birth, it would be most sensible to investigate whether the rate of 
telomere shortening is associated with rate of change in lens transparency in a study of 
participants with a wide age range. Finally, testing whether lens transparency is a predictor of 
mortality or longevity may provide the strongest evidence of its usefulness as a biomarker of 
aging.  
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5.7  TABLES 
 
Table 5.7.1: Baseline characteristics of the Health ABC Study population by prevalent cataract at 
baseline or incident cataract surgery  
 Unilateral cataract  9 yr cataract surgery  
  
Yes 
(N=984) 
No 
(N=1,719)   
Yes 
(N=353) 
No 
(N=1,152)   
  
Mean (SD) 
or N (%) 
Mean (SD) 
or N (%) P* 
Mean (SD) 
or N (%) 
Mean (SD) 
or N (%) P* 
Age (years) 74.1 (2.9) 73.4 (2.8) <0.0001 73.5 (2.8) 73.1 (2.7) 0.05 
Gender       
   Male 428 (43.5) 880 (51.2) 0.0001 157 (44.5) 652 (56.6) <0.0001 
   Female 556 (56.5) 839 (48.8)  196 (55.5) 500 (43.4)  
Race       
   White 584 (59.4) 1014 (59.0) 0.85 215 (60.9) 652 (56.6) 0.15 
   Black 400 (40.6) 705 (41.0)  138 (39.1) 500 (43.4)  
Study site       
   Memphis 466 (47.4) 905 (52.6) 0.008 153 (43.3) 599 (52.0) 0.004 
   Pittsburgh 518 (52.6) 814 (47.4)  200 (56.7) 553 (48.0)  
Smoking status       
   Never 418 (42.5) 752 (43.9) 0.022 161 (45.6) 490 (42.7) 0.14 
   Current 83 (8.4) 194 (11.3)  30 (8.5) 141 (12.3)  
   Former 482 (49.0) 769 (44.8)  166 (45.9) 517 (45.0)  
Comorbidities       
   Diabetes mellitus 173 (17.6) 229 (13.4) 0.003 58 (16.5) 144 (12.6) 0.06 
   Hypertension 397 (40.4) 655 (38.1) 0.46 133 (37.7) 450 (39.1) 0.87 
   Cerebrovascular disease 88 (9.1) 99 (5.9) 0.002 17 (4.9) 74 (6.5) 0.27 
   History of MI 24 (2.5) 51 (3.0) 0.42 11 (3.2) 34 (3.0) 0.88 
   History of cancer 190 (19.4) 272 (15.9) 0.023 60 (17.1) 176 (15.4) 0.46 
Current statin use 123 (12.5) 231 (13.5) 0.46 60 (17.1) 147 (12.8) 0.044 
*P-value from T-test, ANOVA, or χ2-test. 
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Table 5.7.2: Models of lens disease: likelihood of cataract and cataract surgery with each 1,000 
basepair increase in leukocyte telomere length 
Cataract Outcome Prevalence Crude Crude Adjusted Adjusted 
   or Rate  OR/HR 95% CI OR/HR* 95% CI* 
Baseline unilateral cataract 36.4% 0.95 0.89-1.01 0.95 0.89-1.01 
Baseline bilateral cataract 25.6% 0.99 0.93-1.06 0.99 0.92-1.06 
9yr incident cataract surgery 17.2/1000py 1.03 0.96-1.12 1.02 0.94-1.10 
CI, confidence interval. HR, hazards ratio. OR, odds ratio. 
*All adjusted for age, gender, site, smoking, BMI, HDL, cholesterol, and statin use. 
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Table 5.7.3: Models of successful lens aging: odds of lens opacity vs. no opacity with each 1,000 
basepair increase in leukocyte telomere length   
Opacity Outcome N  Mean (SD) LTL (bp) OR (95% CI) OR (95% CI)* 
No opacity 6 5,700 (1,550) Ref Ref 
Nuclear opacity 246 4,780 (1,040) 0.51 (0.27-1.00) 0.48 (0.22-1.03) 
Anterior cortical opacity 205 4,790 (1,040) 0.52 (0.27-1.01) 0.50 (0.23-1.05) 
Posterior cortical opacity 136 4,760 (1,050) 0.50 (0.24-1.02) 0.47 (0.21-1.05) 
Any cortical opacity 214 4,800 (1,040) 0.52 (0.27-1.01) 0.49 (0.23-1.05) 
Any opacity or IOL 253 4,770 (1,040) 0.51 (0.26-0.99) 0.47 (0.22-1.02) 
CI, confidence interval. OR, odds ratio. 
*Adjusted for age and gender. 
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6.1  ABSTRACT 
 
Background: Few primary markers of aging are validated in human population studies. The lens 
is of interest because it remains from birth until death and can be measured accurately and 
noninvasively. To evaluate if the lens is an indicator of aging, disease, both, or neither, we 
determined the association of lens transparency and cataract surgery to markers of aging and 
disease including risk factors for coronary atherosclerosis, coronary artery calcium (CAC), aortic 
calcium (AoC), carotid intima-media thickness (IMT), fasting plasma glucose or insulin, 
cognitive function and ApoE genotype. 
 
Methods: We directly measured lens transparency with Scheimpflug photography (N=136) and 
enumerated self-report of cataract surgery (N=231) in participants of the Healthy Women Study 
(mean (SD) age 73.3 (1.7) years). Atherosclerosis risk factors included age, smoking, waist 
circumference, BMI, lipids, blood pressure, fasting glucose and insulin, interleukin-6, and 
medication use and were measured concurrently with lens transparency and 25 years previously. 
CAC and AoC were measured with electron beam tomography at the time of lens measurements 
and ~7, 10, and 13 years previously. IMT was measured with ultrasound. Cognition was 
measured with the Modified Mini Mental Status exam. 
 
Results: Cross-sectionally, cataract surgery was associated with larger waist circumference and 
diabetes (P<0.05). Lens transparency <95% vs. transparency ≥95% was associated with diabetes 
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(P<0.05). Cataract surgery was associated with greater baseline BMI and higher baseline 
triglycerides. Participants with transparency <95% had higher baseline insulin. Cataract surgery 
or lens transparency was not associated with CAC, AoC, or IMT. Cataract surgery was 
associated with lower median 3MS score. Participants with less transparent lenses were more 
likely to harbor an ApoE 3/4 genotype.       
 
Conclusions: Low lens transparency and cataract surgery are associated with diabetes. Low lens 
transparency is associated with higher frequency of ApoE 3/4 genotype, but not with risk factors 
for atherosclerosis, CAC, AoC, or IMT. Replication in cross-sectional studies in different 
populations could help demonstrate if lens transparency is a noninvasive indicator of brain 
pathology and cardiovascular health. 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
 
6.2  BACKGROUND 
 
Few primary markers of aging have been validated in human population studies. With an 
increasing emphasis on lifecourse epidemiology, which leverages longitudinal analysis to 
examine processes with long incubation periods, such as aging, there is a need to uncover 
predictive markers which could be measured repeatedly over long periods of time. It would be 
ideal to define noninvasive tests of change in tissues that do not turn over because these markers 
may provide insight on the integrity of a human throughout the lifespan.    
The human lens is of interest because it develops in utero and central lens cells (the lens 
nucleus) remain from birth until death. Subsequently, in theory, the lens may provide a record of 
lifetime exposure to risk factors for accelerated aging and/or disease. The lens is freely visible 
and comprised of natively clear proteins named crystallins, allowing it to be measured simply 
and noninvasively with imaging. Furthermore, the biology of the lens suggests it may provide 
insight on tissue integrity throughout the body. Lens crystallins belong to the family of 
chaperone proteins which maintain protein conformation, particularly under stress.115-117 
Perturbation of lens crystallins, which leads to decreased transparency manifested clinically as 
cataract, may indicate breakdown of maintenance machinery, a form of failing stress response, 
which is a process underlying aging.116,117 Lens transparency, a continuous measurement, can 
also be differentiated from a disease phenotype, such as age-related cataract, and thus may serve 
as a more sensitive marker than dichotomous cataract status. Currently it is unknown if the lens 
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is a valid biomarker of aging in humans because it has not been examined in association with 
markers of aging and disease.  
Some of the most common and burdensome age-related diseases are cardiovascular 
disease, diabetes mellitus, and dementia. Subsequently, examining the association of the lens to 
markers of these diseases will provide evidence for the ability of the lens to reflect aging or age-
related disease. Several recent reports from large, longitudinal studies document the strong 
association between coronary artery calcification (CAC) and risk of coronary heart disease and 
death.189-191 CAC is now accepted as a powerful marker of coronary heart disease and predictor 
of cardiovascular disease and death independent of other risk factors for cardiovascular disease, 
such as smoking, lipid levels, blood pressure, waist circumference, and inflammation. Fasting 
glucose and insulin insensitivity are used to define diabetes. They are thus prime measures of 
metabolic health. The Modified Mini Mental Status Exam (3MS) is a marker of cognition used 
clinically to detect dementia. Additionally, Alzheimer’s-type dementia is strongly associated 
with the apolipoprotein E4 (ApoE4) genotype, a genetic marker.  
In this analysis we evaluate the association of lens transparency and cataract surgery to 
markers of aging and disease, including: 1) risk factors for coronary atherosclerosis, the extent of 
noninvasively measured coronary atherosclerosis, fasting plasma glucose or insulin; 2) cognitive 
function measured with the 3MS and ApoE genotype. We utilize a cross-sectional study of the 
association of current measures of aging and disease to lens transparency and history of cataract 
surgery. Furthermore, to more carefully investigate temporality, we conduct a retrospective 
longitudinal analysis by testing the association of previous measures of aging and disease to 
current lens transparency or history of cataract surgery. This analysis will help clarify if the lens 
may be a valid indicator of aging and/or age-related chronic disease. 
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6.3  RESEARCH DESIGN AND METHODS 
 
6.3.1: Study population 
We conducted lens measurements in participants of the Healthy Women Study (HWS). The 
HWS is a community-based longitudinal cohort study that began in 1983-1984 in Pittsburgh, PA, 
selecting a sample of 541 women (mean (SD) age 47.5 (1.6) years), all premenopausal, who did 
not have diabetes or clinical hypertension. The HWS was the first study to determine changes in 
risk factors from the pre- to the postmenopausal period and possible relationship to changes in 
endogenous hormone levels. Women were followed yearly by mail and telephone follow-up and 
had several clinical examinations. The study pioneered in the evaluation of measures of 
subclinical atherosclerosis including the evaluation of coronary and aortic calcification by 
electron beam tomography (EBT). 
In the current HWS visit cycle, participants underwent a fourth EBT scan of CAC 25 
years after the original enrollment, returning when they were 67-79 years old. A blood sample 
was also stored for molecular and genetic study. Approximately 80% of the 289 women that 
would have had their third EBT, i.e., a total of 231, were predicted to return for their fourth 
measurement of CAC. We measured lens transparency when women returned for their fourth 
EBT scan. Data on the lens was obtained for 231 women. The HWS and Aging Lens Sub-study 
were approved by the University of Pittsburgh Institutional Review Board. All participants gave 
consent for the studies.  
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6.3.2: Lens measurements 
At their fourth EBT visit, women were asked about their history of cataract surgery or diagnosis 
of glaucoma, macular degeneration, eye trauma, or other eye diseases (N=231). Women who had 
bilateral cataract surgery (N=64, 27.7%) or those with a history of glaucoma (N=22, 9.5%) who 
are at risk for acute narrow angle glaucoma with dilation were ineligible for lens transparency 
measurement, leaving 145 women eligible for direct measurement of lens transparency. Thirty 
eight women (16.5%) were not interested and 35 women (15.1%) were unavailable for direct 
lens measurement, but did provide data on history of cataract surgery. Participants were 
unavailable due to an inability to return to the clinic for the lens measurements due to scheduling 
conflicts, caregiver responsibilities, or living too far from Pittsburgh. Subsequently, we measured 
lens transparency in 68 right eyes and 72 left eyes (4 participants had undergone cataract surgery 
in only the right eye).   
 Before dilation, participants’ best corrected visual acuity, contrast sensitivity, and depth 
perception were measured using the Bailey-Lovie distance visual acuity test, Pelli-Robson 
contrast sensitivity test, and Frisby stereo test, respectively.182 Lens transparency was measured 
during an eye exam where both pupils were dilated using proparacaine hydrochloride ophthalmic 
solution 0.5% (Ophthetic©, an anesthetic), phenylephrine hydrochloride ophthalmic solution 
2.5% (Mydfrin©), and tropicamide ophthalmic solution, USP 1% (Mydriacyl©). The lens exam 
was performed approximately 10-20 minutes after dilation drops were administered and required 
approximately 10 minutes. Lens transparency was obtained using Scheimpflug 
photography.137,142,146 For Scheimpflug imaging, three to four retroillumination images of each 
intact lens were taken at equal intervals from 90O to -90O for each participant. The optical 
measurements were averaged to give an average quantitative measurement of total lens 
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transparency for each eye. A Nidek EAS-1000 anterior eye segment analysis system was used. 
This system consists of a slit lamp connected to a CCD camera whose position is moved by an 
electric motor based on preset conditions. All photographic and optical density measurements 
were stored in a computer for retrieval and analysis. 
  
6.3.3: Measurement of risk factors for coronary atherosclerosis, coronary artery 
calcification, fasting plasma glucose or insulin 
Risk factors for coronary atherosclerosis included age, smoking (determined from self report), 
waist circumference and body mass index (determined by anthropometric measurement), total 
cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) 
cholesterol, and triglycerides (all measured with NMR spectroscopy), blood pressure 
(determined with sphigmomanometry using a standard protocol), medication for altering lipids or 
blood pressure, and interleukin-6 (IL-6, measured with an enzyme-linked immunosorbent assay), 
and marker of inflammation that increases with age.192 Risk factors measured at the fourth EBT 
examination were used for cross-sectional analysis and risk factors measured at the baseline 
HWS examination (~25 years previously) were used for longitudinal analysis. Some variables 
recorded at the fourth EBT examination (e.g., waist circumference, use of lipid and blood 
pressure medications, IL-6) were unavailable at the baseline HWS examination. EBT scans for 
CAC were performed using a GE-Imatron C-150 (Ultrafast CT ®) scanner (Imatron, South San 
Francisco, CA). For evaluation of the coronary arteries, 30 to 40 contiguous 3 mm thick 
transverse images were obtained from the level of the aortic root to the apex of the heart. Images 
were obtained during maximal breath holding using ECT triggering so that each 100 millisecond 
exposure is obtained at 60% of the R-R interval. Calcium scores for the coronary arteries were 
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calculated using the method of Agatston, resulting in both a total score and a total number of 
calcifications, and more recently by volume scores. Calcification was considered present when at 
least 3 contiguous pixels of 130 Houndsfeld Units are present on a 30 cm matrix. Initial image 
analysis was performed on a DICOM workstation using software provided by Aculmage, Inc. 
Spearman correlations between the Agatston scores and volumetric scores was 0.94 for the 
coronaries. The mean time between first and second EBT examination was 3.19 years. The mean 
time between the first and third EBT examination was 6.44 years. Spearman correlation between 
the 1st and 2nd CAC in the HWS was 0.84, between the 1st and 3rd was 0.84, and between the 2nd 
and 3rd was 0.86. Pearson correlations were similar in magnitude. CAC was classified as 
previously in the HWS: 0, 1-99, and ≥100. Fasting plasma glucose and insulin were measured 
from blood using standardized clinical lab procedures. Diabetes was defined as self-report of 
physician diagnosis, hypoglycemic medication use, or glucose level of 126 mg/dL or higher, as 
established by the American Diabetes Association.167  
 
6.3.4: Measurement of cognition and ApoE genotype 
Cognitive function was measured by trained interviewers using the 100-point Teng Modified 
Mini Mental Status Exam.193 ApoE genotype was detected by isoelectric focusing followed by 
immunoblotting. HWS serum samples were delipidated using the guanidine-  
HCI method194 followed by an isoelectric focusing/immunoblotting protocol.195 
 
6.3.5: Statistical analysis 
We assessed the association of bilateral cataract surgery (a theorized disease phenotype) or lens 
transparency (a theorized aging phenotype) to indicators of aging and age-related chronic 
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disease. For bilateral cataract surgery, participants were categorized into two groups: bilateral 
cataract surgery present (N=64) vs. bilateral cataract surgery absent (N=167). For lens 
transparency, participants were categorized into two groups based on two different cutpoints: 
≥90% total transparency (N=39) vs. <90% total transparency or cataract surgery in that eye 
(N=97); ≥95% total transparency (N=26) vs. <95% total transparency or cataract surgery in that 
eye (N=110). These cutpoints were chosen to 1) establish phenotypes illustrative of successful 
lens aging (i.e., a healthy aging phenotype); 2) to help balance group size based on the 
distribution of total transparency, which was skewed because many participants had relatively 
transparent lenses or had undergone cataract surgery. To be categorized in the successful lens 
aging group (i.e., ≥90% transparency or ≥95% transparency), a participant’s right and left eyes 
both had to have transparency above the cutpoint. If data were available for only one eye then 
that eye was used for categorization. 
 For cross-sectional analysis, we determined the association of lens transparency 
measured at the fourth EBT examination to markers of aging and disease measured at the fourth 
EBT examination. For retrospective longitudinal analysis, we determined the association of lens 
transparency measured at the fourth EBT examination to markers of aging and disease measured 
at the baseline HWS examination (25 years previously), and also to CAC measured at the first 
(13 years previously), second (10 years previously), and third (7 years previously) EBT 
examination. We used the two-sample t-test or χ2-test to assess the association of cataract 
surgery/lens transparency to continuous and categorical variables, respectively. We also used the 
median one-way test to assess the association of cataract surgery/lens transparency to median IL-
6 level, median CAC level, and median 3MS score. A P-value <0.05 was used to determine 
statistical significance. All analyses were conducted with SAS 9.2 (SAS Institute, Cary, NC).       
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6.4  RESULTS 
 
At the fourth EBT examination participants were on average 73.3 (SD 1.7) years old. For their 
age, participants had a healthy profile: 98 (42.4%) had total cholesterol <200 mg/dL, 108 
(46.8%) had a systolic blood pressure <120 mmHg, 214 (92.6%) had a fasting glucose <126 
mg/dL, and only 2.6% were current smokers. Of note, 98 (42.4%) were on lipid-lowering 
therapy, 101 (43.7%) were on blood pressure-lowering therapy, and 16 (6.9%) were on diabetes 
therapy. Fifty five percent of participants with total cholesterol <200 mg/dL were on lipid 
therapy, 39% of participants with systolic blood pressure <120 mmHg were on blood pressure 
therapy, and 3% of participants with fasting glucose <126 mg/dL were on diabetes therapy. 
Sixty four (27.7%) women had previously undergone bilateral cataract surgery, 22 (9.5%) 
had been diagnosed with glaucoma, and 8 (3.4%) had been diagnosed with other eye diseases 
(Table 6.7.1). Transparency in right and left eyes was correlated in the lens nucleus (r = 0.641, 
P<0.0001) and cortex (r = 0.724, P<0.0001), and for total transparency (r = 0.735, P<0.0001). 
Nuclear cataract (the percent of the nucleus scattering light) in left and right eyes ranged from 
0%-15.5%. Cortical cataract ranged from 0%-67.1%, but was overall relatively low, with a 
median (interquartile range) of 3.7% (8.1%) in right eyes and 5.5% (12.3%) in left eyes. Total 
transparency was on average high (mean (SD) 91.9% (10.6%) in right eyes and 88.0% (15.3%) 
in left eyes). Participants’ visual acuity, contrast sensitivity, and depth perception were overall in 
the healthy range (Table 6.7.1). There were 39/136 and 97/136 participants with transparency 
≥90% and <90%, and 26/136 and 110/136 participants with transparency ≥95% and <95%. 
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 Regarding risk factors for coronary atherosclerosis, cross-sectionally, cataract surgery 
was associated with larger waist circumference, use of diabetes medication and diabetes status by 
medication or glucose level (all P<0.05) (Table 6.7.2). Participants with lens transparency <95% 
were also more likely to be diabetic than participants with transparency ≥95%. Cataract surgery 
was associated with greater baseline BMI and higher baseline triglycerides, and participants with 
transparency <95% had higher baseline fasting insulin (Table 6.7.3). Although there was a trend 
that cataract surgery or lower lens transparency was associated with higher IL-6 level, this trend 
was non-significant. Lens measurements were not associated with other risk factors for coronary 
atherosclerosis either cross-sectionally or longitudinally.  
An age-associated increase in mean CAC was clearly seen among HWS participants 
(Table 6.7.4). Cataract surgery or lens transparency was not associated with CAC level measured 
at the same time or previously (Table 6.7.4). Nonetheless, there appeared to be a non-significant 
trend that participants without cataract surgery or with greater transparency had lower CAC 
levels. In additional analyses we tested the association between the lens and EBT-measured total 
aortic calcium score (Table A.1.1), which increases with age and is more reflective of age-
associated arteriosclerosis rather than atherosclerosis, and carotid intima-media thickness (Table 
A.1.2), which also increases with age but also with high blood pressure and atherosclerosis. 
Aortic calcium or carotid intima-media thickness were not associated with cataract surgery or 
lens transparency.   
 HWS participants had high median 3MS scores (Table 6.7.5), far above a score of 80 
used clinically to denote dementia. Despite this ceiling effect, cataract surgery appeared to be 
associated with lower median 3MS score, though lens transparency was not associated with 3MS 
score. Overall, lens transparency was associated with ApoE genotype (P<0.05). As high lens 
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transparency was more stringently identified by the absence of cataract surgery, then ≥90% 
transparency, then ≥95% transparency, the frequency of an ApoE4 allele fell from 19.5% to 
15.8% to 11.5%, which was driven by a lower prevalence of the 3/4 genotype.        
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6.5  DISCUSSION 
 
In a population of relatively healthy older women, we found that cataract surgery or lens 
transparency was not associated with most examined risk factors for coronary atherosclerosis or 
CAC, aortic calcium, or carotid intima-media thickness measured concurrently or previously. 
There was a relatively consistent association between lower transparency and markers of 
diabetes. This was expected given the established relationship between diabetes and cataract. 
Finally, we observed that transparency was overall associated with ApoE genotype, and that 
greater transparency may be associated with a lower frequency of carrying an ApoE4 allele and 
better cognitive function. 
The association between the lens and brain is intriguing. If true, it suggests the lens may 
be an indicator of brain aging or disease. Histological and biochemical studies support the 
hypothesis that the lens may reflect brain pathology. Alpha-B crystallin, a main component of 
the lens, is found in the brain,121 particularly in the limbic and paralimbic regions, which are 
commonly affected in Alzheimer’s patients.126 The number of alpha-B crystallin positive neurons 
increases in parallel with neuronal loss.126 Alpha-B crystallin is upregulated in astrocytes 
associated with senile plaques and cerebral amyloid angiopathy in Alzheimer’s disease 
patients,127 and it inhibits aggregation of A-beta peptide in vitro.128 Recent evidence also 
suggests that ApoE exists in the lens capsule,196 and that beta-amyloid toxically aggregates in the 
lens.197,198 This data supports crystallin’s role as a heat shock protein that maintains protein 
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conformation and responds to intracellular stress, and offers clear links between the lens and 
brain.  
Despite seemingly consistent data from laboratory research, data from clinical studies is 
conflicting. Zetterberg described no association between cataract and ApoE gentoype after 
examining 502 cases of cataract and 187 controls.199 Utheim et al. reported that cataract was 
associated with a lower prevalence of ApoE4 allele, though the examined sample was small 
(N=88) and highly selected.200 Zubenko et al. found a significant reduction in the age-specific 
rate and lifetime cumulative incidence of age-related cataract in individuals >90 years old with 
preserved cognition, a group exhibiting successful aging.136 Comparisons between our study and 
these previous studies is complicated by differences in the study population (e.g., mean age, age 
range, and source of participants from clinics vs. the general population), data source (e.g., 
medical records, self report, grading of cataract severity using standard photographs, direct 
measurement of lens transparency using a technique such as Scheimpflug photography), and 
statistical power. Moreover, because diagnosed cataract and cataract surgery are disease 
phenotypes which may have different associations with markers of aging and age-related chronic 
disease,201 it is difficult to extrapolate results from studies of cataract to studies of lens 
transparency.  
With the growing burden of dementia, consistency of results from laboratory studies, and 
inconsistency of results from previous population-based studies, it seems prudent to study lens 
transparency further as a noninvasive marker of brain aging. Beginning a new prospective cohort 
study correlating the lens to the brain would be highly desirable. This study should recruit 
initially cognitively intact older adults who have not undergone cataract surgery. If a participant 
were to undergo cataract surgery during follow-up, lens transparency could be determined 
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immediately before surgery and the explanted lens would be saved for histologic analysis. 
Several hypotheses could be tested using cross-sectional and prospective data collection. First, 
one could use positron emission tomography to determine if lens transparency was associated 
with amyloid deposition (using Pittsburgh-Compound B) or glucose uptake (using FDG-PET, a 
marker of brain metabolism). Second, one could study the lens in association with anatomic and 
physical findings drawn from magnetic resonance imaging and computed tomography, such as 
macrostructural changes (size of the ventricles; volume of grey matter, white matter, and cerebral 
spinal fluid; white matter grade) and microstructural integrity of the white matter (with diffusion 
tensor imaging). Third, because there is a wide range of cognitive performance at similar levels 
of neuropathology, it would be advantageous to test if lens transparency is strongly correlated 
with global cognition (e.g., using the Mini Mental Status Exam,) and psychomotor speed and 
visuomotor processing (e.g., using the Digit Symbol Substitution Test). This would provide data 
on the association of the lens to functional ability, which is clinically relevant and distinct from 
pathology. Fourth, lens transparency and markers of brain aging could be studied in association 
with systemic markers of glycation (e.g., advanced glycation end products), oxidation (e.g., 
isoprostanes), and cellular senescence (e.g., telomere length, p16) measured in blood. If an 
association between the lens and the brain were attenuated by these systemic markers it may 
suggest a common underlying mechanism for declining transparency and brain aging. 
Prospective data collection would allow one to correlate changes in all of these measures, and 
possibly assess whether cross-sectional lens transparency or changes in lens transparency predict 
death. If lens tissue was analyzed after cataract surgery, one could correlate lens molecules (e.g., 
amyloid deposition, crystalline integrity) with markers of brain aging. A study such as this may 
provide strong evidence for the lens being a non-invasive marker of brain aging. 
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Our findings also indicate that the lens may not be a strong indicator of vascular aging 
and disease, particularly arteriosclerosis and atherosclerosis. This is the first report of the 
association of lens transparency to CAC, aortic calcium, and carotid intima-media thickness. In 
population-based cohort studies, age-related cataract has been associated with diagnosed 
cardiovascular disease, diabetes, obesity, inflammation, smoking, sunlight exposure, and 
mortality.135 Statin use has also been associated with a lower incidence of nuclear cataract, 
though it is unknown if this association is causal or correlative.188 Nearly half of the participants 
in the HWS used lipid-altering drugs at the fourth EBT examination when lens transparency was 
assessed. If risk factors for atherosclerosis or cardiovascular disease are associated with lower 
transparency, and statin use is associated with greater transparency, it may be difficult to detect 
these associations in diseased individuals who use statins because the biological effects may 
obscure each other. Furthermore, it is unknown if associations found between cataract and 
disease markers would be similar in magnitude to possible associations between lens 
transparency and disease markers. Nonetheless, the consistency of results here implies that the 
lens may be an insensitive indicator of vascular aging.     
 Our data’s validity is supported by our detecting as association between cataract surgery 
or lower lens transparency and diabetes, which is established in the ophthalmic epidemiology 
literature.135 The mechanisms behind this association lend credence to the lens reflecting 
systemic aging and/or disease. With excess glucose in the body, formation of advanced glycation 
end products (AGEs), where glucose is non-enzymatically bound to proteins and lipids, occurs 
more often throughout an organism.202-204 AGEs spur oxidation through free radical formation 
and inflammation through signaling by the receptor for advanced glycation end products.205 In 
particular, these processes damage delicate tissues, such as the glomerulus, peripheral nerves, 
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and retina, leading to the diabetes-associated conditions of nephropathy, neuropathy, and 
retinopathy.204 AGEs have also been associated with atherosclerosis and vascular stiffening by 
affecting collagen in vessel walls.202,204 Epidemiologic studies illustrate that higher levels of 
serum carboxymethyl-lysine, a dominant AGE in serum and tissues, is associated with greater 
mortality, slow walking speed, anemia, and increased aortic pulse wave velocity in older 
adults.206-209 The hallmark of AGE formation is a change in molecular structure with addition of 
glucose. Because crystallins maintain protein conformation and can themselves be altered by 
glycation, the lens may reflect systemic AGE production, and thus tissue integrity, throughout 
the body. Future studies should assess if lens transparency is associated with serum AGEs, such 
as carboxymethyl-lysine. This could be accomplished easily by adding lens measurements to 
epidemiologic studies in which AGEs have already been measured, such as the InCHIANTI 
study and the Baltimore Longitudinal Study of Aging.     
An alternative explanation for our results is that we failed to detect true associations 
between the lens and markers of aging and disease due to inadequate power, bias, residual 
confounding, or misclassification. The age range of the HWS was narrow, possibly limiting 
inherent variability in lens transparency. This may have been exacerbated by the fact that 
cataract surgery has become relatively common due to efficiency, effectiveness, and high 
insurance coverage. Subsequently, participants may have been “removed” from the sample by 
treatment, which limits variability in lens transparency and decreases the number of participants 
eligible for direct lens assessment, further reducing power. Participants were also healthy 
survivors and may exemplify the “worried well” who participate in research studies and have 
favorable health behaviors. This may have limited variability in lens transparency and outcomes 
and/or introduced bias in an unknown direction. Because of the sample size and a priori desire to 
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conduct an exploratory analysis, we also chose to examine associations using tests of distribution 
rather than regression, so residual confounding may exist. Only women were included in this 
analysis. Although there is no suggestion in the literature that any potential associations 
examined here would differ by gender, it is unknown if gender is a modifier. Finally, it is 
possible that we misclassified lens transparency or outcomes, though this is unlikely. The 
participants’ high cognitive function suggests they would not forget to report undergoing cataract 
surgery, and Scheimpflug photography provides a quantitative, unbiased, reproducible 
assessment of lens transparency. It also seems appropriate to categorize participants who 
underwent cataract surgery in the control group of lens transparency <90% or <95%. Finally, 
although 94% of the analytic sample was Caucasian, it is possible that admixture due to ancestry 
confounded the association with ApoE genotype.                
This study does have several strengths. Although the narrow age range of the HWS may 
have limited variability in lens transparency and outcomes, it also limits variability in potential 
age-associated confounders. The rich historical data allowed us to conduct a retrospective 
longitudinal analysis to help establish temporality. The HWS employs validated protocols and 
highly experienced staff to gather data, and procedures have remained consistent throughout the 
study. Combined with the staff’s long-time familiarity with study participants, this provides 
confidence that data collection was precise and accurate.  
In conclusion, this is the first study to examine the association between directly-measured 
lens transparency and markers of atherosclerosis (CAC and carotid initima-media thickness) and 
markers of brain health, such as ApoE genotype and cognition. We found that lower lens 
transparency was associated with diabetes and potentially with ApoE4 genotype. Because lens 
transparency can be measured easily, cheaply, and non-hazardously, it has great potential for use 
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in examining human health, potentially across the lifespan. Future studies would benefit from 
serially measuring lens transparency and determining its association with established markers of 
aging and disease and emerging biomarkers of aging, such as telomere length,201 AGEs, and 
insulin-like growth factor.    
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6.7  TABLES 
 
Table 6.7.1: Ocular characteristics of the Healthy Women Study Aging Lens Sub-study population 
  Total N N (%) Mean (SD) Median (IQR) Minimum Maximum 
Bilateral cataract surgery 231 64 (27.7) 
    Glaucoma 231 22 (9.5) 
    Other eye disease 231 8 (3.4) 
    
       Right eyes 
         Nuclear cataract (%) 68 
 
0.5 (1.1) 0.0 (0.4) 0.0 5.6 
   Cortical cataract (%) 68 
 
7.5 (10.1) 3.7 (8.1) 0.2 50.2 
   Total transparency (%) 68 
 
91.9 (10.6) 95.4 (8.0) 47.3 99.8 
   Contrast: No. letters read* 69 
 
29 (5) 30 (3) 6.0 36.0 
   Acuity worse than 20/20† 56 47 (83.9) 
    
       Left eyes 
         Nuclear cataract (%) 72 
 
0.6 (2.1) 0.1 (0.4) 0.0 15.5 
   Cortical cataract (%) 72 
 
11.4 (14.5) 5.5 (12.3) 0.2 67.1 
   Total transparency (%) 72 
 
88.0 (15.3) 94.1 (12.7) 32.2 99.8 
   Contrast: No. letters read* 69 
 
28 (4) 29 (4) 18.0 36.0 
   Acuity worse than 20/20†  56 49 (87.5) 
    
       Depth Perception‡ 
         Failed thick plate 69 3 (4.4) 
       Failed medium plate 65 4 (6.2) 
       Failed thin plate 61 21 (34.4)         
*Pelli-Robson test  
     †Bailey-Lovie distance visual acuity test 
‡Frisby test       
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Table 6.7.2: Association of lens transparency at the 4th EBT examination to risk factors for coronary artery calcium and medications at 4th 
EBT examination 
 
Cataract surgery  
(N=231) 
Cataract surgery and 
transparency (N=136) 
Cataract surgery and 
transparency (N=136) 
Risk factor 
No 
(N=167) 
Yes  
(N=64) P 
≥90% 
Transparent 
(N=39) 
<90% 
Transparent 
(N=97)* P 
≥95% 
Transparent 
(N=26) 
<95% 
Transparent 
(N=110)* P 
Age, years, M (SD) 73.1 (1.7) 73.6 (1.6) 0.05 73.1 (1.8) 73.6 (1.6) 0.12 73.0 (1.5) 73.5 (1.7) 0.15 
Smoking, N (%) 4 (2.6) 2 (3.6) 0.69 0 (0) 2 (2.3) 0.34 0 (0) 2 (2.0) 0.47 
Waist circumference, cm, M (SD) 88.1 (13.1) 94.2 (15.7) <0.01 89.3 (14.2) 91.3 (15.3) 0.49 88.3 (12.1) 91.3 (15.5) 0.38 
Total cholesterol, mg/dL, M (SD) 221 (42) 213 (48) 0.29 211 (43) 220 (46) 0.29 213 (46) 219 (45) 0.58 
HDL, mg/dL, M (SD) 68 (15) 68 (18) 0.78 68 (16) 69 (17) 0.73 68 (16) 69 (17) 0.65 
LDL, mg/dL, M (SD) 129 (38) 122 (42) 0.27 120 (37) 128 (41) 0.33 122 (36) 126 (41) 0.65 
Triglycerides, mg/dL, M (SD) 118 (49) 119 (54) 0.87 114 (50) 117 (54) 0.79 116 (50) 116 (54) 0.97 
Glucose, mg/dL, M (SD) 103 (14) 105 (16) 0.42 104 (13) 105 (17) 0.73 102 (10) 105 (17) 0.23 
Insulin, uIU/mL, M (SD) 13.3 (5.4) 14.9 (11.0) 0.32 13.5 (5.9) 13.6 (9.2) 0.92 12.9 (5.3) 13.8 (8.9) 0.55 
Systolic BP, mmHg, M (SD) 125 (18) 123 (24) 0.63 121 (14) 123 (22) 0.52 121 (12) 123 (21) 0.58 
Diastolic BP, mmHg, M (SD) 66 (9) 67 (13) 0.83 66 (9) 66 (11) 0.99 68 (9) 66 (11) 0.38 
Pulse pressure, mmHg, M (SD) 58 (15) 56 (17) 0.47 55 (12) 57 (16) 0.48 53 (12) 57 (15) 0.24 
Lipid medication, N (%) 73 (46.5) 25 (43.9) 0.73 22 (56.4) 34 (38.2) 0.06 14 (53.9) 42 (41.2) 0.25 
Blood pressure medication, N (%) 76 (48.4) 25 (43.9) 0.56 22 (56.4) 38 (42.7) 0.15 15 (57.7) 45 (44.1) 0.22 
Diabetes medication, N (%) 7 (4.5) 9 (15.8) <0.01 1 (2.6) 12 (13.5) 0.06 0 (0) 13 (12.8) 0.05 
Diabetes by meds/glucose, N (%) 12 (7.2) 11 (17.2) 0.02 2 (5.1) 14 (14.4) 0.13 0 (0) 16 (14.6) 0.04 
Interleukin-6, median (IQR) 1.89 (1.21) 2.16 (1.84) 0.28 2.01 (1.75) 2.16 (1.63) 0.61 1.97 (1.74) 2.15 (1.73) 0.41 
*Includes participants who underwent cataract surgery. M (SD) = mean (standard deviation). 
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Table 6.7.3: Association of lens transparency at 4th EBT examination to risk factors for coronary artery calcium and medications 
at baseline HWS examination 
 
 
Cataract surgery  
(N=231) 
Cataract surgery and 
transparency (N=136) 
Cataract surgery and 
transparency (N=136) 
Risk factor 
No 
(N=167) 
Yes  
(N=64) P 
≥90% 
Transparent 
(N=39) 
<90% 
Transparent 
(N=97)* P 
≥95% 
Transparent 
(N=26) 
<95% 
Transparent 
(N=110)* P 
Age, years, M (SD) 47.5 (1.6) 47.9 (1.5) 0.07 47.4 (1.6) 47.9 (1.6) 0.10 47.2 (1.3) 47.9 (1.6) 0.06 
Smoking, N (%) 35 (21.1) 21 (32.8) 0.06 10 (25.6) 26 (26.8) 0.89 8 (30.8) 28 (25.5) 0.58 
Body mass index, kg/m2, M (SD) 23.2 (4.2) 24.5 (4.7) 0.05 23.8 (4.7) 24.2 (4.4) 0.64 23.3 (2.8) 24.2 (4.8) 0.33 
Total cholesterol, mg/dL, M (SD) 182 (33) 186 (37) 0.40 185 (27) 185 (35) 0.95 186 (28) 184 (34) 0.82 
HDL, mg/dL, M (SD) 60 (14) 58 (14) 0.21 63 (15) 58 (13) 0.09 61 (15) 59 (14) 0.50 
LDL, mg/dL, M (SD) 107 (28) 110 (32) 0.51 107 (29) 110 (31) 0.66 110 (30) 109 (30) 0.82 
Triglycerides, mg/dL, M (SD) 74 (34) 90 (58) 0.03 72 (25) 84 (53) 0.07 73 (24) 83 (51) 0.15 
Glucose, mg/dL, M (SD) 85 (11) 91 (39) 0.24 85 (10) 90 (32) 0.21 85 (10) 89 (30) 0.21 
Insulin, uIU/mL, M (SD) 7.3 (4.2) 8.3 (6.6) 0.29 7.0 (3.8) 8.0 (5.7) 0.21 6.2 (2.7) 8.1 (5.6) 0.02 
Systolic BP, mmHg, M (SD) 106 (10) 110 (14) 0.09 108 (11) 108 (13) 0.94 107 (11) 108 (12) 0.58 
Diastolic BP, mmHg, M (SD) 71 (8) 71 (8) 0.66 71 (8) 71 (8) 0.78 70 (9) 71 (8) 0.45 
Pulse pressure, mmHg, M (SD) 35 (7) 38 (10) 0.05 37 (8) 37 (9) 0.88 37 (6) 37 (9) 0.91 
*Includes participants who underwent cataract surgery. M (SD) = mean (standard deviation).  
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Table 6.7.4: Association of lens transparency at 4th EBT examination to total coronary artery calcium score at 1st, 2nd, 3rd, and 4th EBT 
examinations 
 
Cataract surgery  
(N=231) 
Cataract surgery and transparency 
(N=136) 
Cataract surgery and transparency 
(N=136) 
Total coronary 
artery calcium score No (N=167) Yes (N=64) P 
≥90% 
Transparent 
(N=39) 
<90% 
Transparent 
(N=97)* P 
≥95% 
Transparent 
(N=26) 
<95% 
Transparent 
(N=110)* P 
4th EBT (N=193) 
  
 
  
 
  
 
   0 (N=56), N (%) 44 (30.8) 12 (24.0) 0.60 10 (30.3) 17 (21.8) 0.49 4 (19.1) 23 (25.6) 0.79 
   1-99 (N=69), N (%) 51 (35.7) 18 (36.0)  13 (39.4) 29 (37.2)  8 (38.1) 34 (37.8)  
   100+ (N=68), N (%) 48 (33.6) 20 (40.0)  10 (30.3) 32 (41.0)  9 (42.9) 33 (36.7)  
   Score, median (IQR) 32.1 (196.7) 54.2 (225.2) 0.75 30.3 (164.8) 59.0 (231.7) 0.74 53.1 (198.5) 40.2 (226.3) 0.62 
   
 
  
 
  
 
3rd EBT (N=225) 
  
 
  
 
  
 
   0 (N=85), N (%) 64 (39.5) 21 (33.3) 0.48 15 (38.5) 31 (32.6) 0.64 8 (30.8) 38 (35.2) 0.27 
   1-99 (N=86), N (%) 58 (35.8) 28 (44.4)  13 (33.3) 40 (42.1)  8 (30.8) 45 (41.7)  
   100+ (N=54), N (%) 40 (24.7) 14 (22.2)  11 (28.2) 24 (25.3)  10 (38.5) 25 (23.2)  
   Score, median (IQR) 6.8 (99.9) 10.3 (92.4) 0.63 6.9 (105.1) 10.3 (105.7) 0.85 21.0 (149.7) 9.1 (92.6) 0.66 
   
 
  
 
  
 
2nd EBT (N=200) 
  
 
  
 
  
 
   0 (N=93), N (%) 73 (49.3) 20 (38.5) 0.39 18 (47.4) 33 (40.7) 0.73 11 (44.0) 40 (42.6) 0.30 
   1-99 (N=79), N (%) 55 (37.2) 24 (46.2)  14 (36.8) 36 (44.4)  8 (32.0) 42 (44.7)  
   100+ (N=28), N (%) 20 (13.5) 8 (15.4)  6 (15.8) 12 (14.8)  6 (24.0) 12 (12.8)  
   Score, median (IQR) 1.0 (24.6) 2.8 (55.2) 0.33 2.4 (50.1) 2.8 (41.5) 0.95 5.2 (63.9) 1.9 (28.5) 0.47 
   
 
  
 
  
 
1st EBT (N=229) 
  
 
  
 
  
 
   0 (N=128), N (%) 98 (59.4) 30 (46.9) 0.20 24 (63.2) 48 (49.5) 0.27 13 (52.0) 59 (53.6) 0.43 
   1-99 (N=74), N (%) 48 (29.1) 26 (40.6)  9 (23.7) 37 (38.1)  7 (28.0) 39 (35.5)  
   100+ (N=27), N (%) 19 (11.5) 8 (3.5)  5 (13.2) 12 (12.4)  5 (20.0) 12 (10.9)  
   Score, median (IQR) 0 (13.0) 1.5 (37.9) 0.09 0 (29.0) 1.0 (30.9) 0.15 0 (30.1) 0 (18.0) 0.88 
*Includes participants who underwent cataract surgery. 
 
124 
 
Table 6.7.5: Association of lens transparency at 4th EBT examination to ApoE genotype and Modified Mini Mental Status Exam score 
 
Cataract surgery  
(N=231) 
Cataract surgery and transparency 
(N=136) 
Cataract surgery and transparency  
(N=136) 
  No (N=167) 
Yes 
(N=64) P 
≥90% 
Transparent 
(N=39) 
<90% 
Transparent 
(N=97)* P 
≥95% 
Transparent 
(N=26) 
<95% 
Transparent 
(N=110)* P 
ApoE status, N (%) 
  
 
 
 
  
 
    2,2 1 (0.6) 0 (0) 0.20 0 (0) 0 (0) 0.01 0 (0) 0 (0)  0.04 
   3,2 20 (12.2) 5 (7.9)  4 (10.5) 8 (8.3) 
 
1 (3.9) 11 (10.2) 
    3,3 111 (67.7) 41 (65.1)  28 (73.7) 62 (64.6) 
 
22 (84.6) 68 (63.0) 
    4,2 4 (2.4) 0 (0)  2 (5.3) 0 (0) 
 
0 (0) 2 (1.9) 
    4,3 25 (15.2) 17 (27.0)  3 (7.9) 26 (27.1) 
 
2 (7.7) 27 (25.0) 
    4,4 3 (1.8) 0 (0)  1 (2.6) 0 (0) 
 
1 (3.9) 0 (0) 
 
   
 
 
 
  
 
    2,2 or 3,2 or 3,3  132 (80.5) 46 (73.0) 0.22 32 (84.2) 70 (72.9) 0.17 23 (88.5) 79 (73.2) 0.10 
   4,2 or 4,3 or 4,4 32 (19.5) 17 (27.0)  6 (15.8) 26 (27.1) 
 
3 (11.5) 29 (26.9) 
 
   
 
 
 
  
 
 3MS score, median (IQR) 97 (4) 96 (6) 0.02 98 (5) 97 (5) 0.09 98 (5) 97 (5) 0.33 
*Includes participants who underwent cataract surgery. 
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7.0  DISCUSSION 
 
 
7.1 SUMMARY, CONCLUSIONS, AND FUTURE RESEARCH 
  
The main goal of these studies was to clarify the role of LTL and lens transparency as 
biomarkers in population studies of human aging. The results provide new evidence on the 
overall value of these biomarkers in aging research, particularly their specificity reflecting 
aspects of human aging.    
  
 
7.1.1 Leukocyte telomere length 
LTL is proposed as a biomarker of aging because it ostensibly records inflammation and 
oxidative stress,23,25,158 but the evidence for LTL as a general biomarker of aging remains 
unclear. Notably, previous studies have almost exclusively attempted to associate LTL with 
clinically diagnosed disease in individual organ systems, usually categorized as present or 
absent, despite the fact that chronic disease can build throughout the body over time. 
Subsequently, we chose to study the association of LTL to a marker of disease burden, the 
physiologic index of comorbidity, which tabulates the presence and severity of common chronic 
age-related disease across five major physiologic systems. An important aspect of the five 
systems and their measurement is that they both capture changes from age and age-related 
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chronic disease; they tend to change with age even without other external risk factors. To the 
extent that an index across systems might capture an underlying propensity to age-related 
changes in all systems, a marker of fundamental aging processes such as LTL should be 
associated with it. Using this index we demonstrated that LTL was strongly associated with 
disease burden independent of diagnosed chronic conditions. LTL was less strongly associated 
with disease in individual systems, except possibly carotid intima-media thickness, and was not 
associated with diagnosed chronic conditions or a count of diagnosed chronic conditions. In this 
study LTL was associated with disease burden after removing carotid thickness from the 
physiologic index of comorbidity. This sensitivity analysis was conducted because vascular 
disease appeared to drive the association of the index with LTL, and we wished to see if LTL 
was associated with disease burden independent of vascular disease. The results imply that LTL 
might indicate widespread incremental changes in organ structure and function from age and 
age-related chronic disease in older adults independent of vascular disease.  
There are a large number of cross-sectional studies on LTL that demonstrate few 
consistent results. Given this new data, it is appropriate to ask, are more studies of LTL 
warranted, and, if so, how should these studies be designed? This data implies that there is more 
to learn about LTL’s potential contribution to human biology if it is studied in association with 
less conventional measurements like disease burden rather than standard measurements such as 
clinically diagnosed disease. Telomere length is a fundamental regulator of cellular senescence 
in laboratory studies yet it remains unknown if it contributes to human longevity, apart from its 
involvement in cancer. It would be surprising if telomere length was not even a small 
determinant of human longevity given the strength and consistency of results from the 
laboratory. More research in human populations is needed to test this important hypothesis. 
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Moreover, because LTL can be sampled easily, cheaply, and throughout the lifespan, 
characteristics which are advantageous for translation of an aging biomarker, it seems 
worthwhile to continue studying LTL in epidemiology.  
The most valuable data on LTL would come from longitudinal studies of changes in LTL 
– these studies allow more accurate modeling of LTL dynamics and may illustrate age-associated 
biological mechanisms better than studies with a single measurement of LTL. It would be 
advantageous to determine predictors of change in LTL, which necessitates modeling change in 
LTL as an outcome. Strong data that LTL reflects biological aging would come from studies 
modeling simultaneous changes in LTL, systemic markers of inflammation and oxidation, and 
disease burden. One could model the association between changes in disease burden and 
systemic markers of inflammation and oxidation, such as interleukin-6 and isoprostanes, and add 
change in LTL to the model to see if this mediates the association. If changes in LTL and 
changes in systemic markers of oxidation/inflammation were modeled jointly as predictors of 
aging (e.g., mortality, frailty, disease burden, etc.), it would be possible to test for interactions 
between LTL and oxidation markers. This may identify joint contributions of declining LTL and 
inflammation or oxidation on influencing aging, which may provide evidence in humans that 
inflammation and oxidation may act through changes in LTL. These studies require follow-up 
longer than 10 years to circumvent the problem of measurement error confounding observed 
changes in LTL. At first, data may be derived from measuring LTL in previously gathered blood 
samples from existing cohort studies. Because of the large inter-individual variance in LTL and 
sensitivity of results to measurement error introduced by various assays, cohorts with the widest 
age range possible would be ideal for change studies. The sample should be highly phenotyped 
to allow adjustment for potential confounders, which is chronically absent from studies of LTL. 
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Large sample size will confer more power to counteract variance introduced by measurement 
method, and will also provide stability for models containing many potential covariates. 
Announcement of future measurement of LTL in nearly 100,000 members of the Kaiser 
Permanente health maintenance organization provides confidence that data of this magnitude 
may soon be available. In addition to the benefits listed above, this sample will likely provide 
data that is more generalizeable and can be linked to other useful datasets, such as the National 
Death Index, which would enable survival analysis. Unfortunately, because Kaiser data is 
derived from clinical sources, it is unlikely that the dataset will include measurement of 
subclinical disease, which we have shown is critical to detecting significant associations, or other 
characteristics traditionally assessed in a research setting, such as standardized functional 
measures (e.g., gait speed, grip strength). Using pooled data from research studies with LTL 
measured with similar methods, such as studies included in the CHARGE consortium and related 
European cohorts, may increase power while providing more detailed measurements including 
subclinical disease. This type of pooling was used for a recent genome-wide association study of 
LTL.210 Pooling would enable researchers to construct a similar index of disease burden in a 
sample that also has adequate numbers of diagnosed chronic conditions to test, with adequate 
power, if LTL is associated with age-related chronic disease burden and/or diagnosed chronic 
conditions. Furthermore, using the richness of these datasets, it would be possible to study if 
LTL is associated with a tabulation of functional health, such as frailty, which has been related to 
disease burden.211 In addition to studying the strength of the association of LTL with disease 
burden, frailty, and death, it would be worthwhile to determine the accuracy of LTL predicting 
these outcomes using the area under the receiver-operator curve, particularly if LTL adds 
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additional predictive ability to models including age and other easily acquired indicators of 
health status, such as BMI and smoking history.  
Our analysis of sub-components of the index also suggests that in older adults LTL may 
be most strongly associated with processes which contribute to atherosclerosis and/or 
hypertension specifically, and perhaps processes which contribute to structural and physiological 
changes in other organs, such as accumulation of white matter hyperintensities. This is consistent 
with some previous cross-sectional studies which show atherosclerosis is associated with shorter 
LTL.33,51,53,54,56,57,63,71-75 Further research on LTL and atherosclerosis, provided phenotypes were 
carefully considered, would likely support this association. Because so many studies on LTL and 
atherosclerosis have been conducted more studies of this association are a lower priority.  
Additional research is necessary, though, to confirm if LTL reflects brain aging because 
the few previous studies of LTL and the brain have used very different study populations.81-85 
Furthermore, these previous studies have only used cognitive function or clinically-defined 
dementia as phenotypes rather than anatomic, physiologic, or biologic markers of brain aging. If 
LTL was associated with brain pathology it may stand as a particularly useful marker to explore 
relationships between the brain, immune system, and aging, which are sorely needed given the 
lack of defined risk factors for brain aging. It would be advantageous to study the association of 
LTL to an in vivo marker of brain aging, such as amyloid plaques quantified with Pittsburgh-
Compound B or glucose uptake using FDG;212 macrostructural changes in the size of ventricles, 
grey and white matter volume, CSF volume, and white matter hyperintensity; and 
microstructural integrity of the white matter using diffusion tensor imaging. Some of these 
associations may be studied if LTL was measured in the Ginko Evaluation of Memory (GEM) 
Study, which included anatomic imaging and measurement of amyloid using Pittsburgh-
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Compound B in several hundred participants, and could identify a particular niche where LTL 
might be a useful biomarker.     
From a methodological perspective, these results illustrate that it is necessary to study a 
biomarker against many outcomes to determine its validity. Here, we employed an index that 
combined several other measures using a particular scoring method, continuous measurements of 
disease in individual organ systems, dichotomous classification of diagnosed diseases, and a 
count of diagnosed diseases. This list of outcomes is not comprehensive, and there are many 
methods to combine measurements into an aggregate score, but we nonetheless demonstrated 
different associations between LTL and all of these outcomes. These different associations 
allowed us to clarify which aspects of age-related disease LTL may accurately reflect, which 
would not have been possible if a single outcome definition were used.     
How useful is LTL as a biomarker of aging when evaluated using the four criteria 
(statistical, biological, clinical, and experimental) proposed in 2.4 and 2.5? Although it may add 
additional information in a predictive model, LTL is likely a weaker predictor of incident events 
than chronologic age. Subsequently, LTL may not be an advantageous biomarker to incorporate 
into predictive models because it poorly fulfills the statistical criterion. LTL can be measured 
relatively cheaply, easily, and repeatedly, so it fulfills the clinical criterion, but because LTL 
varies widely between species, it is questionable whether it fulfills the experimental criterion.  
LTL may be most advantageous to human population studies when considered using the 
biological criterion. Basic science studies clearly indicate that telomere shortening is a 
fundamental regulator of cellular senescence and an important safeguard against tumorigenesis. 
In human population studies, the relevance of LTL remains equivocal. In epidemiology, LTL is 
typically measured at only one point in time. It is also often used as a surrogate for telomere 
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length in other tissues, and although there is evidence that telomere lengths are synchronized 
throughout the body, it remains possible that LTL does not reflect telomere length in every 
tissue, particularly because its measurement usually displays average telomere length and 
obscures the distribution of telomere lengths in a population of cells. It is possible that telomere 
length sampled from tissues more proximal to the physiologic systems in the index would be 
more strongly associated with disease in those systems. 
Human population studies of LTL remain in their infancy. Subsequently, much can be 
learned about the biology of human telomere dynamics from future research. Salient questions to 
answer include: What is the normal rate of telomere shortening in a human population? What is 
the variance in telomere shortening? What risk factors accelerate telomere shortening and what 
protective factors ameliorate shortening? Is the rate of telomere shortening predictive of specific 
age-associated outcomes or overall organismal aging measured using different constructs? If 
there truly is a dichotomy between aging and cancer, is telomere shortening the central regulator 
of this dichotomy? Answering these questions requires longitudinal measurement of telomere 
length, likely over decades, in well-characterized populations. This could position telomere 
length as a prime candidate for exploration using the growing subfield of lifecourse 
epidemiology. It would also behoove researchers to standardize measurement techniques while 
developing assays with higher throughput and higher accuracy to facilitate comparisons across 
studies and pooling for meta-analysis. If possible, telomere length should also be sampled from 
non-hematopoetic tissues to learn whether tissue source impacts the strength of associations. 
With these advancements, researchers will be able to more confidently assess telomere length as 
a biomarker of aging in humans.             
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7.1.2 Lens transparency 
The lens is a fascinating tissue. Present from before birth until death with little turnover, it is also 
one of the few tissues that directly interacts with the internal and external environments. It is 
nearly homogenous and comprised almost entirely of a few types of proteins, crystallins, which 
also exist throughout the body. As heat shock proteins, crystallins critically maintain the 
conformation and function of themselves and other proteins, and play a part in an organism’s 
successful response to stress throughout the lifespan. Because it is optically clear, the lens can be 
measured easily, cheaply, and non-invasively using accurate and reproducible imaging 
techniques. Importantly, lens transparency can be measured continuously using imaging to 
distinguish a perceived aging phenotype, declining transparency, from a disease phenotype, 
diagnosed presence of cataract or cataract surgery. These characteristics provide both a 
biological and practical basis for using lens transparency as a biomarker of aging in population 
studies of human aging.  
Despite its theoretical and actual advantages, the lens has not been validated as a 
biomarker of aging. We studied the lens in association with markers of aging and age-related 
disease to advance it as a putative biomarker of aging. We used data from the Health, Aging, and 
Body Composition Study and Age-Related Maculopathy Ancillary study to differentiate between 
diagnosed cataract and cataract surgery, disease phenotypes, and AREDS-graded lens 
transparency, an aging phenotype, while determining the association of these lens measures to 
LTL. The studies also provided a wealth of phenotypic and biologic data to consider as potential 
confounders. We found that participants with highly transparent lenses, a rare group comprising 
less than 3% of the sample, had much longer LTL than participants with lower lens transparency, 
but that cataract surgery was not associated with LTL. It was also remarkable that the difference 
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in mean LTL between participants with highly transparent and less transparent lenses was nearly 
1,000 bp, a much greater difference in mean LTL than seen in the literature with stratification by 
other variables. Participants with highly transparent lenses also had no history of smoking or 
clinically-diagnosed cerebrovascular disease or cardiovascular disease despite being over 70 
years old. This result implies that high lens transparency may be a rare longevity phenotype 
useful for identifying individuals who have aged exceptionally well in other tissues. The results 
also suggest that specific measurements of lens transparency may register aging more accurately 
than dichotomous classification using presence or absence of cataract. As the first study of the 
association of the lens with LTL it is difficult to set these results in context, but they lend 
credence to exploring the lens as a biomarker of aging.    
 In the Healthy Women Study, we examined the association of the lens with a more 
extensive battery of markers of aging and disease to provide broader evidence for the lens as a 
biomarker of aging. The HWS afforded measurement of CAC using EBT, a strong predictor of 
cardiovascular disease and death. It also provided EBT-measurement of aortic calcium, which 
also increases with age but is less associated with cardiovascular disease risk factors, and carotid 
intima-media thickness, which increases with age, high blood pressure, and atherosclerosis. 
Because the study is ongoing we were able to measure lens transparency with high accuracy 
using Scheimpflug photography when participants returned for their fourth EBT examination. As 
a longitudinal cohort study, the HWS also enabled us to conduct both cross-sectional and 
retrospective longitudinal analyses.  
In the HWS, we found that neither cataract surgery nor lens transparency was associated 
with most examined risk factors for coronary atherosclerosis or CAC, aortic calcium, or carotid 
intima-media thickness, measured concurrently or previously. There was a relatively consistent 
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association between lower transparency and markers of diabetes, which was expected given the 
established relationship between diabetes and cataract. Finally, we observed that transparency 
was associated with ApoE genotype, and that greater transparency may be associated with a 
lower frequency of carrying an ApoE4 allele and better cognitive function.  
 Taken together, these results are promising. If the associations are true it suggests that 
lens transparency may be a viable biomarker of aging, particularly as an indicator of brain aging 
and diabetes, but not coronary atherosclerosis or related risk factors. Histological studies support 
a connection between the lens and brain aging, particularly Alzheimer’s type pathology 
characterized by protein aggregation and deposition, due to the presence and similar activity of 
crystallins in the lens and brain. Two previous studies examining an association between cataract 
and ApoE genotype, both of which used a selected sample of participants from eye clinics, found 
no association between cataract and ApoE4 genotype or that cataract was associated with lower 
odds of ApoE4 genotype. 
Given these previous studies and our own data, lens transparency warrants future 
investigation as a noninvasive marker of brain aging. Beginning a new prospective cohort study 
correlating the lens to the brain would be highly desirable. This study should recruit initially 
cognitively intact older adults who have not undergone cataract surgery. If a participant were to 
undergo cataract surgery during follow-up, lens transparency would be determined immediately 
before surgery and the explanted lens would be saved for histologic analysis. Several hypotheses 
could be tested using cross-sectional and prospective data collection. First, one could determine 
if lens transparency was associated with amyloid measured in vivo using Pittsburgh-Compound 
B or glucose uptake using FDG-PET. Second, one could study the lens in association with 
anatomic and physical findings drawn from MRI and CT, such as changes in the size of the 
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ventricles, grey and white matter volume, CSF volume, white matter grade, and microstructural 
integrity of the white matter (with diffusion tensor imaging). These are strong markers of macro 
and microstructural integrity and possibly cognitive reserve. Third, because there is a wide range 
of cognitive performance at similar levels of neuropathology, it would be advantageous to test if 
lens transparency is strongly correlated with global cognition (e.g., using the Mini Mental Status 
Exam,) and psychomotor speed and visuomotor processing (e.g., using the Digit Symbol 
Substitution Test). This would provide data on the association of the lens to functional ability, 
which is clinically relevant and distinct from pathology. Fourth, lens transparency and markers 
of brain aging could be studied in association with systemic markers of glycation (e.g., AGEs), 
oxidation (e.g., isoprostanes), and cellular senescence (e.g., telomere length, p16) measured in 
blood. If an association between the lens and the brain were attenuated by these systemic 
markers it may suggest a common underlying mechanism for declining transparency and brain 
aging. Prospective data collection would allow one to correlate changes in all of these measures, 
and possibly assess whether cross-sectional lens transparency or changes in lens transparency 
predict death. If lens tissue was analyzed after cataract surgery, one could correlate lens 
molecules (e.g., amyloid deposition, crystalline integrity) with markers of brain aging. A study 
such as this may provide strong evidence for the lens being a non-invasive marker of brain aging.          
Would it be useful to conduct more studies on the association of the lens to 
cardiovascular disease? Population-based studies suggest that cataract is associated with 
cardiovascular disease, but CAC, aortic calcium, and carotid intima-media thickness have not 
been studied previously. It is possible that age-related cataract is associated with diagnosed 
cardiovascular disease but not subclinical markers of cardiovascular disease specifically. 
Confounding by statin use may have occurred. Statins have been associated with lower incidence 
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of nuclear cataract but not overall cataract: in 1,299 participants of the Beaver Dam Eye Study, 
five-year incidence of nuclear cataract was 12.2% in statin users compared with 17.2% in 
nonusers (OR 0.55, 95% CI 0.36-0.84), adjusted for age.188 When only never-smokers without 
diabetes were assessed, the age-, sex-, and lipid-adjusted OR for nuclear cataract was 0.40 (95% 
CI 0.18-0.90). Because half of the HWS participants were using statins, and these women were 
predominantly non-smokers without diabetes, this may have counterbalanced a significant 
positive association between cataract and risk factors for atherosclerosis and resulted in non-
detection of a significant association. Nonetheless, our results were relative consistent in that 
neither cataract surgery nor lens transparency were associated risk factors for coronary 
atherosclerosis or CAC, aortic calcium, or carotid intima-media thickness. Significant 
differences detected between groups were in general small and did not demonstrate a clear 
pattern of better transparency being associated with a favorable cardiovascular health profile 
(e.g., lower LDL, lower triglycerides, higher HDL, smaller waist circumference).  
It would be helpful to achieve greater certainty of the specificity of lens transparency as a 
biomarker of aging, particular in regard to cardiovascular disease. Creating new cohort studies 
seems unwarranted, but using existing cohorts could be feasible. In particular, it would be 
advantageous to study the lens in association with additional cardiovascular phenotypes. Ankle 
brachial index is a suitable outcome and a marker of peripheral vascular disease, a different 
phenotype. Pulse wave velocity, an ultrasound-based marker of vascular stiffening more 
intimately tied to blood pressure, is strongly associated with age independent of disease and 
would be another worthy target for investigation. Ankle brachial index and pulse wave velocity 
have been measured in many large cohort studies of aging and cardiovascular disease.213 If data 
was gathered on cataract in these studies, it could be used to conduct a retrospective longitudinal 
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study to determine if cataract is associated with facets of vascular aging and disease. If cataract 
data was not ascertained previously, participants could be re-contacted and diagnosis of cataract 
or cataract surgery could be ascertained via self-report. Alternatively, these studies and others 
could add measurements of lens transparency and test if current lens transparency reflects 
previous levels of vascular disease, or, if clinical examinations are ongoing, if prospectively 
gathered lens transparency is associated with concurrent changes in vascular markers.    
An alternative explanation for the null results from the HWS is that we committed a type 
II error due to inadequate power, bias, residual confounding, or misclassification. The HWS had 
a narrow age range, which could have limited variability in lens transparency and other markers. 
This would decrease power to detect a significant association. The low end of the transparency 
spectrum may also have been eliminated because many participants had cataract surgery fairly 
early, which has become relatively ubiquitous. Although only women were included in this 
analysis, and there is no suggestion in the literature that associations would differ by gender, it is 
still possible that gender modifies any real associations. Subsequently, this bias, as well as other 
unknown biases due to sample selection, may have influenced results. It is possible that we 
misclassified lens transparency, though this is unlikely because participants should accurately 
remember if they underwent cataract surgery (particularly because their cognitive function was 
high when measured with the 3MS), and Scheimpflug photography provides an accurate 
measurement of lens transparency. 
Is lens transparency a valid biomarker of aging in human population studies? To 
determine whether lens transparency adds meaningful data to statistical models predicting age-
related outcomes, in addition to the new specific studies described above concerning brain and 
vascular aging, an efficient first approach may be analysis of data from studies on the 
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epidemiology of cataract. Although these studies often lack very sensitive measurements of lens 
transparency, such as Scheimpflug photography, they are generally large (for increased power), 
tabulate other phenotypic data (for examination as outcomes or for adjustment in models as 
confounders), and include younger participants (which provide a wider age span and potential for 
follow-up for lifecourse analysis). It may be possible to embed new measurements in these 
studies with re-enrollment to convert the studies into aging cohort studies. If resources were not 
available to enroll the entire cohort, participants could be selected for enrollment in case-cohort 
studies, which are more efficient but can maintain statistical robustness.  
Practically, the lens has many advantages. It can be measured easily, reliably, and 
repeatedly using a variety of methods, including direct imaging with photography and grading 
against standard cataract photos. Subsequently, it should be relatively easy to incorporate lens 
measurements into existing human studies. Lower order mammals and some non-mammalian 
model systems, such as Zebra fish, have lenses which might serve to validate results from human 
studies or provide preliminary data for human studies. Indeed, imaging devices have been used 
successfully to provide quantitative lens data from mice. Furthermore, model systems can be 
used to conduct experiments, allowing researchers to determine if changes in genes or the 
environment may be concurrently reflected in the lens and other tissues, which may suggest that 
the lens and other tissues are linked. For example, caloric restriction has been shown to delay 
many age-associated changes as well as reduce the incidence of cataract. With increased 
incorporation of sensitive lens measurements into animal and human studies, researchers will be 
able to validate the lens as a biomarker of aging, and potentially position it for use as a tool in 
studies hoping to optimize aging.   
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7.1.3 Studying aging using the extremes versus the mean 
Epidemiology is concerned with studying health patterns in populations. Typically, this is 
achieved by measuring the distribution of risk factors and outcomes in general population 
cohorts and noting associations between risk factor variation and outcome variation. Essentially, 
it is a study of the association between the mean level of risk factors and the mean level of 
outcomes: when one mean increases the other mean increases, and when one mean falls the other 
mean falls. A benefit of studying general populations is that data are more generalizable. A 
drawback to studying general populations is that within a distribution there can exist a great deal 
of heterogeneity. Although heterogeneity provides variance, and differences cannot be detected 
without variance, it also introduces a higher amount of background noise which can obscure 
detecting associations of interest.     
 Rather than studying differences in means from wide distributions, another way to detect 
differences is by studying means from less variable but extremely divergent distributions. More 
simply put, rather than compare people within a large general population, instead focus on the 
outliers, those that are highly different from the average. Although data derived from outliers 
may not be as generalizable, one often finds interesting associations at the extremes because 
there is a large difference between the mean of the general population and the mean of the 
outliers. Furthermore, gathering a small number of people at an extreme may create a more 
homogeneous phenotype, dampening the noise effect which can obscure associations at the cost 
of reducing statistical power.  
 These differences in approach, studying outliers vs. studying the general population 
mean, have particular relevance to aging research. As discussed in the Background of this 
dissertation, the crux of aging research is defining what is aging vs. what is disease. As opposed 
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to basic research in model systems where distinct phenotypes can literally be engineered or 
clinical research where subjects are recruited due to their expression of overt disease, it is 
difficult in population-based aging research to classify who exactly we are studying. Is it the 
normal aged? The diseased aged? The long lived who are healthy? The long lived who are sick? 
Typically, the consequence of this identity crisis is that we doggedly try to tease apart groups in a 
general population or tease apart an aging phenotype from a disease phenotype by relying on 
physical tools (more precise measurements, measurements at finer levels) or statistical tricks 
(increasing sample size to afford more variability and increased power). The other solution is to 
intelligently design studies which force distributions as far apart as possible by focusing on the 
extremes: people who age very rapidly and people who age very slowly. Advancement of LTL 
and lens transparency as biomarkers of aging in epidemiology may be best achieved by 
examining the extremes.  
At one end of the aging spectrum are people who age rapidly, often lumped into a group 
of progeroid syndromes. These syndromes, such as Werner’s syndrome, Hutchinson-
Gilford Progeria Syndrome (HGPS), and Xeroderma pigmentosum (XP), have characteristics 
which appear like accelerated aging. They also allow probing of distinct molecular pathways due 
to their genetic origins. For example, in Werner’s syndrome, which is caused by a mutation in 
the WRN gene, patients have a faulty 5’ 3’ DNA helicase and exonuclease. Interestingly, the 
molecular hallmark of Werner’s syndrome is accelerated telomere attrition, and one clinical 
hallmark is that nearly 100% of patients suffer from early onset of bilateral cataracts.40,180 HGPS 
is characterized by a defect in lamin A (coded by LMNA), a cytoskeletal protein which supports 
the nuclear envelope.214 The defect causes accumulation of the protein around the nuclear 
envelope, misshaping of the envelope, improper interaction between the envelope and adjacent 
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chromatin, disordered nuclear function, and inability of the cell to divide. HGPS patients have 
short stature, thinned skin, low frequency conductive hearing loss, growth hormone deficiency, 
insulin resistance, and many signs of cardiovascular aging including age-associated elevated 
blood pressure, reduced vascular compliance, decreased ankle–brachial indexes, and adventitial 
thickening, but usually normal cognition.215 Patients die at an average age of 13 years old from 
myocardial infarction or stroke due to massively accelerated arteriosclerosis. XP can manifest 
from one of many point mutations in genes encoding proteins involved in nucleotide excision 
repair.216,217 The genomic instability causes apoptosis and mutagenesis in many tissue types and 
clinically manifests as neurodegeneration (loss of neurons), endocrine dysfunction (loss of 
somatotrophic axis), photoaging of the skin and eyes, proliferation of cutaneous tumors, and 
hematopoetic failure (replicative senescence of hematopoetic stem cells). The drawback of using 
these syndromes to probe aging is that there are small numbers of patients (limiting power) and 
aspects of their presentation are different from “normal” aging. The syndromes can be replicated, 
though, in model systems, particularly rodents, which may afford studying certain aspects of 
their biology in association with LTL and lens transparency. 
At the other end of the aging spectrum are people who age slowly. These people have 
been described as exhibiting longevity, healthy aging, or exceptional survival, among other terms 
which are not necessarily interchangeable. Opportunities to study the epidemiology of healthy 
aging are increasing rapidly.218 The Long Life Family Study recruited nearly 5,000 individuals 
clustered in families with exceptional longevity (and their spouses) to participate in a study of 
the genetics of healthy aging. Compared to age-matched controls from population-based cohorts 
not selected for longevity, Long Life Family Study participants exhibit better health.219 LTL has 
been measured in most Long Life Family Study participants and analysis of LTL heritability, 
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genetic associations, and associations with other phenotypes is underway. Centenarians have 
been gathered in the New England Centenarian Study. By virtue of living to be at least 97 years 
old, these adults exhibit exceptional longevity. LTL was examined in 36 members of this study, 
specifically comparing 19 “healthy” centenarians with physical function in the independent 
range and the absence of hypertension, congestive heart failure, myocardial infarction, peripheral 
vascular disease, dementia, cancer, stroke, chronic obstructive pulmonary disease, and diabetes 
to 19 “unhealthy” centenarians with physical function limitations and ≥ 2 of the above 
conditions. Healthy centenarians had significantly longer telomeres than did unhealthy 
centenarians (p=0.0475).178 In another study of 32 supercentenarians (age 110-119), it was noted 
that 88% had cataracts.220 What is surprising here is that 12% did not have cataracts despite 
being 110-119 years old. Seventh-Day Adventists, a self-selected cohort who adhere to strict 
dietary, social, and religious customs, and the Okinawan Japanese, a geographically and 
ethnically defined cohort also with a unique dietary, social, and religious makeup, have been 
found to exhibit exceptional longevity compared to general population references.221-223 LTL and 
lens transparency have not been examined in these groups. Other populations of interest include 
long lived individuals derived from general population cohorts, such as members of the 
Cardiovascular Health Study-All Stars study. The All Stars study re-recruited 1,677 participants 
of the Cardiovascular Health Study who were alive in 2005-2006 to assess cognitive and 
physical function.224 With a mean age of 85 years old, an age range of 77-102 years old, and 
nearly two decades of extensive phenotyping, the All Stars could be a particular interesting 
population within which to examine LTL and lens transparency. Another approach is pooling 
general population cohorts to achieve a sufficiently large sample of long lived individuals, as 
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was done in the CHARGE consortium.225 Clearly there are many opportunities to explore LTL 
and lens transparency among these extremes. 
In the future, epidemiologists who study aging will employ a number of tools to more 
sensitively probe human biology. At the epicenter of the toolbox will be classical epidemiologic 
techniques employed in artful ways, like studying extremes of the population. Second, better 
assays and imaging systems will enable researchers to more accurately and specifically quantify 
biomarkers of interest. High-throughput systems will allow epidemiologists to link large 
populations with deep phenotyping to variations in molecules and genes. Finally, advancing 
statistical techniques, such as joint modeling, longitudinal trajectory latent class analysis, mixed 
modeling, and lifecourse analysis will shift our rudimentary representation of biology toward a 
more sophisticated representation. With these new tools epidemiologists will help uncover the 
secrets to living a healthy, long life and be integral to the design, implementation, and 
assessment of interventions to promote longevity.       
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7.2 PUBLIC HEALTH IMPLICATIONS 
 
The world’s population is aging at an increasing rate. This demographic transition has noticeable 
impacts on the health, economies, and social structure of developed and developing countries. If 
aging is viewed as an unalterable decline, the transition will continue to result in negative 
consequences, such as a growing burden of chronic disease and markets taxed by a flood of 
dependents that require more social services while paying less into the system.  
To soften these negative consequences, attempts should be made to promote healthy 
aging. This requires an intimate understanding of the biology and physiology of aging. Once 
aging is more fully understood, population-based or individually-based treatments can be 
designed to target particular health behaviors or biologic pathways. This may result in the most 
beneficial health effects and savings on a population level.  
Biomarkers of aging are tools which can be used to dissect aging and predict age-
associated outcomes in the hopes of promoting healthy aging and longevity. Biomarker research 
has the potential to “accelerate the discovery of the causes and risk factors associated with 
disease and disability among older adults” and “bridge basic discovery and intervention 
development,” areas identified as critically important by the National Institute on Aging’s 
strategic plan. Unfortunately, few primary markers of aging have been validated and translated to 
clinical practice, which is complicated by extrapolating effects from population averaged models 
into to individuals.   
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With this research we aimed to determine the association of LTL and lens transparency to 
markers of aging and disease to advance them as potential biomarkers of aging in humans. These 
biomarkers were selected for investigation for several reasons. First, both are relatively novel. 
Thus, future studies will be valuable to the scientific community. Second, these biomarkers are 
measured in different tissues and may reflect different processes which contribute to aging. 
Telomeres are part of DNA and are believed to integrate measurement of systemic oxidation, 
inflammation, and cellular senescence, and may reflect the aging immune system and/or the 
immune system’s interaction with the rest of the body, particularly the vasculature. Transparency 
is a physical property of the lens that is a function of protein integrity. The proteins that comprise 
the lens are used throughout the body for the same purpose, to maintain protein conformation, 
especially under stress, and because few direct markers of the maintenance of protein integrity 
are available to use in epidemiologic research lens transparency might be particularly valuable 
for measuring this key aspect of aging. Third, LTL and lens transparency can be measured 
relatively easily, facilitating clinical translation. LTL is measured using modern molecular 
techniques such as PCR and Southern blot that are increasingly high-throughput and low cost. 
Lens transparency can be measured using optical devices repeatedly and accurately, and other 
alternatives exist, such as grading scales for cataract severity. These theoretical and practical 
aspects of LTL and lens transparency provide a basis for their investigation as biomarkers of 
aging and/or age-related disease. 
The literature illustrates relatively consistently that LTL is shorter in older vs. younger 
people, men vs. women, and Caucasians vs. African Americans. Associations with other age-
related phenotypes are equivocal. Our data help demonstrate that LTL may be an independent 
marker of age-related disease burden which may have common causes across tissues, but may be 
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most strongly associated with cardiovascular disease or white matter disease. What does this new 
data imply about LTL’s relevance to public health? First, the new data implies that LTL may be 
an intermediate marker for enumerating mechanisms which underlie the pathogenesis of disease 
across systems. This could aid development of screening tools and interventions to detect and 
prevent aging and/or disease throughout the body, which would be more efficient than 
developing select interventions to detect or slow aging or disease in individual systems. Second, 
it supports previous data which suggests LTL may not be a useful marker for studying or 
predicting some specific age-related diseases, either because it is weakly associated with these 
specific diseases or because more accurate and biologically relevant predictors are known for 
which we already have targeted therapy (e.g., in the case of cardiovascular disease, statin therapy 
to treat high cholesterol and nicotine replacement therapy to promote smoking cessation). Thus, 
it helps researchers target their resources. Third, the data highlights that researchers must 
investigate other parameters of LTL to see if they are predictive of relevant outcomes, such as 
studying the shortest telomere lengths vs. mean telomere length vs. longitudinal change in 
telomere length. This may illustrate that certain aspects of telomere dynamics, such as premature 
shortening or rate of shortening, are more valuable for monitoring aging or disease than mean 
telomere length. Fourth, we feel that researchers should investigate if telomere length in different 
tissues is differently associated with aging-related outcomes rather than relying on LTL as a 
representative marker of telomere lengths. Because telomere length is a fundamental regulator of 
cellular senescence it seems unwise to disregarding it as a potential biomarker of aging without 
clarifying these additional points. In the future, if, for example, the rate of telomere shortening is 
found to correlate strongly with the rate of disease pathogenesis across tissues, the rate of 
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telomere shortening could serve as a useful first-pass screening tool to illustrate the overall 
biologic integrity of a human throughout the lifespan. 
Previous studies of lens transparency have been focused on the evolution and correlates 
of age-related cataract, the accuracy and reproducibility of cataract grading scales and lens 
imaging devices, or changes in lens parameters (e.g., density, width, curvature) with age. Our 
studies are the first to specifically assess lens transparency vs. cataract surgery as putative 
biomarkers of aging and/or disease by associating them with LTL, measurements of 
cardiovascular and metabolic health, cognition and ApoE genotype. Our results suggest that the 
lens may be a poor indicator of atherosclerosis, but that low lens transparency may be a marker 
for drastically shorter LTL, diabetes, worse cognition, and ApoE genotype. Of these findings, the 
most intriguing and relevant to public health is the association with cognition and ApoE 
genotype. Because there is no effective screening method currently used for Alzheimer’s disease, 
and the pathogenesis of this disease is still unclear, lens transparency may be a promising 
candidate for clinical translation and mechanistic studies of amyloid-related brain pathology. 
This may help in detecting brain pathology early or tracking pathology over time. Longitudinal 
studies correlating changes in lens transparency with changes in cognition and in vivo markers of 
amyloid aggregation may provide strong evidence for use of lens transparency as an indicator of 
brain health.  
Ultimately, the goal of aging research is to determine the biology of aging in order to 
develop interventions which promote healthy aging and longevity. Although aging is universal, 
irreversible, and deleterious, it is clear from animal models and human studies that aging can be 
modulated and that some members of the same species age better than others. In humans it is 
critical to develop and validate interventions to extend healthspan to ameliorate the negative 
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effects of aging. Examples of promising interventions undergoing assessment include structured 
exercise programs (e.g., the LIFE study),226 caloric restriction regimens (e.g., the CALERIE 
study),227 and community-based prevention programs (e.g., 10 Keys to Healthy Aging).228,229 
Once their specificity is more clearly defined, LTL and lens transparency may serve as 
biomarkers to test the effectiveness of these interventions and others to promote healthy aging 
and longevity. Because they can be measured over time, LTL and lens transparency may be 
particularly amenable to clinical translation as markers of health throughout the lifespan.     
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Supplementary Table A.1.1: Association of lens transparency at 4th EBT examination to total aortic calcium score 
at 1st, 2nd, 3rd, and 4th EBT examinations 
 
Cataract surgery 
(N=231) 
Cataract surgery and 
transparency (N=136) 
Cataract surgery and 
transparency (N=136) 
Total aortic calcium 
score No (N=167) Yes (N=64) 
≥90% 
Transparent 
(N=39) 
<90% 
Transparent 
(N=97) † 
≥95% 
Transparent 
(N=26) 
<95% 
Transparent 
(N=110) † 
4th EBT (N=200) 
         0 (N=8), N (%) 6 (4.0) 2 (4.0) 0 (0.0) 3 (3.8) 0 (0.0) 3 (3.3) 
   1-99 (N=17), N (%) 13 (8.7) 4 (8.0) 5 (13.2) 5 (6.3) 3 (11.5) 7 (7.6) 
   100+ (N=175), N (%) 131 (87.3) 44 (88.0) 33 (86.8) 72 (90.0) 23 (88.5) 82 (89.1) 
   Score, median (IQR) 1783 (3811) 1595 (5455) 1796 (3903) 1721 (4360) 1710 (4232) 1721 (3978) 
       3rd EBT (N=222) 
         0 (N=29), N (%) 22 (13.6) 7 (11.7) 5 (12.8) 10 (10.9) 3 (11.5) 12 (11.4) 
   1-99 (N=27), N (%) 20 (12.4) 7 (11.7) 6 (15.4) 8 (8.7) 5 (19.2) 9 (8.6) 
   100+ (N=166), N (%) 120 (74.1) 46 (76.7) 28 (71.8) 74 (80.4) 18 (69.2) 84 (80.0) 
   Score, median (IQR) 659 (1654) 663 (2476) 891 (1649) 663 (2457) 1053 (2069) 651 (2103) 
       2nd EBT (N=198) 
         0 (N=33), N (%) 22 (15.0) 11 (21.6) 7 (18.4) 14 (17.5) 4 (16.0) 17 (18.3) 
   1-99 (N=47), N (%) 34 (23.1) 13 (25.5) 7 (18.4) 19 (23.8) 3 (12.0) 23 (24.7) 
   100+ (N=118), N (%) 91 (61.9) 27 (52.9) 24 (63.2) 47 (58.8) 18 (72.0) 53 (57.0) 
   Score, median (IQR) 144 (530) 114 (652) 153 (404) 143 (634) 295 (350) 139 (592) 
       1st EBT (N=225) 
         0 (N=60), N (%) 43 (26.5) 17 (27.0) 9 (25.0) 23 (24.0) 7 (29.2) 25 (23.2) 
   1-99 (N=62), N (%) 43 (26.5) 19 (30.2) 9 (25.0) 27 (28.1) 4 (16.7) 32 (29.6) 
   100+ (N=103), N (%) 76 (46.9) 27 (42.9) 18 (50.0) 46 (47.9) 13 (54.2) 51 (47.2) 
   Score, median (IQR) 83 (341) 52 (405) 96 (291) 91 (413) 124 (308) 87 (373) 
*P<0.10. †Includes participants who underwent cataract surgery. 
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Supplemental Table A.1.2: Association of lens transparency at 4th EBT examination to carotid intima-media thickness at 4th 
EBT examination 
 
Cataract surgery 
(N=231) 
Cataract surgery and 
transparency (N=136) 
Cataract surgery and 
transparency (N=136) 
Intima-media thickness (mm) 
No 
(N=167) Yes (N=64) 
≥90% 
Transparent 
(N=39) 
<90% 
Transparent 
(N=97) † 
≥95% 
Transparent 
(N=26) 
<95% 
Transparent 
(N=110) † 
Mean (SD) of average measurements 0.80 (0.12) 0.81 (0.13) 0.80 (0.13) 0.81 (0.12) 0.82 (0.15) 0.81 (0.12) 
Mean (SD) of maximum measurements 1.01 (0.17) 1.04 (0.18) 1.02 (0.18) 1.03 (0.18) 1.03 (0.21) 1.03 (0.17) 
*P<0.10 
      †Includes participants who underwent cataract surgery. 
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